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Introduction
1 Introduction
S
um
m
ary
Over the past two decades major advances have been made in unravelling the 
inflammatory process in rheumatoid arthritis. A dominant role for TNF has 
been implicated and has led to the development of a new class of drugs: TNF 
blocking agents. Currently three TNF blocking agents have been approved 
in the Netherlands for the treatment of rheumatoid arthritis: the soluble p5 
TNF receptor fusion protein Etanercept (Enbrel®), the chimerical monoclonal 
anti-TNF antibody infliximab (Remicade®) and the human monoclonal anti-
TNF antibody adalimumab (Humira®).
These agents have shown remarkable efficacy and acceptable safety profiles 
in clinical trials. Long-term safety and effectiveness, however, need to be further 
elucidated in longitudinal observational studies, as important safety issues 
have emerged from clinical use.
At the Radboud University Nijmegen Medical Centre a longitudinal observational 
study was set up to monitor the long-term effectiveness and safety of TNF 
blocking therapy in patients with rheumatoid arthritis (the Nijmegen Biologics 
Registry). The purpose of this study was to investigate clinical aspects of TNF 
treatment, including, amongst others, drug survival, effectiveness, toxicity and 
treatment modulation, which form the major subjects of this thesis.
 TNF blocking therapy in RA
r h E u M aTo i d  a r T h r i T i s
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which primarily 
affects the joints and is characterized by inflammation of synovial joints in a sym-
metrical pattern. Active disease is characterised by pain, swelling and stiffness of 
joints in combination with raised levels of inflammatory markers. RA follows a 
variable disease course with remissions and exacerbations. The inflammatory pro-
cess can lead to destruction of cartilage and bone, resulting in joint deformities, 
permanent functional impairment and disability [1]. Systemic involvement may 
occur and includes, amongst others, fever, fatigue, nodulosis, pulmonary fibrosis, 
vasculitis and serositis. Due to a large inter-individual variability in disease activity, 
degree of joint destruction and systemic involvement RA is a very heterogeneous 
disease.
The prevalence of RA has been estimated on 0.5% to 1% in populations worldwide [2]. 
The estimated incidence is 0.2 per 1000 in males and 0.4 per 1000 in females [3].
paT h o g E N E s i s  o F  r h E u M aTo i d  a r T h r i T i s
The exact cause of RA still remains unknown, but major advances have been made 
over the past two decades in understanding the inflammatory processes in RA. 
Experimental studies have implicated a dominant role for cytokines, like tumour 
necrosis factor alpha (TNF) and interleukin-1 (IL-1) [4]. Current hypotheses assume 
an inappropriate immune response, triggered by a yet undiscovered exogenous or 
endogenous antigen. Antigen presenting cells (tissue macrophages or dendritic cells) 
activate CD4+ T-cells, which stimulate macrophages, monocytes and fibroblasts to 
produce a number of cytokines, including TNF. This inflammatory response remains 
active due to a disequilibrium between proinflammatory and anti-inflammatory 
cytokines, and is assumably driven by dendritic cells or CD4+ T-cells [4,5]. The dis-
covery of key proinflammatory cytokines in RA, like TNF, has offered therapeutic 
targets for treatment.
T r E aT M E N T  o F  r h E u M aTo i d  a r T h r i T i s
At present RA cannot be cured. Pharmacological treatment is aimed at reducing and 
controlling disease activity, thereby improving functional disability and preventing 
the destruction of joint cartilage and bone. Non-Steroidal Anti-Inflammatory drugs 
(NSAIDs) are used to control symptoms of pain and morning stiffness. Corticosteroids 
and disease modifying anti-rheumatic drugs (DMARDs), like methotrexate and leflu-
nomide, are being used to control disease activity and to reduce the progression of 
cartilage and bone destruction. The observations that DMARD therapy initiated early 
in the course of the disease and that combining different DMARDs with each other 
and with corticosteroids at high doses are more effective in reducing disease activity 
and slowing joint destruction have led to a more aggressive pharmacological approach 
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of RA [6,7]. A major advance over recent years in the treatment of RA has been the 
introduction of biological therapies, like TNF blocking agents.
Non-pharmacological therapies, like cooling, orthotics, physical therapy and joint 
surgery are aimed at controlling symptoms, like pain and stiffness, and improving 
functional impairment [8-11].
T N F  b lo C k i N g  ag E N T s
Alongside an improved understanding of the immune mechanisms involved in the 
pathogenesis of RA, a new class of drugs has been developed since the early 1990s. 
These so-called ‘biologics’ have been designed specifically at targeting and antago-
nizing key cytokines, thereby suppressing inflammation and preventing cartilage and 
bone destruction. At present drugs that inhibit TNF are the most successful competi-
tors of this new class of drugs in the treatment of RA. TNF blocking agents can be 
divided in soluble TNF receptors and antibodies against TNF. Three TNF blocking 
agents are currently approved for RA treatment: etanercept (soluble TNF receptor), 
infliximab and adalimumab (both monoclonal anti-TNF antibodies). The structure 
and activity of these agents are described below and are summarized in table 1.1.
Other TNF blocking agents, like a pegylated p55 TNF-receptor (pegsunercept), 
a pegylated TNF antibody fragment (certolizumab), humanized anti-TNF anti-
bodies (CDP-571, AME-527) and a fully human anti-TNF-alpha monoclonal antibody 
(golimumab) are currently under investigation or await approval from the regula-
tory agencies [12-14].
Table 1.1: characteristics of TNF blocking agents 
 infliximab Etanercept adalimumab
 (remicade®) (Enbrel®) (humira®)
Agent Murine MoAb  p5-Fc IgG1  Human MoAb
 (IgG1) fusion protein (IgG1)
Distribution volume, L (SD) Primarily 12 (6) 4.-6.0*
 intravascular
Peak plasma concentration,   2.0-2. (1.4) 5.5 (2.3)
days (SD)  
Half-life, days (SD) .-.5* 2.6-4.3 (1.3) 10-13.6*
Binding complex with Soluble TNF	 Soluble TNF	 Soluble TNF
 Membrane bound  Membrane bound Membrane bound
 TNF	 TNF	 TNF
  TNF (lymphotoxin) 
Cell lysis yes no yes (in vitro)
Legend: *no standard deviation given. Abbreviations: IgG = immunoglobulin G, L = litre,  
MoAb = monoclonal antibody, SD = standard deviation.
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E Ta N E r C E p T
Etanercept (Enbrel®) is a fusion protein of two soluble human p75 TNF receptors, 
linked to the FC portion of IgG 1 [15]. It is produced in genetically engineered 
Chinese hamster ovary cells. Etanercept binds both soluble and cell-bound TNF, 
and lymphotoxin (TNF) [16]. Breakdown and clearance are believed to occur through 
proteolysis with recycling or elimination as by-products in bile or urine. Peak plasma 
concentration is reached in 2 to 3 days, with a plasma half-life of approximately 3-4 
days [17-20].
Etanercept is administered as subcutaneous injection and the recommended 
dose in RA is 25 milligram (mg) twice a week or 50 mg once a week [19,21], either as 
monotherapy or in combination with DMARDs.
i N F l i x i M a b
Infliximab (Remicade®) is a chimeric human-mouse monoclonal anti-TNF antibody, 
consisting of a murine TNF binding region combined with a human IgG1 [22]. 
Infliximab binds with high affinity to cell-bound TNF and soluble TNF monomers 
and trimers and forms stable complexes [16,23]. Infliximab inhibits binding of TNF 
to TNF-receptor-1 (TNF-RI or p55) and TNF-RII (p75) and it may dissociate TNF 
already bound to TNF-R. Unlike etanercept, infliximab does not bind or inhibit 
lymphotoxin. The estimated half-life of infliximab is 7.7 to 9.5 days, although it can 
be detected as long as 28 weeks after infusion (mean 12 weeks) [20,24]. The half-life 
increases with higher doses and decreases with anti-infliximab antibody formation, 
which occurs in 8-17% of RA patients [24-27].
Current treatment recommendations in RA state a starting dose of 3 mg/kg body 
weight, administered intravenously at 0, 2 and 6 weeks, followed by eight-weekly 
infusions thereafter. In case of insufficient response it is possible to increase the 
dose or to reduce the interval to 4 weeks [24]. Although in clinical practice a maxi-
mum corresponding dose of 10 mg/kg per 8 weeks has been used in patients with 
insufficient response, the European Commission has recently approved a maximum 
dose of 7.5 mg/kg per 8 weeks, which has been adapted by the regulatory authorities 
in the Netherlands as the maximum dose [28].
a da l i M u M a b
Adalimumab (Humira®) is a fully human monoclonal antibody directed against 
TNF. It is derived by phage-display techniques. Adalimumab binds both soluble 
TNF and cell-bound TNF and can lyse TNF-expressing cells in the presence of 
complement [20,29]. In theory, adalimumab is less immunogenic than other TNF 
blocking agents. The estimated half-life of adalimumab is 10-14 days, which slightly 
increases with higher age and higher dose [20,30-32]. 
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Adalimumab is administered subcutaneously at a recommended starting dose of 
40 mg every two weeks with the possibility of reducing the interval to one week in 
case of insufficient response [30]. It has been approved as monotherapy or in combi-
nation with DMARDs.
E F F i CaCy  o F  T N F  b lo C k i N g  ag E N T s
Efficacy of etanercept was shown in randomized clinical trials (RCTs) in patients 
with established RA, both as monotherapy [33-35] and in combination with DMARDs 
[36,37]. In patients with early RA treatment with etanercept resulted in a more rapid 
improvement and less adverse events than methotrexate (MTX) [38]. The combina-
tion of etanercept and MTX has been shown to reach higher efficacy than either 
etanercept or MTX alone [36,37]. Reported effects were sustained in open-label exten-
sion trials with 3 to 4 years follow-up both for monotherapy and for combination 
therapy with MTX [39-42].
Efficacy of infliximab has been shown in RCTs as monotherapy [43,44] and in 
combination with methotrexate in patients with established RA [26,45] and patients 
with early RA [46,47]. Reported efficacy was sustained over a two-year period [48]. 
Combination therapy with methotrexate resulted in higher response rates, compared 
to infliximab monotherapy [26]. The combination provided evidence for a possible 
synergism by reducing the development of anti-infliximab antibodies and increasing 
serum infliximab levels [26].
Adalimumab efficacy has been shown in RCTs with long-term RA patients for 
monotherapy and for combination therapy with MTX [32,49-51]. Sustained efficacy 
was shown in combination with methotrexate over a four-year follow-up period [52]. 
Combining adalimumab with methotrexate showed higher response rates than 
adalimumab monotherapy in patients with early, active RA [53]. 
s a F E T y  o F  T N F  b lo C k i N g  ag E N T s
Safety profiles from RCTs with RA patients are generally considered acceptable for all 
three agents [36,38,41,45,47,50]. The most common reported adverse events associated 
with TNF blocking therapy include infusion and injection reactions. Other adverse 
events associated with TNF blocking therapy in RCTs are infections, like the reacti-
vation of latent tuberculosis, and skin disease, like vasculitis. Most control arms in 
RCTs added placebo to background methotrexate. The limited number of studies 
with true placebo control arms also reported no differences, except for one study 
which reported statistically significantly more incidences of headache and skin rash 
in patients on adalimumab [49].
From post-marketing observations more adverse events have been attributed to 
TNF blocking therapy, including drug-induced SLE, demyelinating disease and 
worsening of heart failure. Further concern exists regarding the occurrence of 
malignancies, especially lymphoma’s [54].
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Following the important role of TNF in immune responses, inhibition of TNF has 
raised concerns regarding the occurrence of serious adverse events, especially serious 
infections and malignancies. Although most RCTs did not suggest an increases risk 
for serious infections, some trials reported an increased risk for serious infections 
in patient groups treated with adalimumab or infliximab in combination with 
methotrexate, both compared to patients on placebo plus methotrexate [47,50,53,55]. 
Also, the rate of serious infections was higher in patients on adalimumab plus 
methotrexate, compared to adalimumab monotherapy (2.3 versus 0.7 events per 100 
patient years (pt-yr)) [53]. A recent meta-analysis, combining data of adalimumab 
and infliximab RCTs, reported an increased risk for serious infections [56], including 
pneumonia, a reactivation of latent tuberculosis , urinary tract, skin and soft tissue 
infections, infection with Herpes zoster and Histoplasma [26,27,47,50,51,53,55].
Observational studies have also reported the reactivation of tuberculosis, as well 
as infections with intracellular pathogens and opportunistic infections [57-60]. The 
first line of defence against Mycobacterium tuberculosis is the formation of granu-
lomas by macrophages, stimulated by TNF. This mechanism is impaired by TNF 
blockade and accounts for the numerous reports of reactivation of tuberculosis, as 
well as the relative frequent disseminated state of the infection [61-63]. The suscep-
tibility for reactivation of latent tuberculosis and other granulomatous infections 
might be higher in monoclonal antibodies like infliximab, compared to soluble 
receptor fusion proteins, like etanercept. This difference possibly results from the 
induction of leukocyte apoptosis by monoclonal antibodies [61,62].
Another major concern is the development of malignancies, especially lym-
phoma’s, following TNF blocking therapy. At present, there is no clear answer but 
it is believed possible that TNF blocking therapy might add to an already increased 
background risk for lymphoma’s in RA patients, resulting from altered immune 
responses by the disease itself and by the use of immunosuppressive drugs [64]. 
A meta-analysis including nine placebo-controlled trials with infliximab and adali-
mumab showed a significant increased risk for malignancies in high-dose treatment 
arms [56]. Ten out of 24 encountered non-skin malignancies were lymphomas.
Other important adverse events associated with the use of TNF blocking agents 
include demyelinating disease, drug-induced lupus and worsening of pre-existent 
heart failure [58,65-67]. Current prescription guidelines state NYHA class III/IV to be 
an absolute contra-indication for therapy with [24]. Relative contra-indications for 
all TNF blocking agents are chronic infection, including latent tuberculosis and 
hepatitis B virus carrier state, demyelinating disease, malignancy, hepatic failure, 
pregnancy and breast-feeding [24,30,54,68].
M o N i To r i N g  E F F E CT i v E N E ss  a N d  s a F E T y  o F  T N F 
b lo C k i N g  ag E N T s
Several large post-marking studies have been initialised, mainly in Europe and in the 
United States. The rationale for these so-called biologic registries was to facilitate 
detailed data collection on long-term safety and effectiveness [69]. Examples of these 
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registries are the BSR Biologics Registry in England, the Swedish registries STURE 
and STAGG, and the German RABBIT registry [70-72].
Registries use pre-specified monitoring protocols for follow-up, which can include 
standardized measures of disease activity, radiographic evidence of progression and 
functional capacity. A well validated and widely used measurement of disease activity 
is the Disease Activity Score (DAS28), a composite index consisting of the erythrocyte 
sedimentation index, 28-joint counts for swelling and tenderness and a patient 
assessed general health score on a visual analogue scale [73,74]. 
Monitoring and analysis of long-term safety are aided by standardized adverse 
event recording systems, which facilitate coding and grading of adverse events. 
Examples are the Rheumatology Common Toxicity Index or the MedDRA system 
[75,76].
T h E  N i j M E g E N  b i o lo g i C s  r E g i s T r y
The Nijmegen Biologics Registry was set up as a longitudinal observational study for 
monitoring TNF blocking therapy in RA patients [77]. The registry investigates 
several clinical aspects of TNF blocking therapy, including, amongst others, drug 
survival, effectiveness, toxicity and treatment modulation, which form the subject 
of this thesis.
In this registry all patients were monitored who started on biologic therapy at 
the rheumatology departments of the Radboud University Nijmegen Medical Centre 
(RUNMC) and the St Maartenskliniek Nijmegen (SMN), a categorical hospital. Patients’ 
characteristics were collected at start and information on TNF blocking therapy, 
second-line therapy, disease activity (DAS28) and adverse events (AEs) were collected 
3-monthly during therapy and 1-yearly after stop, according to a standardized proto-
col. Data were entered into an electronic patient registry, developed in collaboration 
with the department of Medical Technology Assessment for long term registration 
and monitoring of RA patients.
o u T l i N E  o F  T h E  T h E s i s
The objective of this thesis was to study the drug survival, effectiveness and safety of 
TNF blocking therapy in RA patients, as well as treatment modulations of infliximab 
therapy. The content of the chapters in this thesis is outlined below.
Chapter two investigates long-term drug-survival, effectiveness and safety of etaner-
cept, infliximab and adalimumab in RA patients in the Nijmegen Biologics Registry. 
Drug survival was investigated overall and for different reasons of drug discontinua-
tion. Effectiveness was investigated using the disease activity score (DAS28) and the 
European League Against Rheumatism (EULAR) criteria for response and remission 
[73,78]. All adverse events were grouped according to an adverse events index, adapted 
from the Proposed Rheumatology Common Toxicity Index [79].
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The chapter also describes the predictive value of patient, disease and concomitant 
therapy characteristics at baseline for drug-survival, effectiveness and adverse events, 
investigated in multivariate analysis.
In chapter three the effectiveness and safety of the combination of infliximab and 
leflunomide is studied. Combining two or more DMARDs can enhance efficacy by 
additive or synergistic effects [80]. In RCTs the only drug combined with infliximab 
has been methotrexate. Leflunomide may be an important alternative for combina-
tion therapy in patients who do not respond to or do not tolerate methotrexate. This 
chapter described the disease activity, treatment response and safety of infliximab 
administration after or simultaneously with leflunomide in RA patients, in com-
parison to patients not using leflunomide. Due to the long half-life of leflunomide 
two separate analyses were carried out. The first included all patients who had used 
leflunomide during infliximab therapy or within six months prior to starting inflix-
imab. The second analysis was performed with the leflunomide group consisting 
only of patients on active leflunomide. Furthermore, in a subanalysis the incidence 
of antinuclear antibodies (ANA) at start and seroconversion to ANA positivity during 
TNF blocking therapy was studied, together with the predictive value of ANA posi-
tivity on effectiveness and safety.
Chapter four describes an open-label study in which the course of the disease activity 
and the response to therapy was evaluated in RA patients starting on infliximab 
therapy. The disease activity in patients with a moderate response after 14 weeks 
was closely observed during the next 8 week interval and the pattern was used to 
guide adjustments of infliximab therapy. This strategy was based on the hypothesis 
that part of the moderate responders might in fact have a good but short-lived 
response and thus flare before the next infliximab infusion has been administered. 
This hypothesis is based on previous observations showing a large variation in both 
dosage and time interval needed to maintain low disease activity [81,82], which 
might result from individual variations in pharmacokinetics of infliximab [83].
Next to the frequent reports of skin reactions in RCTs, various dermatological condi-
tions have been reported after the use of TNF blocking agents in RCTs and clinical 
practice. Some conditions were severe and lead to hospital admission or withdrawal 
of TNF blocking therapy. In chapter five a prospective study is described investi-
gating clinically important dermatological conditions in RA patients receiving TNF 
blocking therapy. The number and nature of the dermatological conditions are 
described in detail, including time-relations, comedication, histological findings and 
treatment. Patient on TNF blocking agents experiencing a dermatological reaction, 
resulting in a dermatological consultation, were compared with a control group, 
naive to TNF blocking therapy and matched for follow-up period.
Psoriasiform skin reactions occurring during TNF blocking therapy are paradoxal 
and interesting phenomena, as etanercept, infliximab and adalimumab have recently 
been registered for plaque psoriasis after promising results in RCTs [19,24,84]. 
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Chapter six describes in detail the de novo development of psoriasiform skin lesions 
in five RA patients and reviews the literature concerning 110 cases of patients develop-
ing psoriasiform lesions during TNF blocking therapy.
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objective | To investigate drug survival, effectiveness and safety of TNF 
blocking agents and their predictors in RA patients.
Methods | All RA patients, starting with infliximab, etanercept or adalimumab 
at two hospitals were followed prospectively. Patients’ characteristics were 
collected at start and information on TNF blocking therapy, second-line 
therapy, disease activity (DAS2) and adverse events (AEs) were collected 
3-monthly during therapy and 1-yearly after stop. Predictive factors for drug 
survival, DAS2 over time and AEs were analyzed by multiple regression 
analyses.
results | 42 patients were included: 36 infliximab, 4 adalimumab, 30 
etanercept. Baseline characteristics indicated longstanding severe RA. Over-
all drug-survival rates after year 1, 2 and 3: 63%, 42% and 34%. Longer drug 
survival was predicted by concomitant MTX or non-MTX DMARD therapy, 
compared to monotherapy.
Overall responses over time were: moderate 41-4%, good 22-33%, remission 
12-24%. DAS2 over time was predicted by monotherapy, gender, age, baseline 
DAS2, DMARD history and corticosteroid use.
11 AEs were recorded (105/100pt-yrs), mostly infections (3%) and derma-
tological conditions (15%). Major AEs during therapy: infliximab 15/100pt-yrs, 
adalimumab 1/100pt-yrs, etanercept /100pt-yrs. Infections were predicted by 
concomitant MTX therapy and steroid use. Other adverse events were predicted 
by weight, age, gender and DMARD history.
Conclusion | This prospective study in patients with longstanding severe RA 
showed lower drug-survival rates of TNF blocking therapy, compared to 
previous reports. Disease activity over time did not differ between TNF 
blocking agents. Both drug-survival and effectiveness of TNF blocking agents 
was positively influenced by the use of concomitant DMARDs, including MTX. 
Concomitant MTX and corticosteroids were independently associated with an 
increased risk for infections.
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i N T r o d u CT i o N
Tumour necrosis factor alpha (TNF) plays an important role in the pathogenesis of 
rheumatoid arthritis (RA) [1]. Currently two monoclonal anti-TNF antibodies 
(infliximab and adalimumab) and one soluble TNF receptor (etanercept) are being 
used in RA clinical practice, after demonstration of remarkable efficacy and accept-
able safety profiles in clinical trials [2-4].
However, clinical trials are not designed to provide information on long-term 
safety and efficacy and on the occurrence of rare adverse events. Furthermore, trial 
designs often exclude patients with serious comorbidity and carry restrictions on 
the use of comedication. These factors influence extrapolation of efficacy and safety 
results from trials to the RA population in daily clinical practice [5]. Furthermore, 
several safety issues have arisen after clinical use, including, amongst others, reac-
tivation of tuberculosis, opportunistic infections, demyelinating disease and drug-
induced lupus [6-8].
These arguments stress the importance of post-marketing observational studies 
investigating effectiveness and safety of long-term use of TNF blocking therapy. All 
patients on TNF blocking therapy at the Radboud University Nijmegen Medical 
Centre and the Sint Maartenskliniek Nijmegen are being followed in longitudinal 
observational study, focusing on long-term effectiveness and safety of TNF blocking 
agents [9]. The aim of the study presented here was to describe the long term survival, 
effectiveness and safety of TNF blocking therapy and to investigate the predictive 
value of baseline and treatment characteristics, including concomitant DMARDs 
and corticosteroids, for drug-survival, long-term effectiveness and safety of TNF 
blocking agents in RA patients.
paT i E N T s  a N d  M E T h o d s
All consecutive RA patients, fulfilling the 1987 American College of Rheumatology 
(ACR) criteria [10], who started TNF blocking therapy, were followed as part of a 
Biological Registry in the Netherlands [9]. Patients were required to meet the Dutch 
guidelines for biological therapies: moderate to high disease activity (DAS28 ≥ 3.2) 
and failure or intolerability of at least two disease modifying antirheumatic drugs 
(DMARDs), including methotrexate in adequate dosages.
Patients were recruited at Rheumatology departments of two participating centres: 
the Radboud University Nijmegen Medical Centre (RUNMC) and the St Maartenskliniek 
Nijmegen (SMN), a categorical hospital. All RA patients who had started TNF blocking 
therapy before January the 1st 2004 were included in this prospective study.
Therapy
Infliximab (INF) and etanercept (ETA) therapy were administered in daily clinical 
practice. Adalimumab (ADA) was administered in clinical trials.
Daily clinical practice: Therapy was started according to recommendations by 
the manufacturer, i.e. INF intravenously (i.v.) 3 milligram per kilogram (mg/kg) body 
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weight at weeks 0, 2 and 6 and 8-weekly thereafter, and ETA subcutaneously (s.c.) 
25 mg twice weekly. Dose or interval changes were made according to the judgement 
of the treating rheumatologist. INF doses were rounded up to 10 mg (SMN) or to 100 
mg (RUNMC).
Clinical trials: ADA was administered intravenously or subcutaneously. After 
completion of phase 1 and 2 trials all patients entered an open-label extension phase 
and received 40 mg subcutaneously every other week with the possibility of a dose 
increase to 40 mg every week in case of insufficient response, similar to daily clinical 
practice.
Measurements
Patients entered a standardized monitoring protocol at start of TNF blocking 
therapy consisting of three monthly visits during therapy and one-yearly visits after 
discontinuation of TNF blocking therapy. At baseline age, gender, weight, disease 
duration, rheumatoid factor (RF), anti-nuclear antibodies (ANA), the number of 
previously used DMARDs, current DMARD therapy, oral or intramuscular corticoste-
roid use were collected. At each visit erythrocyte sedimentation rate (ESR), 28 joint 
counts for swelling and tenderness and a visual analogue scale for general well- 
being were collected for calculation of the disease activity score (DAS28) [11], as well 
as dose and interval changes of TNF blocking agents, concomitant DMARD and 
corticosteroid therapy. Date and reason for discontinuation were recorded in case of 
treatment discontinuation.
Adverse events (AE) and exacerbations of pre-existing diseases were recorded, if 
considered clinically important by the treating physician, and classified according to 
an adverse events index, adapted from the Proposed Rheumatology Common Toxicity 
Index [12]. They were graded into minor or major events; the latter defined as any 
event requiring hospitalization or being considered potentially life threatening.
s TaT i s T i Ca l  a N a ly s i s
TNF  blocking therapy
Analyses for drug-survival, effectiveness and adverse events were performed with RA 
patients, who were naïve to TNF blocking therapy. Patients were grouped according 
to the first TNF blocking they used. Baseline characteristics were compared between 
the groups using chi-square test or one-way analysis of variance (ANOVA). Variables 
were transformed to obtain normality, if appropriate. Total follow-up time, time on 
TNF blocking therapy and time after discontinuation of therapy (time off therapy) 
was calculated for each patient (patient-years (pt-yrs) of follow-up).
drug survival  and reasons for discontinuation
The number and percentages of patients permanently discontinuing TNF blocking 
agents were calculated for different reasons of discontinuation. 
Drug-survival to permanent discontinuation of the first course of TNF blocking 
therapy was investigated for the TNF blocking agent overall and separately for 
2
discontinuation due to ineffectiveness and adverse events (Kaplan-Meyer, censoring 
date January 1st 2004). 
The predictive value of baseline characteristics (age, gender, weight, disease 
duration, baseline DAS28, RF positivity, ANA positivity, number of previously used 
DMARDs, the use of concomitant DMARD therapy and the use of prednisone at base-
line) on drug survival was investigated using Cox regression analysis. Concomitant 
DMARD therapy was grouped in patients using methotrexate (MTX group), patients 
using other DMARDs (non-MTX group) and patients on monotherapy with TNF-
blocking agents. Hazard ratio (HR) and p-values were calculated. A staged approach 
to model building was used and models were corrected for treatment centre and 
TNF-blocking agent. Variables with p-values greater or equal to 0.10 were excluded 
from the models.
switching of  TNF  blocking agents
Drug-survival of second treatment courses were explored overall and for each TNF 
blocking agent separately.
Effectiveness
The DAS28 over time was investigated in two models: intention to threat (ITT) and last 
observation carried forward (LOCF) in which the last DAS28 value when the patient 
used TNF blocking treatment was carried forward. Percentages of response and 
remission, according to the EULAR-criteria [13,14] were calculated after 6, 12, 24 and 
36 months of treatment overall and for each TNF blocking agent separately (ITT).
The influence of baseline characteristics on the DAS28 over time was investigated 
by GEE with correction for treatment centre and TNF blocking agent. For the GEE the 
exchangeable correlation structure was found to be appropriate and the identity 
link function and the Gaussian variance model were applied.
Since the patients in this study were not randomized and the patients using ADA 
started treatment in an RCT setting drug survival and effectiveness are not formally 
statistically tested and the estimated values should be interpreted with caution. 
adverse events
The number of adverse events per pt-yr of follow-up was calculated for the total 
follow-up period and during active therapy, including a period up to one month 
after discontinuation to account for carry-over effects.
The predictive value of baseline characteristics on the occurrence of adverse 
events during the first course of TNF blocking agent was tested using multivariate 
logistic regression analysis with correction for first TNF blocking agent, treatment 
centre and duration of treatment with first TNF blocking agent. Independent 
variables were considered the occurrence of any adverse event, infection, allergic 
reaction, dermatological event, and major events (all dichotomized). 
Analyses were performed using SAS statistical software (version 8.0, SAS Institute 
Inc, USA), and SPSS statistical software (version 12.0, SPSS Inc, USA). P-values less 
than 0.05 were considered as statistically significant.
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TNF blocking therapy was initiated in 492 RA patients, who were naïve to TNF 
blocking therapy: INF in 368 (75%) patients (RUNMC 146, SMN 222), ADA in 94 (19%) 
patients (all RUNMC) and ETA in 30 (6%) patients (RUNMC 18, SMN 12).
Baseline characteristics of the groups are presented in table 2.1, showing statisti-
cally significant differences in RF positivity, ANA positivity, DMARD history and 
concomitant DMARDs or corticosteroids use.
Table 2.1. Patient characteristics
   infliximab adalimumab Etanercept Total group p-value 
   n=368 n=94 n=30 N=492 
Age, mean (SD) 56.4 (12.) 55.6 (11.) 52.0 (14.4) 56.0 (12.) n.s.
Male gender, % 4 (25.5) 34 (36.1)  (26.) 136 (2.6) n.s.
RA duration, mean (SD) 11.2 (.) 11.2 (.4) 12.3 (13.3) 11.2 (.1) n.s.
RF positive, % 2 (1.3)  (4.) 26 (6.) 414 (4.1) 0.00
DAS2, mean (SD) 5. (1.1) 6.1 (1.0) 6.1 (1.5) 5. (1.1) n.s.
ANA positive, % 165 (44.) 26 (2.)  (26.) 1 (40.4) 0.004
Previous DMARD use,  3. (1.) 4.4 (1.) 4.2 (2.0) 4.0 (1.) 0.03
mean (SD)
      
Concomitant corticosteroids and DMARDs     
Patients on corticosteroids, % 101 (2.4) 4 (51.1) 12 (40.0) 161 (32.) 0.001
Prednisolone dose,  .5 (2.5-30) 10 (2.5-15) 5.0 (4-15) 10 (2.5-30) n.s.*
median (range)
Patients on concomitant  2 (.3) 16 (1.0) 1 (56.) 321 (65.2) 0.001
DMARDs, %
• One DMARD 24 (6.4) 16 (1.0) 13 (43.3) 2 (56.3) 
 - MTX 150 (40.) 16 (1.0) 6 (20.0)) 12 (35.0) 
 - Other**  (26.6) -  (23.3) 105 (21.3) 
• Two DMARDs 3 (10.1) - 4 (13.3) 41 (.3) 
 - Including MTX 32 (.) - 4 (13.3) 36 (.3) 
 - Other 5 (1.4) - - 5 (1.0) 
• Three DMARDs 3 (0.) - - 3 (0.6) 
*after Log transformation. **in descending frequency: azathioprine 11%, leflunomide 6%,  
sulphasalazine 3%, hydroxychloroquine 1%, cyclosporine and parenteral gold <1%.
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Total follow-up time was 1147 pt-yrs: 452 pt-yrs INF, 296 pt-yrs ADA, 130 pt-yrs ETA 
and 269 pt-yrs off therapy. Maximum follow-up time for INF, ADA and ETA were 45, 
79 and 42 months, respectively. During follow-up 53 patients were lost-to-follow-up 
(30 residential move, 22 deceased, 1 unknown).
Treatment adjustments of first treatment courses with TNF blocking agents: 
290 treatment changes were applied for INF in 165 patients (45%; 122 dose increases, 
142 interval reductions, 11 dose-reductions and 15 interval increases). Interval reduc-
tions of ADA (’open-label’ phase only) were applied in 33 patients (35%). Two interval 
reductions and one interval increase were applied in 3 ETA treated patients (10%).
drug survival  and reasons for discontinuation
Overall drug survival rates of 1st treatment course after the 1st, the 2nd and the 3rd 
year of therapy were 63%, 42% and 34%. Figure 2.1A shows the drug survival for all 
patients and figures 2.1B, C and D show drug survival for the three TNF blocking 
agents separately. The mean survival time for INF, ADA and ETA was 20.4, 47.8 and 
21.0 months, respectively. Statistical comparison between the three agents was not 
considered appropriate (see before). 
A longer drug survival was predicted by concomitant MTX therapy (HR (95% CI) 0.50 
(0.37-0.61), p<0.001) or by non-MTX DMARD therapy (HR (95% CI) 0.59 (0.42-0.83), 
p<0.005), compared to monotherapy. A longer survival to ineffectiveness was 
predicted by concomitant MTX therapy (HR 0.48 (0.27-0.82, p<0.0001), but not by 
non-MTX DMARDs (HR 0.82 (0.46-1.48), p=0.5). A longer survival to discontinuation 
because of adverse events was associated with both concomitant MTX therapy (HR 
0.53 (0.36-0.80), p<0.0001) and non-MTX DMARDs (HR 0.50 (0.30-0.83), p<0.01), as well 
as a shorter disease duration (HR 1.02 (1.002-1.04), p<0.05).
Age, gender, weight, baseline DAS28, RF positivity, ANA positivity, the number of 
previously used DMARDs and the use of prednisone at baseline did not predict drug 
survival in multivariate analysis. 
Overall, TNF blocking therapy was temporarily discontinued 188 times in 115 
patients (24%) and permanently discontinued in 272 patients (55%). Reasons for dis-
continuation are presented in table 2.2.
switching of  TNF  blocking agents
168 Patients (34%) switched to other TNF blocking agents (See table 2.2). Overall 
drug survival of 2nd treatment courses was comparable with 1st treatment courses. 
The largest group consisted of patients switching from INF to ETA (n=121 (25%): AE 
70, ineffectiveness 28, other reasons 23). Exploring drug survival of ETA as second 
TNF blocking therapy after INF showed a comparable drug survival for different 
reasons of INF discontinuation (Log rank p=0.73).
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Figure 2.1. Drug survival of TNF blocking agents
Figure 2.1A shows the drug survival of the three agents combined. Figures 2.1B, 2.1C  
and 2.1D show the drug survival of adalimumab, infliximab and etanercept, respectively.  
Solid line is overall drug survival, dotted line is survival to ineffectiveness, dashed line  
is survival to AE.
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Table 2.2. Reasons for discontinuation
  infliximab adalimumab Etanercept Total group
  (n=368) (n=94) (n=30) (N=492)
   n (%)* n (%) n (%) n (%)
Temporary discontinuation** /1 (1.3) 105/40 (42.6) 5/4 (13.3) 1/115 (23.4)
 Adverse events 0/64 (1.4) 44/30 (31.) 0/0 114/4 (1.1)
  Surgery 3/3 (0.) 44/26 (2.) 2/2 (6.) 4/31 (6.3)
 Other reasons 5/5 (1.4) 1/13 (13.) 3/2 (6.) 25/20 (4.1)
    
Permanent discontinuation 1 (54.1) 54 (5.4) 16 (53.3) 26 (54.6)
  Ineffectiveness 5 (15.) 23 (24.5) 10 (33.3) 1 (1.5)
  Adverse events 112 (30.4) 2 (2.) 3 (10) 143 (2.1)
  Other reasons 2 (.)# 3 (3.2) 3 (10) 35 (.1)
    
  Switch to other TNF	 132 (35.) 24 (25.5) 12 (40.0) 16 (34.1)
 blocking agents
  Switch to DMARDs 6 (1.2) 30 (5.5) 4 (13.3) 101 (20.5)
    
Continuing 16 (45.) 40 (42.6) 14 (46.) 223 (45.3)
Reasons for discontinuation of TNF blocking agent first treatment courses. *No. of patients  
(% of patients), unless stated otherwise. **Displayed are no. of events/no. of patients (% of patients).  
# 22 of 2 patients stopped infliximab because of availability of etanercept.
Effectiveness
Baseline DAS28 values were available for 486 patients (99%) and follow-up DAS28 for 
3959 of 4858 visits (81%). Table 2.3 shows EULAR-response and remission percentages. 
Overall responses varied between 41% and 49% for moderate response, between 22% 
and 33% for good response and between 12% and 24% for remission.
Figure 2 shows the mean DAS28 per TNF blocking agent over the first thee years. 
For ADA the mean DAS28 (95% CI) at year 4, 5 and 6 were respectively 4.0 (3.6-4.4), 4.3 
(3.9-4.6) and 4.0 (3.3-4.6). 
Factors independently associated with a higher disease activity over time were: 
Female gender, younger age, higher baseline DAS28, higher number of previously used 
DMARDs, the use of concomitant corticosteroids and the absence of concomitant 
DMARD therapy at baseline (table 2.4).
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Table 2.3. Patients fulfilling EULAR response and remission criteria and mean DAS28*
  3 months 6 months 1 year 2 years 3 years
  n (%)** n (%) n (%) n (%) n (%)
infliximab (n=36) 312 253 214 121 3
 No response  (2.) 6 (34.0) 1 (33.2) 24 (1.)  (1.4)
 Moderate response 14 (4.1) 105 (41.5)  (41.1) 53 (43.) 1 (4.4)
 Good response  (25.0) 62 (24.5) 55 (25.) 44 (36.4) 13 (34.2)
 Remission 4 (15.1) 35 (13.) 30 (14.0) 2 (23.1) 10 (26.3)
 DAS2, mean (SD) 4.1 (1.4) 4.21 (1.4) 4.1 (1.43) 3. (1.2) 3.0 (1.3)
     
adalimumab (n=4) 6 6  61 56
 No response 2 (32.6) 2 (31.4) 23 (2.1) 13 (21.3) 10 (1.)
 Moderate response 4 (54.) 36 (41.) 40 (50.6) 32 (52.5) 2 (4.2)
 Good response 11 (12.) 23 (26.) 16 (20.3) 16 (26.2) 1 (33.)
 Remission 6 (.0) 14 (16.3)  (.) 11 (1.0) 12 (21.4)
 DAS2, mean (SD) 4.65 (1.3) 4.31 (1.54) 4.3 (1.52) 3. (1.42) 3.6 (1.3)
     
Etanercept (n=30) 13 1 15 11 10
 No response 4 (30.)  (4.1) 6 (40.0) 5 (45.5) 3 (30.0)
 Moderate response  (53.) 5 (2.4) 6 (40.0) 5 (45.5) 5 (50.0)
 Good response 2 (15.4) 4 (23.5) 3 (20.0) 1 (.1) 2 (20.0)
 Remission 1 (.) 3 (1.6) 1 (6.) 1 (.1) 2 (20.0)
 DAS2, mean (SD) 4.3 (1.33) 4.35 (1.) 4.30 (1.33) 4.4 (1.51) 4.33 (1.3)
     
Total group (n=42) 411 356 30 13 104
 No response 11 (2.0) 121 (34.0) 100 (32.5) 42 (21.) 20 (1.2)
 Moderate response 201 (4.) 146 (41.0) 134 (43.5) 0 (46.6) 50 (4.1)
 Good response 1 (22.1)  (25.0) 4 (24.0) 61 (31.6) 34 (32.)
 Remission 54 (13.1) 52 (14.6) 3 (12.3) 40 (20.) 24 (23.1)
 DAS2, mean (SD) 4.2 (1.52) 4.24 (1.4) 4.25 (1.4) 3. (1.45) 3.5 (1.46)
*intention to treat analysis. ** unless stated otherwise
Table 2.4. Model for predictive factors for high disease activity over time
baseline variables Estimate sE** 95% Ci# p-value
Age* 0.014 0.004 0.00-0.02 0.0002
Female gender 0.4 0.10 0.2-0.6 <0.001
Number of prior DMARDs 0.0 0.03 0.03-0.13 0.003
DAS2 0.45 0.04 0.3-0.52 <0.0001
Concomitant DMARDs -0.35 0.11 -0.15- -0.56 0.000
Prednisolone 0.20 0.0 0.02-0.3 0.03
Analysis of GEE parameter estimates. *Age: estimate per one year increment.  
**Standard error, #5% confidence interval
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Figure 2.2. Disease activity over the first three years
Disease activity (DAS2) over the first three years for infliximab (solid line), adalimumab  
(dashed line) and etanercept (dotted line). Error bars indicate 5% confidence intervals.  
Figure 2.2A: ITT analysis. Figure 2.2B: LOCF analysis.
a
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Table 2.5. Allergic reactions and major adverse events during TNF blocking therapy
  Total  infliximab adalimumab Etanercept
  n rate* n rate* n rate* n rate*
allergic reactions        
Infusion reactions 111 12,5 106 23,1 5 5,6# - -
 Acute reactions** 3 10,4  1,2 5 5,6 - -
 Delayed systemic reactions 1 2,0 1 3, 0 0,0 - -
Injection reactions 26 2, 1 0,2 14 6,$ 11 ,3
 Local reactions 20 2,2 1 0,2 12 5,  5,3
 Systemic reactions 6 0, 0 0,0 2 1,0 4 3,0
Exanthema/erythema 52 5, 33 ,2 12 5,  5,3
        
Major aEs        
Infections 41 4,6 24 5,2 14 4, 3 2,3
 Pneumonia 12 1,3  2,0 3 1,0 0 0,0
 Sepsis 4 0,4 1 0,2 3 1,0 0 0,0
 Septic arthritis  0, 2 0,4 4 1,3 1 0,
 Bacterial skin infections  0, 4 0, 2 0, 1 0,
 Other major infections 11 1,2  1, 2 0, 1 0,
        
Malignancy 10 1,1 4 0, 5 1, 1 0,
 Non-skin  0, 3 0, 4 1,3 1 0,
 Skin 2 0,2 1 0,2 1 0,3 0 0,0
        
Other major AEs        
Myocardial infarction 15 1,  1,  2,3 0 0,0
Cardiovascular other  0, 4 0, 3 1,0 0 0,0
Neurological 20 2,2 10 2,2  2, 2 1,5
Allergic  1,0 6 1,3 2 0, 1 0,
Pulmonary 5 0,6 3 0, 2 0, 0 0,0
Gastrointestinal 4 0,4 1 0,2 1 0,3 2 1,5
Renal disease 4 0,4 1 0,2 3 1,0 0 0,0
Dermatological 3 0,3 1 0,2 2 0, 0 0,0
Rheumatological 3 0,3 3 0, 0 0,0 0 0,0
Other major AEs  0, 3 0, 5 1, 0 0,0
        
Total major aEs 12 14,5 6 14, 52 1,3  6,
*Rate in number of events per 100 pt-yrs. **acute systemic and/or dermatological reactions.  
#adalimumab intravenously. $adalimumab subcutaneously. 
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adverse events
A total of 1199 adverse events (AEs) were recorded in 376 (76%) patients, naïve to TNF 
blocking therapy (event rate 104.6 events per 100 pt-yrs):
• 1126 AEs (94%) occurred during active therapy (126.4 AE/100pt-yrs).
• 160 AEs (13%) led to permanent discontinuation of TNF blocking therapy in 137 
 (28%) patients (18.0 AE/100pt-yrs).
The most frequently reported AEs included infections (457 AEs (38%) in 223 patients 
(45%)), dermatological conditions (183 AEs (15%) in 133 patients (27%)) and allergic 
reactions (141 AEs (12%) in 109 patients (22%)).
Major AEs were reported 155 times (13%) in 109 (22%) patients. Major AEs occur-
ring during therapy (n=129, 11%) are shown in table 2.5. Baseline factors, predictive for 
the occurrence of adverse events are shown in table 2.6. Concomitant steroid use was 
associated with the occurrence of any AE, with infections and with the occurrence 
of major AEs. Concomitant use of MTX, but not non-MTX DMARDs, was associated 
with the occurrence of infections. 
Table 2.6. Predictive variables for adverse events in multivariate logistic regression models*
independent variable** predictive variables odds ratio (95% Ci) p-value
Any adverse event Concomitant steroid use 2.10 (1.26-3.4) <0.005
 Weight## 1.25 (1.05-1.4) <0.05
   
Infectious AEs Concomitant steroid use 2.00 (1.2-3.0) <0.005
 Concomitant MTX# 2.2 (1.2-4.01) <0.01
 Concomitant DMARDs, other than MTX# 1.43 (0.3-2.) 0.30
 Male gender 0.6 (0.40-1.04) 0.0
   
dermatological AEs Weight## 1.30 (1.0-1.55) <0.005
 Age## 1.25 (1.03-1.52) <0.05
 Number of previously used DMARDs 1.12 (0.-1.2) 0.0
   
   
allergic AEs Male gender 0.53 (0.2-0.5) <0.05
 Number of previously used DMARDs 1.1 (1.03-1.34) <0.05
 Age## 0.4 (0.0-1.01) 0.06
   
   
major AEs Age## 1.36 (1.10-1.6) <0.005
 Concomitant steroid use 1. (1.0-2.3) <0.05
*stepwise backward approach with correction for TNF blocking agent, time on therapy and centre; 
all variables with p<0.10 included. **dichotomized independent variables. #compared to monotherapy 
with TNF blocking agents. ##For weight and age: OR per decimal increment.
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This longitudinal observational study investigated the drug survival, efficacy and 
safety of three TNF blocking agents, i.e. infliximab, adalimumab and etanercept, 
in a cohort of RA patients with active and mostly longstanding, severe RA. Further-
more, the predictive value of baseline factors for drug survival, disease activity and 
adverse events were analyzed. Patients were included in two Hospitals in the east of 
the Netherlands, which provide nearly all second-line RA treatments in an area 
with an estimated population size of half a million.
Observed drug survival rates are relatively low, compared to survival rates reported 
previously in clinical trials and biologics registries. One-year survival rates in the 
present study ranged between 50% for etanercept and 74% for adalimumab. In clinical 
trials one-year drug survival rates ranged between 73-86% for the three agents for 
treatment groups resembling current clinical practice [2,15-17]. Reported one-year 
survival rates in post-marketing observational studies vary around 65-95% [18-22]. 
Although in general these studies have similar baseline characteristics regarding 
disease duration and severity, differences exist in prescription criteria, availability 
of TNF blocking agents and the use of comedication, which can contribute to 
encountered differences in drug survival.
In the present study drug survival rates are presented without formal comparison 
between the three agents. This was considered inappropriate mainly because of two 
reasons. Firstly, all adalimumab patients originated from RCTs, which might have a 
positive influence on drug-survival because of stringent exclusion criteria like comor-
bidity. Recently is has been shown that RA patients who are ineligible for RCTs 
exhibit lower response rates to TNF blocking agents [23]. The authors comment on 
the ‘flare design’ of most recent RCTs, which includes only patients who have a high 
disease activity at baseline and thus a larger potential for improvement.
Secondly, the number of patients who started with etanercept was small, resulting 
from limited access of etanercept in the Netherlands until the end of 2003, due to 
scarcity of the drug.
A substantial number of patients switched from TNF blocking agent, mostly 
from infliximab to etanercept. Overall, survival rates of second treatment courses 
were good and comparable to previous reports on switching of TNF blocking agents 
[24]. In the present study the reason for discontinuation of infliximab did not seem 
to influence drug survival of second treatment course with etanercept. Patient 
numbers for other switching combinations were small and not further explored.
Disease activity over time and the response and remission rates were comparable 
to other observational studies [19,25-28]. Adverse events were reported frequently 
and led to discontinuation in 30% of the patients. The pattern of adverse events was 
similar to previous reports; with infections and dermatological conditions reported 
most frequently [2-4,15,19,29].
It is possible that therapy with TNF blocking agents increases the risk for 
infections. A number of clinical trials have reported an increased risk following 
TNF blocking therapy for serious infections in general [15,30,31], contrasted 
by studies reporting similar infection rates between patients with and without 
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TNF blocking therapy [2-4]. A meta-analysis of nine trials with infliximab and 
adalimumab has also reported an increased risk for serious infections [32]. 
Substantial evidence has emerged associating TNF blocking agents with an 
increased risk for tuberculosis reactivation and infections with intracellular 
pathogens [6,7,33-35]. More recently, large observational studies have reported an 
increase in serious infections in general [36,37], as well as serious skin and soft 
tissue infections [38].
Next to infections, the risk for malignancies remains subject to debate. A recent 
meta-analysis of 9 RCTs with infliximab and adalimumab showed a dose dependent 
increased risk in the first treatment year, compared to controls [32], although com-
ments have been made on the choice of included trials and the unexpected low 
malignancy rate in control arms [39,40]. In the present study a total of ten non-skin 
malignancies of different origin were reported during follow-up, which does not 
exceed the expected malignancy risk in RA patients in general [41].
This study further investigated the predictive value of baseline and treatment 
characteristics on effectiveness and safety outcomes. The use of both concomitant 
MTX therapy and concomitant non-MTX DMARD therapy was shown to be associated 
with a longer drug survival time and lower disease activity over time. This is in line 
with previous observations. The use of concomitant MTX has been extensively studied 
in clinical trials, which reported overall better response rates [16,42,43]. In observa-
tional studies, higher response rates have been reported for the combination of 
etanercept and MTX, compared to monotherapy [25]. Similar trends were shown for 
infliximab, although not statistically significant [25]. Similarly, a significantly longer 
drug survival of TNF blocking therapy in combination with MTX has been reported 
in comparison to monotherapy with TNF blocking agents [44].
One study reported the combination of TNF blocking therapy with MTX to result 
in higher response rates compared to TNF blocking therapy with non-MTX DMARDs 
[25]. A more recent study confirmed that both MTX and non-MTX DMARDs predict 
treatment responses, with MTX being a better predictor [52]. Although the present 
study did not perform a direct comparison, the MTX subgroup predicted a longer 
drug survival time to ineffectiveness and reached higher statistical significance for 
the other outcomes, compared to the non-MTX DMARD subgroup.
The observation that the use of concomitant non-MTX DMARDs is associated 
with a better drug survival and effectiveness is interesting, particularly for patients 
who do not tolerate MTX. These patients might benefit from the combination of TNF 
blocking therapy with non-MTX DMARDs. In clinical trials only combinations with 
MTX have been tested. Other observational data on the comparison of concomitant 
non-MTX DMARDs versus monotherapy is lacking and the observations in this study 
need further confirmation. It must be noted that in the present study most patients 
on concomitant non-MTX DMARDs originated from the infliximab group.
Increased effectiveness and a decrease in number of treatment-related adverse 
events rate both could result from suppression of the formation of antibodies 
against TNF blocking agents by using concomitant DMARDs like methotrexate, as 
has been shown for infliximab in Crohn’s disease [45]. Formation of antibodies to 
the other two TNF blocking agents occurs at very low rates [15,46].
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Other factors predictive for a low disease activity over time were older age, male 
gender, lower baseline DAS28, no concomitant corticosteroids and less previously 
used DMARDs. The latter two could indicate patients with a less severe disease 
course. The other factors are known markers for RA disease severity [47,48]. Observa-
tional studies have reported higher remission rates in patients with a lower baseline 
DAS28, less previously used DMARDs, concomitant methotrexate and male gender 
[25,26,28].
Baseline DAS28 differs between biological registries, resulting from differences 
in national prescription criteria. In England a DAS28 score above 5.1 is required, 
whereas German and Swedish criteria hold no restriction regarding disease activity 
[22,25,44]. 
Concomitant corticosteroid use predicted adverse events in general and infec-
tions. Infections were furthermore predicted by the use of concomitant MTX. The 
association of infections with non-MTX DMARDs was not statistically significant. 
Corticosteroid and DMARD therapy has previously been associated with a higher 
infection rate [36,49-51]. Weight and higher age were also associated with the occur-
rence of adverse events, possibly by associated comorbidity. Allergic reactions were 
predicted by female gender and a higher number of previously used DMARDs. 
The latter might indicate patients with a high DMARD turnover due to toxicity or 
intolerability.
In conclusion, the observed survival rates of TNF blocking agents in a Dutch 
cohort with longstanding, severe RA are relatively low and only a small percentage 
achieved remission during follow-up. For comparison of effectiveness between the 
different agents randomized studies are preferential. The concomitant use of 
DMARDs, including MTX, was found to be associated with a longer drug survival 
and a lower disease activity over time. For MTX, these effects were more pronounced 
than for non-MTX DMARDs, but this advantage was countered by an increased risk 
for infections, associated with concomitant MTX. The authors do not dispute the 
advocation of concomitant MTX therapy when prescribing a TNF blocking agent, 
but further studies are needed to clarify the exact risk-benefit ratio regarding the 
increased risk for infections.
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objective | To investigate the influence of previous and concomitant leflunomide 
on the efficacy and safety of infliximab therapy in rheumatoid arthritis (RA) and 
to compare it to infliximab in combination with other disease-modifying anti-
rheumatic drugs.
Methods | RA patients starting infliximab therapy were prospectively followed 
from January 2000. Every 3 months data were collected regarding disease 
activity (DAS2), adverse events and treatment changes. In the primary analyses 
all patients were classified into a leflunomide group (LEF group) if they had 
used leflunomide during infliximab therapy or within 6 months prior to starting 
infliximab therapy, the latter because of the long half-life of leflunomide. All 
other patients were considered as controls (non-LEF group). Secondary drug 
survival analyses were performed with the LEF group consisting only of 
patients on active leflunomide at the start of infliximab (active LEF group).
results | A total of 162 RA patients started infliximab therapy (5 in the LEF 
group, 105 in the non-LEF group). No statistically significant differences in base-
line characteristics were observed between the groups. Maximum follow-up 
time was 46 months for both groups. No differences in drug survival, disease 
activity or adverse events were observed between the groups.
In both groups an increase in patients positive for antinuclear antibodies (ANA) 
was seen. ANA positivity at start did not predict DAS2 or the occurrence of 
adverse events. Secondary drug survival analyses showed no differences 
between the active LEF group and the non-LEF group.
Conclusion | The results indicate that the administration of infliximab after or 
simultaneously with leflunomide is safe and efficacious in RA patients.
TNF blocking therapy in RA44
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i N T r o d u CT i o N
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that affects 
between 0.5 and 1% of the adult population [1]. It predominantly affects the joints, 
characterized by chronic synovial inflammation, and can cause severe, irreversible 
joint destruction and functional disability. Disease-modifying antirheumatic drugs 
(DMARDs) can reduce the inflammatory process and slow progression of joint 
destruction. Early diagnosis and initiation of DMARD treatment are important for 
an optimal reduction in disease progression.
Leflunomide is a relatively new DMARD, which has proven efficacy and safety in 
randomized controlled trials in RA [2, 3]. It is an isoxazole derivate and its active 
metabolite inhibits de novo pyrimidine synthesis, resulting in inhibition of T-cell 
proliferation. Leflunomide has a long elimination half-life of 15 to 18 days.
The development of anti-rheumatic drugs has shifted from empirically based 
strategies towards drugs specifically designed to target critical elements in the 
inflammatory process in RA. An important cytokine in RA is tumour necrosis factor 
alpha (TNF) [4]. Inhibition of TNF by monoclonal antibodies or by soluble receptors 
has proved to be a major advance in the treatment of RA. Two monoclonal anti-TNF 
antibodies (infliximab and adalimumab) and one soluble receptor (etanercept) have 
proved to be efficacious in clinical trials and are currently being used in clinical 
practice [5–7].
Combining two or more DMARDs can enhance efficacy by either additive or syner-
gistic effects, without a decrease in tolerability [8]. Although infliximab has proved to 
be efficacious as monotherapy in RA [9, 10], combining infliximab with concomitant 
methotrexate resulted in a sustained therapeutic response at lower infliximab doses, 
compared with both drugs administered as monotherapy [10]. Furthermore, the 
incidence of antibodies to infliximab was reduced when infliximab was administered 
with concomitant methotrexate, which might explain the apparent synergy between 
infliximab and methotrexate. In patients with Crohn’s disease the development of 
anti-infliximab antibodies has been shown to be associated with a reduction in the 
duration of response and with a higher risk of infusion reactions. In addition to 
this, concomitant immunosuppressive treatment was associated with a reduction 
in antibody titres [11].
The results of Maini et al. [10] provided the rationale for the combination of 
infliximab and methotrexate, which has further been evaluated in clinical trials 
and is now the recommended strategy for infliximab therapy in RA [5, 12]. However, 
not all patients tolerate or respond to methotrexate, which warrants research into 
the combination of infliximab with other DMARDs like leflunomide.
At present three studies have been published investigating the combination of 
infliximab and leflunomide in RA [13–15]. All three studies report the combination 
to be efficacious. A marked reduction of disease activity in RA patients was reported 
in two studies, one 32-week open-label prospective study and one retrospective 
study, both with a small number of patients. However, in two studies with small 
patient numbers approximately half of the patients in both studies were withdrawn 
from therapy due to adverse events, which were in some cases severe [13, 15]. 
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Another retrospective study in 88 RA patients showed the combination to be effica-
cious and well tolerated over an average of 6.6 months [14].
The reported studies lack a control group, have a limited follow-up time and 
two of them are retrospective. In this prospective cohort study we investigated the 
efficacy and safety of infliximab in RA patients with previous and concomitant use of 
leflunomide over a longer period and compared it with the combination of infliximab 
with other DMARDs.
paT i E N T s  a N d  M E T h o d s
patients
All RA patients starting treatment with infliximab in one academic centre were 
included in a prospective follow-up study starting in January 2000. To be eligible for 
treatment with infliximab patients had to fulfil the diagnosis of RA according to 
the criteria of the American College of Rheumatology [16] and were required to meet 
the Dutch guidelines criteria for biological therapies: moderate to high disease 
activity (DAS28≥3.2) and failure or intolerance of treatment with methotrexate up 
to 25 mg/week and at least one other DMARD in adequate dosage regimens.
Treatment
Infliximab was administered intravenously and was started according to a standard 
dosing regimen with a dosage of 3 mg/kg, which was rounded off to a multiple of 
100 mg and was administered at the start of treatment, weeks 2, 6 (loading dose phase) 
and every 8 weeks thereafter. After the loading dose phase the dose or interval in 
individual patients could be adjusted if the response was insufficient. Guidelines for 
maximum infliximab dose per interval corresponded with 10 mg/kg every 8 weeks. 
Guidelines at the treatment centre recommended infliximab to be administered in 
combination with methotrexate, in accordance with general recommendations [12]. 
If methotrexate was ineffective or not tolerated the choice of concomitant DMARD 
treatment was made by the treating physician.
Evaluations
At the start of infliximab therapy the following patient characteristics were collected: 
age, gender, weight, duration of RA, rheumatoid factor (RF) (considered positive if 
RF >10 IU/ml; by enzyme-linked immunosorbent assay), antinuclear antibody (ANA; 
by immunofluorescence on Hep-2 cells). Previously and currently used DMARDs were 
recorded, as well as orally administered corticosteroids. Patients were assessed every 
3 months. Assessments consisted of joint evaluations (28 joint counts for tenderness 
and swelling), erythrocyte sedimentation rate (ESR; Westergren method) and a patient 
assessment of disease activity on a visual analogue scale (VAS). Furthermore, at every 
visit the dosage and interval of infliximab, changes in concomitant DMARDs and sys-
temic corticosteroids, and adverse events were recorded. ANA was measured at base-
line and once a year thereafter.
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Adverse events were defined as any new medical condition or worsening of a pre-
existing medical condition occurring during or after treatment with infliximab and 
were recorded by the rheumatologist if they were considered clinically important. 
They were divided into minor and major events. Major events were defined as those 
events for which intravenous therapy or hospitalization was necessary.
In cases where infliximab therapy was discontinued the reason for discontinua-
tion was recorded and follow-up was continued. Reasons for discontinuation were 
classified as discontinuation due to inefficacy, adverse events or other reasons. Disease 
activity was assessed using the DAS28, a composite index consisting of 28 joint 
counts for tender and swollen joints, the ESR and the VAS for disease activity [17, 18]. 
Response to treatment was evaluated using the European League Against Rheuma-
tism (EULAR) response criteria, based on the DAS28 [19].
statist ical  analysis
Patients were classified into two groups. They were classified into the leflunomide 
group (LEF group) if they were using leflunomide during infliximab treatment or if 
they had used leflunomide within the last 6 months prior to starting infliximab 
therapy, the latter because of the long half-life of leflunomide. All other patients 
were considered in the control group (non-LEF group). These groups were compared 
for baseline characteristics, drug survival, adverse events, reason for discontinua-
tion, DAS28 over time and ANA status. Secondary analyses were performed with the 
LEF group consisting only of patients on active leflunomide therapy at the start of 
infliximab (active LEF group). All other patients were considered as controls. Baseline 
characteristics were compared and drug survival analyses were repeated. Furthermore, 
patients on infliximab monotherapy were compared with patients on infliximab-
DMARD combinations for differences in baseline characteristics, adverse events and 
ANA status.
Differences in baseline characteristics between groups were compared by chi-
square tests for dichotomous variables and Student’s t-tests for continuous variables. 
Life table analysis was performed to compare drug survival on infliximab between 
groups with 1 January 2004 as the date of censoring. Separate drug survival analyses 
were performed for inefficacy and for adverse events as reasons for discontinuation. 
To correct for possible differences in baseline characteristics between the groups 
Cox regression analysis was used. In addition, the same analyses were repeated for 
the active LEF group.
Adverse events and reasons for discontinuing infliximab therapy were compared 
between the treatment groups. The DAS28 over time was compared between groups 
by longitudinal regression analysis using generalized estimating equations (GEE). 
Differences in baseline characteristics between the groups were corrected for. The 
exchangeable correlation structure was used and the identity link function and the 
Gaussian variance model were applied. Percentages of response were calculated for 
the groups at 3, 6, 12, 18 and 24 months.
Differences between groups in ANA status at start and during follow-up were 
compared by chi-square tests. Relative risks of developing adverse events over the first 
year of follow-up were calculated for ANA-positive patients at baseline as opposed to 
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ANA-negative patients at baseline for both treatment groups, and for conversion to 
ANA positivity as opposed to patients who remained ANA negative during infliximab 
therapy for both treatment groups. The DAS28 over time was compared overall 
between patients who were ANA positive and ANA negative at the start of infliximab 
using GEE with the exchangeable correlation structure. Analyses were performed 
using SAS statistical software (version 8.0, SAS Institute Inc., USA), and SPSS statistical 
software (version 11.0, SPSS Inc., USA).
Ethical approval was obtained from the Ethical Committee of the University 
Medical Centre St Radboud for the observational study. Patient informed consent 
was obtained verbally; no written informed consent was required.
r E s u lT s
Since January 2000 a total of 162 RA patients started infliximab therapy, of whom 
57 used leflunomide during infliximab therapy or in the 6 months prior to starting 
infliximab therapy. The characteristics of these patients are shown in table 3.1. 
Although some small differences in baseline characteristics were seen, none of 
them were statistically significant.
Table 3.1: Baseline characteristics at start of infliximab therapy
  lEF group NoN-lEF group p-value
  (n=57) (n=105) 
Age in years, mean (SD) 54.2 (14.3) 5.1 (11.5) 0.0
Female sex, n (%) 41 (1.) 4 (0.5) 0.
Weight in kg, mean (SD) 4.2 (14.2) 4.1 (12.3) 0.
Duration of disease in yr, median (range) . (1.2-3.) 11.0 (1.2-44.) 0.23
RF positivity, n (%) 52 (1.2) 6 (1.) 0.11
ANA positivity, n (%) 24 (4.1)* 3 (3.0)* 0.24
Disease activity score (DAS2), mean (SD) 5. (1.0) 5. (1.1) 0.4
No. of prior DMARDs, median (range) 4 (1-) 3 (2-) 0.12
No. of concomitant DMARDs, n (%)
 0  11 (1.3) 22 (21.0)
 1 40 (0.2) 66 (62.)
 2 6 (10.5) 16 (15.1)
 3 0 (0.0) 1 (1.0) 
Concomitant prednisone at baseline, n (%) 1 (31.6) 2 (25.) 0.52
Prednisone dose in mg/d at baseline, median (range) .5 (5-20) 10 (5-30) 0.22
*ANA at baseline available for 51 and 100 patients in the LEF group respectively NON-LEF group
4
dMard treatment
The LEF group consisted of 33 patients (58%) who used leflunomide at the start of 
infliximab therapy and 24 patients (42%) who had stopped leflunomide therapy in the 
last 6 months before starting infliximab therapy (median 3.7 months (range 0.0-6.0) 
before starting infliximab). Thirteen patients had stopped leflunomide because of 
adverse events, seven for inefficacy and four for both adverse events and inefficacy. 
Of these 24 patients 11 had started infliximab as monotherapy, seven used metho-
trexate, five used azathioprine and one used sulphasalazine as concomitant therapy. 
Of the 33 patients on infliximab and leflunomide five also used methotrexate and 
one also used hydroxychloroquine. Oral corticosteroids were used by five patients 
(46%) on infliximab monotherapy and by 13 patients (28%) on infliximab and con-
comitant DMARDs in the LEF group. No statistically significant differences in base-
line characteristics were found between patients on active leflunomide therapy and 
patients who had stopped leflunomide in the 6 months prior to start of infliximab.
The median duration of leflunomide treatment was 11 months (range 0-66 months) 
with a median dose of 20 mg/day (range 10-30 mg/day). In the 33 patients who used 
leflunomide during infliximab therapy 12 (36%) stopped leflunomide during inflix-
imab therapy (five for inefficacy and seven for adverse events) and three (9%) stopped 
leflunomide after infliximab therapy was discontinued (three adverse events). The 
median duration of leflunomide treatment during infliximab was 9 months (range 
2-32 months). 
In the non-LEF group 22 patients used infliximab as monotherapy. Concomitantly 
used DMARDs were methotrexate (n=62), sulphasalazine (n=19) and azathioprine 
(n=12), hydroxychloroquine (n=1) and parenteral gold (n=1). Oral corticosteroids 
were used by four patients (18%) on infliximab monotherapy and by 23 patients 
(24%) on infliximab and concomitant DMARDs in the non-LEF group.
infl iximab therapy
Mean infliximab dose at the start of therapy was 253 mg in the LEF group and 257 
mg in the non-LEF group. After 6 months of infliximab therapy two dosage increases 
and no interval reductions were seen in the LEF group, compared with seven dosage 
increases and four interval reductions in the non-LEF group. After 12 months of 
therapy 12 dosage increases and one interval reduction were seen in the LEF group, 
compared with 10 dosage increases and five interval reductions in the non-LEF 
group. Mean doses at 6 and 12 months were 262 mg and 317 mg every 8 weeks in the 
LEF group, and were 268 and 300mg every 8 weeks in the non-LEF group. Patients’ 
body weight did not differ between the two groups.
drug survival
Maximum follow-up time was 46 months in both groups. No difference in survival on 
drug was found between the two groups, as shown in figure 3.1A. Median survival 
time was 23 months in the LEF group and 25 months in the non-LEF group. After 
correction for differences in baseline variables also no differences in drug survival 
were seen. In separate drug survival analyses no differences between the two groups 
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could be shown for discontinuation of infliximab therapy due to inefficacy and due 
to adverse events (figures 3.1B and 3.1C). In secondary analyses drug survival was 
compared between patients on active leflunomide treatment at the start of inflix-
imab (active LEF group) and controls. No significant differences between the two 
groups were found, also after correction for differences in baseline characteristics.
Figure 3.1. Drug survival on infliximab. 
(A) Drug survival on infliximab for the LEF group and the non-LEF group. (B) Survival to drug  
discontinuation for inefficacy. (C) Survival to drug discontinuation for adverse events.
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disease activity
Disease activity over time, as measured by the DAS28, is shown in figure 3.2. No statis-
tically significant differences in disease activity over time were found between the 
groups, also after correction for possible confounding baseline differences. The 
response percentages for both groups at each time point are shown in figure 3.3. 
In the LEF group between 67 and 77% of the patients showed a response at any point 
in time, and in 14 to 44% of the patients the response was good, according to the 
EULAR criteria for response. In the non-LEF group between 63 and 75% of the 
patients showed a response at any point in time, and in 21 to 32% of the patients the 
response was good.
Figure 3.2. Disease activity (DAS28) over time
Figure 3.3. Response to treatment over time
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reasons for discontinuation
Table 3.2 shows the reasons for discontinuation of infliximab. In both groups the 
major reasons for discontinuation were adverse events. Inefficacy as a reason for dis-
continuation was reported equally in both groups. A small number of patients dis-
continued infliximab because of other reasons, like a desire for pregnancy, increased 
availability of etanercept and patient’s initiative.
Table 3.2. Reasons for discontinuation of infliximab
reasons for discontinuation, N (%) lEF group NoN-lEF group
 (N=57) (N=105)
Inefficacy 10 (1.5) 16 (15.2)
Adverse events 14  (24.6) 2 (2.6)
Other 4  (.0) 4 (3.)
All reasons 2  (4.1) 4 (46.6)
adverse events
The adverse events encountered are listed in table 3. In the LEF group 32 patients (56%) 
reported a total of 65 adverse events, of which seven were major events. In the non-
LEF group 61 patients (58%) reported 103 adverse events, of which 14 were reported 
as major. Major infection was reported once in the LEF group and nine times in the 
non-LEF group. In the LEF group one patient was hospitalized for a pneumonia and 
sepsis with Streptococcus pneumoniae. The major infections reported in the non-LEF 
group were four pneumonias (one pulmonary tuberculosis), one septic oligoarthritis 
(Staphylococcus aureus), one bacterial discitis with urosepsis (Escherichia coli), one 
perforated appendicitis, one infected leg ulcer and one patient with infected osteo-
synthetic materials. No malignancies were reported in the LEF group and two malig-
nancies were reported in the non-LEF group. One breast carcinoma with metastasis 
occurred during infliximab. Also, one leukaemia reaction with leucopenia was 
reported. Initially, a spontaneous recovery was seen after stopping infliximab, but 2 
yr later the patient developed acute myeloid leukaemia. In the LEF group six other 
serious adverse events were reported, as well as three in the non-LEF group (see 
table 3.3).
The most frequent minor adverse events reported in both groups were infections, 
infusion reactions, allergic reactions and dermatological conditions. A systemic lupus 
erythematosus (SLE)-like syndrome was reported in three patients in the LEF group 
only (two major adverse events). One major and five minor neurological events were 
reported, all in the non-LEF group. They included headache (n=2), one radicular syn-
drome (major adverse event), one peripheral nerve palsy, one optic neuritis and one 
demyelinating disease. The latter presented with peripheral nerve palsy and white 
matter lesions.
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Table 3.3. Adverse events
  lEF group NoN-lEF group
  (N=57) (N=105)
No. (%) of patients with adverse events 32 (56) 61 (5)
  
No. (%) of adverse events*  
Major adverse events  (10.) 14  (13.6)
 Infections 1 (1.5)   (.)
 Myocardial infarction 2 (3.1) 1  (1.0)
 SLE-like syndrome 2 (3.1) -
 Polymyositis -  1  (1.0)
 Malignancy -  2  (1.)
 Myalgia 1  (1.5) -
 Fatigue 1  (1.5) -
 Spinal stenosis -  1  (1.0)
Minor adverse events 5  (.3)   (6.4)
 Infections 20 (30.) 33  (32)
 Allergic/infusion reactions 1 (26.2) 26  (25.2)
 Dermatological conditions 12 (1.5) 12  (11.)
 Constitutional symptoms 2 (3.1) 1  (1.0)
 Cardiovascular 2 (3.1) 3  (2.)
 Neurological -  5  (4.)
 Laboratory abnormalities 2 (3.1) 3  (2.)
 SLE-like syndrome 1 (1.5) -
 Gastrointestinal -  3  (2.)
 Pulmonary -  2  (1.)
 Diabetes mellitus 1 (1.5) 1  (1.0)
 Gingival hyperplasia 1 (1.5) -
Total adverse events 65 (100) 103  (100)
*Percentage of total adverse events per group
anti-nuclear antibodies
ANA status at the start of infliximab therapy was available for 51 patients (90%) in the 
LEF group and 100 patients (95%) in the non-LEF group. ANA status during follow-up 
was available for 46 patients (81%) in the LEF group and for 79 patients (75%) in the 
non-LEF group. In the LEF group 24 patients (47%) were ANA positive at start and in 
the non-LEF group 38 patients (38%) were ANA positive at start of infliximab therapy.
Of the patients who were ANA negative at the start 70% in the LEF group and 65% 
in the non-LEF group converted to ANA positivity during infliximab therapy. Of these 
patients 70 and 82% respectively remained ANA positive throughout infliximab 
therapy in the LEF group and non-LEF group respectively. Of the patients who were 
ANA positive at the start 4% in the LEF group and 11% in the non-LEF group con-
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verted to ANA negative. The differences between the two groups in number of ANA-
positive patients at the start and during follow-up were not statistically significant 
(P=0.29, respectively P=0.18).
Overall, no differences in DAS28 over time were found between patients who were 
ANA positive and ANA negative at the start.
The estimated relative risks for ANA positivity at baseline of developing adverse 
events over the first year of follow-up were calculated and are shown in figure 3.4. 
For both treatment groups ANA positivity at baseline did not increase or decrease 
the risk for adverse events.
Furthermore, patients who converted to ANA positivity did not have a higher 
relative risk (RR) for adverse events [RR=0.83 (95%CI=0.29–2.37) in the LEF group, 
RR=1.32 (95%CI=0.74–2.35) in the non-LEF group].
Figure 3.4. Estimated relative risks of developing adverse events in the first year of follow-up 
for ANA positivity at start of infliximab.
Total AE's
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infl iximab monotherapy
A total of 33 out of 162 patients started infliximab without concomitant treatment 
with DMARDs, equally distributed between the LEF group and the non-LEF group (see 
results, DMARD treatment). No statistically significant differences were found in 
baseline characteristics, except for the mean prior number of DMARDs [4.7 (SD=1.7) 
in patients on monotherapy versus 3.9 (SD=17) in patients on concomitant DMARDs, 
P=0.03].
Forty-one adverse events (six major adverse events, were recorded in 20 of 33 
patients (61%) on monotherapy, compared with 130 (15 major) in 73 of 129 (57%) 
patients on concomitant treatment with DMARDs. No statistically significant 
differences were found in the number of patients experiencing adverse events 
(P=0.67) or in the number of adverse events per patient (P=0.56).
ANA conversion from negative to positive occurred in 77% of the patients on 
monotherapy and in 60% of the patients on concomitant treatment with DMARDs 
(P=0.22). Conversion from positive to negative occurred in 9% of the patients on 
monotherapy and in 8% of the patients on concomitant DMARDs (P=0.96).
d i s C u ss i o N
In this study the safety and efficacy of infliximab was investigated in patients with 
RA, who previously or concomitantly used leflunomide therapy, compared with 
patients treated with infliximab, either as monotherapy or in combination with 
other DMARDs. The results indicate that previous or concomitant leflunomide 
therapy in combination with infliximab is safe and effective for the treatment of 
RA patients in daily clinical practice.
We investigated the clinical consequences, in terms of survival on drug, efficacy 
and safety, of a possible interaction between infliximab and leflunomide. An inter-
action can take place in the period of active use of both drugs in combination, as well 
as during the elimination phase after withdrawal of one of the drugs. The active 
metabolite of leflunomide (A771726) has a relative long half-life of 15 to 18 days in 
RA patients [2], which results from low hepatic clearance and enterohepatic cycling. 
The standard deviation is 9 days (in a group of RA patients who received 25 mg/day 
in a phase II study) [20], indicating large differences in the duration of the elimina-
tion phase between individuals. In our analysis we included patients who stopped 
leflunomide in the 6 months prior to the start of infliximab into the LEF group in 
the study. Six months is approximately 10 times the mean halflife of A771726, after 
which only 0.1% of the original plasma concentration is present. To investigate the 
effect of the chosen group definition on the results a second analysis was performed 
including only patients who used leflunomide during infliximab therapy in the 
leflunomide group.
In this study the two treatment groups showed no statistically significant differ-
ences in baseline characteristics, although patients in the LEF group were more 
often RF positive and had used more DMARDs before starting infliximab therapy, 
both indicating a more severe course of the disease. The survival on drug was 
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comparable between both groups, with a median survival time of approximately 2 yr. 
Also, in the secondary analyses drug survival was comparable between groups.
The disease activity was comparable between the groups. In both groups the mean 
DAS28 showed a marked decrease after onset of infliximab therapy, which then 
remained more or less stable over the course of follow-up. Also, the response per-
centages observed were comparable for both groups. Both treatment groups showed 
variation in response over time, but overall no consequent pattern was seen.
The effects on disease activity in the LEF group are similar to the effects of a 32-
week open-label study with 20 RA patients [15]. All patients first started on leflunomide 
and shortly thereafter on infliximab. At start these patients had a very high disease 
activity, probably due to a washout period. The mean DAS28 dropped from 7.18 at the 
start to 5.18 at week 4 and remained between 3.85 and 4.85 throughout the study.
In a retrospective multicentre study with 88 RA patients who had received leflu-
nomide in combination with infliximab, Hansen et al. [14] also showed a marked 
decrease in disease activity parameters. Most patients had used leflunomide for 
several months before starting infliximab, as in our study. The authors did not 
present response measures because the data set was incomplete.
The reasons for discontinuation of infliximab reported in the present study were 
more often adverse events than inefficacy. These findings are in line with previous 
reports, although drug survival rates differ. Kiely et al. [15] reported 12 of 20 patients 
to have stopped combination therapy before 32 weeks because of adverse events, 
which consisted of skin reactions, infusion reactions, respiratory infections, diarrhoea, 
elevated liver enzymes, hypertension and mucosal ulceration, and were in some 
cases severe. Godinho et al. [13] retrospectively assessed the safety of the combination 
of leflunomide and infliximab in 17 RA patients. Adverse events were reported in 13 
(76%) patients. Eight patients (47%) stopped the combination therapy because they 
experienced adverse events before the fifth infusion. The adverse events that led to 
discontinuation included heart failure, hypertension with thoracic pain, eczematous 
patches and neutropenia. In all three patients with neutropenia white cell counts 
returned to normal after stopping leflunomide.
The retrospective data collection in one study and the small number of patients 
in both previous studies makes interpretation difficult. Furthermore, in the study 
by Kiely et al. patients started both drugs within a short period of time [15]. This 
could have contributed to the high number of adverse events, compared with the 
present study in which most patients had started leflunomide in the months or 
years before infliximab. They either tolerated the drug or had stopped using it in 
the 6 months prior to start of infliximab. It must be noted that in the present study 
adverse events were only reported if they were considered as clinically important by 
the treating rheumatologist.
In the study by Hansen et al. [14] 88 patients received infliximab in combination 
with leflunomide over an average of 6.6 months. Ten patients (11%) had discontinued 
infliximab therapy during the follow-up period, six (7%) because of adverse events. 
These findings are more in line with the survival rates in the present study than the 
studies reported above. In the present study 16% had discontinued infliximab after 
7 months, as shown in figure 3.1A.
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Major and minor adverse events were reported in equal percentages of patients in 
the two treatment groups, but the number of adverse events per patient was slightly 
higher in the LEF group. The most common minor adverse events were skin reac-
tions, infusion reactions and infections and were reported slightly more frequently 
in the LEF group. To our knowledge most adverse events in the present study have 
been reported previously during infliximab therapy [5, 10], with the exception of 
diabetes mellitus and gingival hyperplasia.
ANA are commonly found in RA patients and an increase in ANA-positive 
patients during infliximab treatment has been observed [13, 15, 21–23]. In previous 
reports no association of ANA has been found with the rate of discontinuation [21], 
the occurrence of adverse events [13] or loss of efficacy of infliximab [23].
In the present study no differences in DAS28 over time were found between 
patients who were ANA positive and ANA negative at the start of infliximab. Also, ANA 
positivity at baseline and conversion to ANA positivity during infliximab treatment 
were not associated with an increased risk for adverse events in either treatment 
group. For ANA conversion patient numbers were small and interpretation needs to 
be made with caution.
Combining DMARDs and biological therapies could increase treatment options 
and enhance treatment effect in clinical practice. The combination of infliximab with 
DMARDs other than methotrexate is of special interest, firstly because infliximab is 
an important new therapeutic option in RA treatment and secondly because mono-
therapy is not widely accepted as an option because of the possible problem of 
immunogenicity. Thirdly, not all patients tolerate or respond to methotrexate, 
which is the only DMARD investigated in combination with infliximab in randomized 
controlled trials.
The present study shows that previous or concomitant treatment with lefluno-
mide does not decrease the efficacy of infliximab therapy in RA patients. Further-
more, the safety data presented in this study are reassuring and show previous or 
concomitant treatment with leflunomide in combination with infliximab to be safe 
and well tolerated. The results indicate that infliximab is safe and efficacious after 
previous treatment with leflunomide and that the combination of infliximab and 
leflunomide is a valuable therapeutic option in RA.
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4 Infliximab titration based on response patterns
S
um
m
ary
objectives | To observe the course of the disease activity in rheumatoid arthritis 
(RA) patients treated with the standard infliximab dosing regimen and to adjust 
treatment guided by the pattern of disease activity.
Methods | All RA patients starting infliximab treatment were included and 
observed for at least 3 weeks. At infusion 4 (week 14), European League 
Against Rheumatism response was assessed. In moderate responders the 
dose was unchanged and the disease activity was carefully observed. In case of 
stable disease activity, the dose was increased at infusion 5 (week 22). In case 
of a temporary response the interval was reduced. Paired t-testing was applied 
to the disease activity score with 2-joint counts (DAS2) at week 22 and study 
endpoint.
results | A total of 6 patients were included. Response after 14 weeks: good 
22 (2%) patients, moderate 26 (34%) patients, and non-response in 21 patients. 
Seven patients (%) dropped out before week 14 due to adverse events (5) or 
patients’ initiative (2). In patients with moderate response, the following disease 
course between infusion 4 and 5 was observed: improvement to good response 
6, temporary response 6, stable disease activity 6, drop out . In moderate 
responders, interval reduction and dose increase resulted in a decrease in mean 
DAS2 from 5.1 to 3.6 [P=0.005, mean interval 5.6 weeks, mean infliximab dose 
4. mg/kg/ week (endpoint)] and from 4.1 to 3.6 [P=0.04, mean infliximab dose 
.3 mg/kg/ week (endpoint)], respectively.
Conclusion | Three different patterns of disease activity were observed in moder-
ate responders after 14 weeks of infliximab treatment, i.e. further improvement, 
no change in disease activity or a temporary response. Both interval reduction 
and dose increase significantly reduced disease activity, however, with different 
mean infliximab dosages. In good responders the response was often sustained 
over follow-up, whereas non-responders showed modest or no improvement 
despite dose adjustments.
62 TNF blocking therapy in RA
63
i N T r o d u CT i o N
Infliximab, a chimeric monoclonal antibody directed against tumour necrosis factor- 
(TNF), is efficacious in rheumatoid arthritis (RA) [1]. The recommended starting dose 
is 3 mg/kg, administered by intravenous infusion at weeks 0, 2 and 6 and every 8 weeks 
thereafter [2]. However, this dosage regimen seems to be insufficient in a subset of 
RA patients. In clinical practice, both dose increase (up to 10 mg/kg every 8 weeks) and 
interval reduction (to minimal 4 weeks) are being used [3–5].
At present no clear recommendations exist regarding the strategy that should 
be used in case of moderate or non-response. Previous studies have shown that dose 
titration as well as interval titration with TNF blocking agents can be used to achieve 
disease activity improvement in individual RA patients [6, 7]. A large variation in 
dosage as well as in time interval was shown in these studies in order to maintain 
low disease activity.
In this open-label study, we evaluated the course of the disease activity with a 
disease activity score with 28-joint counts (DAS28) and the European League Against 
Rheumatism (EULAR) response criteria in RA patients starting infliximab treatment. 
In addition to this, the effect of dose increase and interval reduction on the disease 
activity was investigated in those patients who had a moderate response after 22 
weeks. The decision to increase the dose or to reduce the interval was based on 
observations of the course of the DAS28 in the period between the 4th and 5th 
infusion.
paT i E N T s  a N d  M E T h o d s
study design
All consecutive patients with RA, according to the American College of Rheumatology 
(ACR) criteria [8], starting infliximab therapy between April 2002 and January 2004, 
were prospectively followed. According to the Dutch guidelines for biological thera-
pies, infliximab was started in RA patients with active disease (DAS28 ≥ 3.2) after 
treatment failure of at least two disease-modifying anti-rheumatic drugs (DMARDs), 
including methotrexate up to 25 mg/week.
Evaluations
At the start of infliximab treatment, the following data were collected: age, sex, 
disease duration, rheumatoid factor (RF) positivity, the number of previously used 
DMARDs and the use of concomitant DMARDs and systemic corticosteroids. Follow-up 
visits took place on each infusion day just prior to infusion; in moderate responders, 
additional visits were made at weeks 18 and 20 (between the 4th and 5th infusion). 
Disease activity was assessed at each visit, using the DAS28, which is a validated 
composite score of the erythrocyte sedimentation rate tender and swollen joint 
count and the visual analogue scale general health of the patient [9]. Treatment 
response was evaluated at week 14 (4th infusion), using the EULAR response criteria 
[10], dividing patients into good, moderate and non-responders. All patients were 
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followed for 38 weeks of infliximab treatment (37–41 weeks in patients who received 
an interval reduction). Reasons for discontinuation were recorded, if appropriate.
Treatment
Infliximab was started in the standard dosing regimen of 3 mg/kg body weight with 
infusions at week 0, 2, 6 and every 8 weeks thereafter. Doses were rounded off to 200 mg 
for patients with a body weight <70 kg and to 300 mg for patients of 70 kg or more.
Good responders. Infliximab was continued at 8-week intervals until week 38. If 
disease activity increased during follow-up, dose increases were possible after week 22.
Moderate responders. The dose was kept stable between week 14 (4th infusion) and 
week 22 (5th infusion). At week 22, infliximab treatment was tailored according to 
the course of the disease activity between weeks 14 and 22. Moderate responders 
with a stable disease activity in this period were assigned to the dose increase group 
in which the dose was increased to 6 mg/kg every 8 weeks. Prior to every upcoming 
infusion, disease activity was re-evaluated. If the DAS28 remained ≥ 3.2, the dose 
was further increased to 10 mg/kg/8 week. 
According to the flare criteria [6], patients received an interval reduction if the 
DAS28 showed, after an initial improvement, an increase of more than 1.2 points 
between weeks 14 and 22, or an increase of more than 0.6 points up to a value above 
5.1. (figure 4.1B). The new interval was calculated by subtracting 1 week from the week 
in which the patient flared. If the patient flared again despite the interval reduc-
tion, the interval was further reduced stepwise to a minimum of 4 weeks. To be eli-
gible for the tailored treatment protocol, patients were not allowed to have received 
changes in concomitant DMARDs within 6 weeks prior to baseline or changes in 
corticosteroids (oral or intramuscular) after week 8 of baseline until the end of the 
study.
Non-responders. The dose was increased to 6 mg/kg/8 week at week 14. Dose in-
creases up to 10 mg/kg/8 week were possible in case of a persisting non-response. 
Patients who stopped before week 38 because of inefficacy were considered non- 
responders.
statist ical  analysis
Normal distribution of the DAS28 was verified (Shapiro–Wilk’s statistic). Two-sided 
paired t-testing (P-value <0.05) was applied to the DAS28 at week 22 and at the end 
of the study for moderate responders in the dose increase group and in the interval 
reduction group. Analyses were done on an intention-to-treat basis. SPSS software 
was used for statistical analyses (version 11.0, SPSS inc., USA).
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Figure 4.1. Disease activity (DAS28) over time
Figure 4.1A: Mean DAS2 (SD) over time in patients with a good response and with a non- 
response at week 14. Figure 4.1B: Mean DAS2 (SD) over time in patients with a moderate  
response at week 14.
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r E s u lT s
A total of 76 RA patients started infliximab. Baseline characteristics were: mean age 
at start 55.7 yr [standard deviation (SD) 13.2], male sex 34%, median disease duration 
7.4 yr (range 1.0–35.8), RF positivity 82%, mean DAS28 5.4 (SD 1.1) and median number 
of prior used DMARDs three (range 2–8).
At the start of infliximab treatment, 67 patients (88%) used concomitant DMARDs, 
55 (72%) used one DMARD and 12 (16%) used two DMARDs. Nineteen patients (25%) 
used prednisolone with a median dose of 8 mg/day (range 5–15). Seven (9%) patients 
were on infliximab monotherapy. Figure 2 shows the study flowchart with patient 
distribution.
Figure 4.2. Study flowchart with patient distribution
*Endpoint between week 3 and 41 for patients receiving interval reduction. **AEs, adverse events. 
#Mean infliximab dose calculated per eight weeks. ##Three of 21 patients received a dose increase 
between weeks 22 and 3. $All 15 patients received a dose increase, three patients two dose  
increases and three patients interval reduction.
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response to treatment at  week 14
Twenty-two patients (29%) were good responders, 26 patients (34%) moderate 
responders and 21 patients (28%) were non-responders. Seven patients (9%) had 
stopped infliximab before week 14 [5 adverse events (AEs) and 2 patients’ initiative, 
see figure 4.2].
good responders
Twenty-one out of 22 were still on infliximab at the end of the study. Thirteen patients 
(59%) had remained in their good-responder status, seven patients (32%) had a moder-
ate response and one patient (5%) had changed into a non-responder, compared with 
baseline disease activity. One patient had discontinued infliximab because of an AE. 
Three patients had received a dose increase after week 14. No interval reductions 
were applied. The mean DAS28 was 4.9 (SD 0.9), 2.4 (SD 0.7) and 2.9 (SD 1.1) at base-
line, week 14 and week 38 (39% change to baseline DAS28), respectively (figure 4.1A). 
The mean infliximab dose had increased from 3.6 mg/kg/8 week at the start to 3.9 
mg/kg/8 week.
Concomitant therapy changes after week 14 in good responders. Concomitant DMARD 
therapy was reduced in four patients and stopped in three (one low disease activity 
and two AE). Oral prednisolone (median 6.5 mg/day at start, range 5–10) was reduced 
in three patients and stopped in one due to low disease activity. One patient received 
an intramuscular corticosteroid injection after an increase in disease activity.
Moderate responders
In the patients who were classified as moderate responders at week 14, three differ-
ent patterns of disease activity were observed in the period between week 14 and 22: 
(A) improvement to good response (n=6), (B) stable pattern of disease activity (n=6) and 
(C) flare of disease activity after an initial improvement (n=6) (figure 4.2). Eight patients 
dropped out between weeks 14 and 22: four protocol violation, three AEs, one patient 
initiative. In the remaining moderate responders, concomitant DMARD treatment 
(used by 15 patients) and prednisolone treatment (used by two patients, median 8 
mg/day, range 6-10) were kept stable throughout the study.
In patients who flared, the interval was reduced to 7 (n=1), 6 (n=3) and 5 weeks 
(n=3). One patient flared in the next interval and received a further interval reduction 
from 6 to 5 weeks. After reducing the interval, the DAS28 decreased by 1.5 (mean, SD 
0.7). The mean DAS28 was 5.1 (SD 1.0) at week 22 and 3.6 (SD 0.8) at the endpoint 
(P=0.005, compared with week 22). The mean interval was 5.6 weeks and the mean 
infliximab dose increased from 3.8 mg/kg/8 week at week 22 to 4.8 mg/kg/8 week at 
the endpoint.
In patients with a stable disease activity pattern, the dose was increased to 6 
mg/kg/8 week at week 22. Two patients received a further dose increase to 10 mg/
kg/8 week at week 30. The mean DAS28 was 4.1 (SD 0.7) at week 22 and 3.6 (SD 1.0) at 
the endpoint (P=0.04, compared with week 22). The mean infliximab dose had 
increased from 4.0 mg/kg/8 week at week 22 to 7.3 mg/kg/8 week at the endpoint.
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Patients who improved to good responders at week 22 remained good responders. 
The mean DAS28 was 2.7 (SD 0.4) at week 22 and 2.7 (SD 0.2) at week 38. No dose or 
interval adjustments were applied. The mean infliximab dose was 3.7 mg/kg/8 week.
Non-responders
At week 14, one patient was lost to follow-up and two patients stopped treatment 
due to inefficacy. All other patients received a dose increase. At the endpoint, 15 
patients had continued treatment and three patients had stopped due to inefficacy. 
Four patients had received a further dose increase and three patients had received an 
interval reduction. Five patients improved to moderate responders and 10 patients 
remained non-responders.
The DAS28 decreased by 0.4 (median, range -1.6 to 3.3). The mean DAS28 was 5.5 
(SD 1.2), 5.3 (SD 1.4) and 5.0 (SD 1.3) at baseline, week 14 and week 38 (9% change to 
baseline DAS28), respectively figure 4.1A). The mean infliximab dose had increased 
from 3.4 mg/kg at the start to 5.7 mg/kg/8 week. Concomitant therapy changes after 
week 14 in non-responders. Concomitant DMARD therapy was increased in two but, 
reduced in two patients because of side-effects and stopped in four (three inefficacy 
and one AE). Prednisolone dose (median 10 mg/day at start, range 5-15) was increased 
in two patients and started in one patient. Four patients received an intramuscular 
corticosteroid injection after week 14.
End of  study evaluations
Overall, at the study endpoint, 25 patients (33%) were good responders, 19 (25%) 
moderate and 18 (24%) were nonresponders (including five patients who had stopped 
due to inefficacy). Nine patients (12%) had stopped due to AEs and five (7%) due to 
other reasons. The AEs as reason for discontinuation were: two infusion reactions 
(patients on concomitant hydroxychloroquine and azathioprine, respectively), one 
drug-induced lupus erythematosus after 7 weeks of infliximab monotherapy [char-
acterized by anti-nuclear antibodies (ANA) and anti double-stranded DNA (anti-ds-
DNA) positivity, anaemia, thrombocytopaenia, polyarthritis and proteinuria), one 
urosepsis with suspicion of bacterial discitis, one radicular syndrome, one wound 
abscess, one papular skin eruption, one diarrhoea and one hypertension. Two of 
these patients were hospitalized (urosepsis and radicular syndrome).
d i s C u ss i o N
In the present study, disease activity was closely observed in RA patients starting 
infliximab treatment. After 14 weeks of treatment, 29% had a good response, 34% 
had a moderate response, 28% were non-responders and 9% had stopped treatment. 
In most good responders the response was sustained over follow-up. In moderate 
responders, remarkably three different patterns of disease activity were observed 
between the 4th and 5th infusion: (A) further improvement to good response, (B) a 
constant moderate pattern of disease activity and (C) a flare of disease activity after 
an initial improvement. Non-responders showed modest or no improvement despite 
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dose adjustments. The different response patterns seen in moderate responders might 
be explained by individual variations in pharmacokinetics of infliximab [11]. Serum 
trough concentrations of infliximab show large differences between individual 
patients and correlate with response [11, 12]. It has been hypothesized that patients 
who flare during the 8-weekly interval receive adequate therapeutic dosages, but 
eliminate infliximab more rapidly from the bloodstream than do patients with a 
constant response pattern.
Treatment adjustments of infliximab occur frequently in daily clinical practice 
[3, 4]. The rationale for dose increases up to 10 mg/kg/8 week was provided by the 
ATTRACT trial, in which part of the outcome measurements showed a dose-response 
relationship [1]. The pharmacokinetic modelling study of the ATTRACT data showed 
that interval reduction might be more effective in raising serum infliximab concen-
trations than dose increase [11]. At present, no randomized controlled trial has been 
conducted to investigate the benefit of these two options. 
In the present open-label study, infliximab treatment was tailored, guided by the 
observed disease activity patterns, in patients with a moderate response after 14 
weeks of treatment in an open-label trial setting. Interval reduction and dose increase, 
both resulted in a statistically significant reduction in disease activity (despite the 
small number of patients receiving the adjustments). The infliximab dose was 1.5-fold 
higher in patients receiving a dose increase than in patients receiving an interval 
reduction (after recalculation to 8-weekly intervals). Costs are estimated after dose 
increase on 3506 euro plus 316 euro (cost price for one administration in day care 
clinic) per 8 weeks in an average 70 kg patient (Dutch tariff 2003¼686 euro per 100 
mg infliximab). After the interval reduction, infliximab costs are 2305 euro plus 462 
euro for 1.5 administrations per 8 weeks. Furthermore, the observed efficacy was more 
pronounced in patients receiving an interval reduction, compared with patients 
receiving a dose increase. Although patient numbers are small, these findings are 
considered remarkable in the light of the high costs of infliximab treatment. 
However, the open-label setting of this study excludes a comparison between the 
treatment groups. Randomized clinical trials with larger patient numbers are needed 
to confirm the observed differences in moderate responders receiving dose increase 
or interval reduction. Such a trial should include a treatment group receiving the 
standard treatment without treatment adjustments, as delayed responses and regres-
sion to the mean of disease activity might occur.
The results of this study show that RA patients with an initial moderate response 
on infliximab later on show different patterns of disease activity, i.e. further improve-
ment, no change or a temporary response. Treatment adjustments show efficacy in all 
moderate responders, whereas non-responders often continue to have high disease 
activity despite treatment adjustments. The observed response was more pronounced 
in patients who received an interval reduction.
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S
um
m
ary
introduction | Various dermatological conditions have been reported during 
tumour necrosis factor alpha (TNF) blocking therapy, but until now no 
prospective studies have been focused on this aspect. The present study was 
set up to investigate the number and nature of clinically important dermato-
logical conditions during TNF blocking therapy in patients with rheumatoid 
arthritis (RA).
Methods | RA patients starting on TNF blocking therapy were prospectively 
followed up. The numbers and natures of dermatological events giving rise to 
a dermatological consultation were recorded. The patients with a dermato-
logical event were compared with a group of prospectively followed up RA 
control patients, naive to TNF blocking therapy and matched for follow-up 
period. 
results | 2 RA patients started TNF blocking therapy. 12 dermatological 
events were recorded in 2 patients (25%) during 11 patient-years of follow-up. 
TNF blocking therapy was stopped in 1 (26%) of these 2 patients because of 
the dermatological event. More of the RA patients given TNF blocking therapy 
(25%) than of the anti-TNF-naive patients (13%) visited a dermatologist during 
follow-up (P < 0.0005).
Events were recorded more often during active treatment (0.16 events per 
patient-year) than during the period of withdrawal of TNF blocking therapy 
(0.0 events per patient-year, P < 0.0005). The events recorded most frequently 
were skin infections (n = 33), eczema (n = 20), and drug-related eruptions (n =15). 
Other events with a possible relation to TNF blocking therapy included vasculitis, 
psoriasis, drug-induced systemic lupus erythematosus, dermatomyositis, and 
a lymphomatoid-papulosis-like eruption. 
Conclusion | This study is the first large prospective study focusing on derma-
tological conditions during TNF blocking therapy. It shows that dermatological 
conditions are a significant and clinically important problem in RA patients 
receiving TNF blocking therapy.
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i N T r o d u CT i o N
The introduction of biological agents such as TNF blocking agents has dramati-
cally changed the therapeutic approach to rheumatic diseases in recent years. TNF 
blocking therapy has had a remarkable effect on disease activity in an increasing 
number of rheumatic diseases, including rheumatoid arthritis (RA) [1-3], juvenile 
idiopathic arthritis [4], ankylosing spondylitis [5,6], and psoriatic arthritis [7]. At 
present, two monoclonal anti-TNF antibodies (infliximab and adalimumab) and one 
soluble p75 TNF receptor (etanercept) are being used in rheumatological practice.
Various skin conditions have been reported in clinical trials, including urticaria, 
rash, and stomatitis (during infliximab therapy) [8]; rash and injection-site reactions 
(during adalimumab therapy) [3,9]; and injection-site reactions (during etanercept 
therapy) [2].
However, clinical trials are not designed to provide information about the occur-
rence of rare adverse events associated with TNF blocking therapy. More severe 
cutaneous reactions, such as erythema multiforme, discoid and subacute cutaneous 
lupus erythematosus, atopic dermatitis, necrotizing vasculitis, and bullous skin 
lesions, have been reported, mostly as singlecase observations [10-15]. 
Larger observational studies such as biological registries are needed to provide 
information on the nature and number of such dermatological adverse events 
during TNF blocking therapy. The aim of this study was to investigate whether 
dermatological conditions after TNF blocking therapy are a significant and clini-
cally important problem in RA patients receiving TNF blocking therapy.
M aT E r i a l s  a N d  M E T h o d s
study design
In a prospective cohort study, all consecutive patients with a diagnosis of RA according 
to the criteria of the American Rheumatism Association [16] who were starting on 
TNF blocking therapy at the Department of Rheumatology at the Radboud Univer-
sity Nijmegen Medical Centre were followed as part of a Biological Registry [17]. 
Approval was obtained by the hospital’s ethics committee.
Patients were required to meet the criteria set out in the Dutch guidelines for 
biological therapies: a moderate to high disease activity score (DAS) based on 28 joints 
(DAS28 ≥ 3.2), and failure or intolerability of at least two disease-modifying anti-
rheumatic drugs (DMARDs), including methotrexate, in adequate dosage regimens. 
Besides therapy with registrated TNF blocking agents – infliximab, etanercept, and 
adalimumab – some patients were treated in clinical trials with lenercept, a soluble 
p55 TNF-receptor [18].
The number and nature of dermatological conditions that led patients in this 
cohort to consult a dermatologist during follow-up were investigated. The RA patients 
treated with TNA--blocking agents who experienced dermatological events were 
compared with a control group of patients who had RA but had never had TNF 
blocking therapy. The control patients were selected from the Nijmegen inception 
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cohort, in which 500 RA patients have been followed since 1985 [19]. Each control 
was paired with a anti-TNF-treated patient for duration and season of the follow-
up period, within a 2-month window.
variables
Data collected at the start of TNF blocking therapy were age, sex, duration of 
disease, presence or absence of rheumatoid factor (measured by ELISA; considered 
positive if results showed >10 IU/ml), antinuclear antibody (tested for by immuno-
fluorescence on Hep-2 cells), number of DMARDs previously used, and start date of 
TNF blocking therapy. Baseline information obtained included erythrocyte sedimen-
tation rate (ESR), 28-joint counts for swelling and tenderness, and general wellbeing 
as indicated on a visual analogue scale, and the disease activity score (DAS28) was 
calculated [20].
Variables about which information was collected during TNF blocking therapy 
were the use of concomitant DMARDs and prednisolone, dose and interval changes 
of TNF blocking agents and, if appropriate, date and reason for discontinuation. 
All patients who visited a dermatologist during follow-up were identified. Clinically 
important dermatological events were defined as any new manifestation or any 
exacerbation of pre-existing skin disease during follow-up. A standardized chart 
review form was used to record the following: start date of event, dermatological 
history, medication, morphological description, localization, histopathological and 
immunohistological information if available, working diagnosis, additional investi-
gations, topical and systemic therapeutic actions, outcome of event, and any available 
information on rechallenge.
Drug-related eruptions were defined as skin reactions with a probable or definite 
relation to the use of TNF blocking agents, based on a time relation with the admin-
istration of the agent, morphological pattern, and/or histological information. 
Drug-related eruptions were classified morphologically according to the criteria of 
Fitzpatrick and colleagues [21]. Events were also classified as major or minor, major 
events being any requiring hospitalization.
Patient-years of follow-up were calculated for total follow-up, time on active 
therapy, and time after discontinuation of therapy (time off therapy). The number 
of events per year of follow-up was calculated for each RA patient for total time of 
follow-up, time on active treatment, and time off treatment, if appropriate.
In the control group, the following baseline characteristics were collected: age, 
sex, disease duration, rheumatoid factor, antinuclear antibody, DAS28, the number 
of DMARDs previously used, and prednisolone use. All visits to a dermatologist 
during follow-up were identified. Events were not recorded in the control group.
statist ical  analyses
The baseline characteristics of RA patients on TNF blocking therapy were compared 
according to whether or not the patients experienced dermatological events. The 
chi-square test was applied for dichotomous variables and Student’s t-test was used 
for continuous variables. Nonparametric tests were applied when appropriate. The 
Wilcoxon signed rank test was used to compare the number of events per patient-
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year of follow-up in patients receiving and patients not receiving active TNF blocking 
therapy.
Univariate and multivariate logistic regression analyses were performed to iden-
tify possible predictive factors for the occurrence of a dermatological visit (indepen-
dent variable, dichotomous) in RA patients on TNF blocking therapy. Dependent 
variables tested were sex, age at diagnosis, rheumatoid factor, antinuclear antibody, 
disease duration, DAS28 at baseline, prior number of DMARDs, use of prednisolone, 
and duration of follow-up. Odds ratios (ORs) and 95% confidence intervals (95% CIs) 
were calculated.
The number of patients who visited a dermatologist was compared between RA 
patients on TNF blocking therapy and controls, using the chi-square test. P values 
and ORs were calculated.
All tests were two-sided, with P < 0.05 considered statistically significant. Statistical 
analyses were performed using SPSS statistical software (v 12.0.1, SPSS Inc, USA).
r E s u lT s
patients
A total of 289 RA patients started TNF blocking therapy between June 1994 and 
December 2003. Their baseline characteristics are shown in table 5.1.
The median follow-up time was 2.3 years (range 0.02 to 9.6). The total follow-up 
time was 911 patient-years, with 627 patient-years representing active therapy. 
Table 5.1. Baseline characteristics of patients with rheumatoid arthritis (RA) studied
 given TNF blocking therapy Controlsa
 all patients patients with
  dermatological events
 N=289 N=72 N=289
Male sex, n (%)  (31) 20 (2) 110 (3)
Age (yr) at diagnosis, mean (SD) 44.5 (14.) 43.4 (12.) 54.6 (14.1)**
RF positive, n (%) 24 () 6 (4) 205 (1)*
Disease duration (yr) at baseline,  .2 (0.1-44.) 10.3 (0.3-44.)$ 6.2 (0.0-12.6)**
median (range)
DAS2 at baseline, mean (SD) 5. (1.1) 6.1 (1.1) 3.6 (1.4)**
ANA positive at baseline, n (%)b 112 (50) 33 (4) 11 (41)
Prior DMARDs, median (range) 4 (1-10) 5 (2-) 1 (0-6)**
Prednisolone at baseline, n (%) 112 (3) 34 (4) 21 ()**
aNot given TNF blocking therapy. b ANA at start was present in respectively 261 and 6 patients  
on TNF blocking therapy. *P < 0.001, **P <0.0001, compared with RA patients on TNF blocking 
therapy; $P < 0.001 compared with RA patients on TNF blocking therapy who experienced no 
dermatological events. 
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Seventy of the 289 RA patients (24%) received more than one TNF blocking agent 
and 8 (3%) received more than two agents. Infliximab was administered to 167 
patients, adalimumab to 108, etanercept to 78, and lenercept to 31.
Dermatological events were recorded in 72 of the 289 RA patients (25%) receiving 
TNF blocking therapy and in 37 (13%) of the control group (n = 289). The odds ratio 
(OR) of TNF blocking therapy for a dermatological referral was 2.26 (95%CI 1.46 to 3.50, 
P < 0.0005). Dermatological history of patients on TNF blocking therapy consisted of 
fifty-six instances of dermatological conditions recorded in 34 patients (47%) and 
included, among others, 10 drug reactions – while the patient was receiving gold (7), 
nonsteroidal anti-inflammatory drugs (2), or methotrexate (1) – 10 cases of eczema, 
9 of mycosis, 3 of other infections, and 5 of chronic venous insufficiency.
predictive factors
In univariate analyses, duration of follow-up (OR 1.27, 95%CI 1.14 to 1.41, P < 0.0005) 
and of disease (OR 1.03, 95%CI 1.003 to 1.07, P < 0.05) were statistically significant 
predictive factors for a dermatological event. In a multivariate model, only duration 
of follow-up was a statistically significant predictive factor (OR 1.30, 95%CI 1.12 to 
1.52, P < 0.001).
dermatological  events
One hundred and twenty-eight dermatological events were recorded during follow-
up in RA patients on TNF blocking therapy (0.14 event per patient-year), as listed in 
table 5.2. The event per patient-year ratio was 0.16 during active treatment and 0.10 
off treatment (P < 0.001). The number of events recorded during or after treatment 
was 56 for adalimumab (0.12 event per patient-year), 49 for infliximab (0.14 per 
patient-year), 16 for etanercept (0.13 per patient-year), and 13 for lenercept (0.07 per 
patient-year). TNF blocking therapy was permanently withdrawn because of der-
matological events 21 times in 19 patients.
infections
Thirty-three infections were recorded in 27 patients, consisting of 20 fungal, 11 bac-
terial, and 2 viral infections (see table 5.3). Two patients had had a previous episode 
of dermatomycosis. None of the patients required hospitalization. One patient, who 
temporarily discontinued adalimumab monotherapy twice because of elective 
surgery, developed a bacterial superinfection of pre-existing eczema after every restart.
Eczema
Eczema was diagnosed 20 times in 19 patients and appeared in various morphological 
patterns. Most events were described as erythematosquamous (n = 8) or erythematous 
(n = 3) lesions or plaques, localized on hands and feet (n = 3), arms and legs (n = 5), 
face (n = 1), neck (n = 1), and buttocks (n = 1). A vesicular rash on hands and feet was 
described five times. A papular rash was described in three cases, with localization 
around the eyes, on the back, and once on the back and lower legs. Diagnoses com-
prised dyshidrotic (n = 5), contact (n = 4), nummular (n = 1), atopic (n = 1), papular 
(n = 1), and nonspecific eczema (n = 8). Two patients had a prior history of dyshidrotic 
eczema.
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Biopsies were performed in five events. Histology showed dermatitis and spongiosis in 
all cases, with high dermal perivascular infiltration in three. One biopsy also showed 
mild psoriasiform acanthosis and another showed additional keratinocyte necrosis.
Three patients stopped TNF blocking therapy because of the dermatological 
event, after which the lesions resolved. Hospitalization was necessary for treatment 
of eczema in one patient. In another patient the eczematous lesions recurred after 
adalimumab therapy was restarted. Adalimumab was continued and topical steroids 
were applied with good effect. TNF blocking therapy had already been stopped in 
4 patients before the onset of eczema and was continued in 13 patients, of whom 7 
had persisting or recurring lesions. Therapy consisted mostly of topical corticoste-
roids.
drug-related eruptions
Drug-related eruptions occurred frequently during the first 5 months of TNF blocking 
therapy and were caused by all four TNF blocking agents (see table 5.4). In two cases, 
a generalized drug-related eruption followed subcutaneous injection of etanercept. 
In two cases, the eruption developed during infusion (patient numbers 8 and 11, 
table 5.4). In the other cases the time of onset ranged between 2 and 57 days after 
the most recent infusion.
Most drug-related eruptions consisted of a combination of morphological patterns, 
including exanthema, urticarial eruptions, lichenoid skin lesions, and purpura. In 
four patients, an eczematous drug-related eruption was seen. Classification as drug-
related eruption was based on a time relation with administration of the TNF 
blocking agent, the morphological pattern, and/or histological information. Two 
patients had experienced a previous drug-induced eruption (1 dermatitis in response 
to gold, 1 dermatitis after indomethacin). The histological findings were compatible 
with the diagnosis in all cases. Perivascular infiltrations – predominantly lympho-
cytic – epidermal exocytosis, and hyperorthokeratosis were described. Interface 
dermatitis was described in three instances. One biopsy revealed focal infiltrations 
with marked vascular and endothelial proliferation. 
Seven patients stopped and 8 patients continued therapy; 6 of them had a positive 
rechallenge and recurring lesions. One major event was recorded: an RA patient was 
hospitalized for an extensive eczematous eruption with urticaria on arms and legs 
(figure 5.1, and Patient no. 6 in table 5.4). Treatment consisted mostly of topical 
application of corticosteroids and sometimes of systemic antihistamines.
Tumours and actinic  keratosis
Events of skin malignancies were recorded five times, in four patients. One RA patient 
developed three basal cell carcinomas simultaneously on her left arm, right nostril, 
and right eyelid after 2.7 years of adalimumab therapy, which was subsequently 
stopped. One 74-year-old RA patient developed Bowen’s disease on his right hand 2 
years after adalimumab therapy had been stopped. The same patient later developed 
a squamous cell carcinoma on the left earlobe after the start of etanercept therapy. 
Other skin malignancies recorded were a squamous cell carcinoma (earlobe) after 
1.5 months of adalimumab therapy and a low-grade basalioma (Pinkus epithelioma) 
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Figure 5.1. Drug-related eczematous eruption 
Eczematous drug-related eruption a patient with rheumatoid arthritis after infliximab 
therapy: Eczematous eruptions on the left arm (A) and right arm (B) and erythematous 
eruptions with purpura on the left leg (C) and right leg (D).
on the leg after 6 months of adalimumab therapy. In all cases, histology confirmed 
the diagnosis and therapy consisted of excision. No recurrences were seen.
Actinic keratosis was recorded in five patients (three receiving adalimumab, one 
infliximab, and one lenercept). Excision or cryotherapy was successful in four. One 
patient had recurring actinic lesions on the scalp.
Benign tumours were recorded seven times during TNF blocking therapy. One 
patient experienced an increased growth of a facial telangiectatic nevus, present 
since childhood, 2 months after starting etanercept therapy. Seborrhoic keratosis 
(n = 3), oral hyperkeratosis (n = 1), histiocytoma (n = 1), and fibroma (n = 1) were also 
recorded.
vasculit is
Vasculitis was recorded five times: four during and one after cessation of TNF 
blocking therapy. The diagnosis was confirmed by biopsy in four cases. One patient 
developed a superficial necrotizing leukocytoclastic vasculitis with ulceration after 
7 months of infliximab therapy, with complete recovery after discontinuation of 
infliximab. One patient developed a papular erythema in the groins after 5 years of 
adalimumab therapy. Histological examination was compatible with vasculitis with 
infiltration of mononuclear cells and presence of eosinophilic granulocytes. One 
patient developed a purpuric vasculitis on the legs after 1.5 months of lenercept 
therapy, improving spontaneously despite continuation of lenercept. One patient 
developed isolated digital vasculitis on his toes after one year of adalimumab therapy, 
which was continued. The lesions persisted. No biopsy was performed. One patient 
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developed a generalized urticarial exanthema after therapy with etanercept 2 years 
earlier. Current therapy consisted of hydroxychloroquine and prednisolone. Histology 
showed a mild leukocytoclastic vasculitis.
ulcers
The nine events with ulcers included four pressure ulcers, two ulcers due to depen-
dency edema, one traumatic ulcer, one ulcer secondary to an unguis incarnatus, 
and one ulcer without further specification. Biopsies were taken in two patients, but 
no signs of vasculitis were found. A patient had a pressure ulcer with secondary infec-
tion and a fistula on his ankle, which contained osteosynthetic material. The patient 
was admitted to the hospital for intravenous antibiotic therapy and infliximab was 
stopped for several months. After recovery, the patient restarted infliximab without 
recurrence of his skin problems. TNF blocking therapy was continued in the other 
eight patients, and in four of these the ulcers recovered; follow-up was missing in 
the other four.
stasis dermatitis, edema, varices and chronic venous insufficiency
In 10 patients, a dermatological consultation was recorded for stasis dermatitis (n = 3), 
edema (n = 3), varices (n = 2), or chronic venous insufficiency (n = 2). In one patient 
with extensive varices, infliximab therapy was stopped temporarily because of a com-
plicating thrombophlebitis. One patient had edema of both legs of unknown cause, 
with livid discoloration and induration. One patient had lymphedema secondary to 
RA. All other events were considered to be related to comorbidity, other than RA.
psoriasis and psoriasiform eruptions
Psoriatic or psoriasiform eruptions were recorded in three RA patients. One devel-
oped a vesiculopustular erythematosquamous rash on hands and feet after 9 months 
of adalimumab therapy. Histology showed a mixed psoriasiform and spongiotic 
dermatitis. A second RA patient developed psoriasis guttata-like eruptions on her 
lower legs after 4 years of therapy with adalimumab. The lesions diminished after 
adalimumab was withdrawn. A third patient developed a psoriasiform eruption on 
arms and legs after 16 months of adalimumab therapy. Histology obtained in the 
latter two patients was consistent with psoriasis.
other dermatological  condit ions
Other dermatological conditions that occurred during or after TNF blocking therapy 
included, among others, dermatomyositis (1), drug-induced systemic lupus erythemato-
sus (1), and lymphomatoid papulosis-like eruption (1). Details are shown in table 5.5.
One RA patient developed a macular rash on the inner sides of the upper arms and 
legs after 2.5 months of lenercept monotherapy. A skin biopsy showed a nonspecific 
chronic dermatitis. A soft-tissue biopsy, including skin, fascia and muscle, showed 
fascial and muscular infiltration, consistent with dermatomyositis.
One RA patient developed a drug-induced systemic lupus erythematosus after 
20 months of infliximab therapy in combination with methotrexate, consisting of 
discoid lupus erythematosus lesions on her hands and scalp, aphthous lesions, con-
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version to antinuclear antibody positivity, and a positive anti-double stranded-DNA 
(titre 60 U/L). The skin lesions flared within one week after infusion and disappeared 
after discontinuation of infliximab.
A third RA patient developed macular erythematosquamous lesions on her lower 
arms, upper legs and trunk after 2.6 months of adalimumab monotherapy. Histology 
showed a dermal infiltration with CD30-positive atypical T cells. Although the lesions 
appeared to be lymphomatoid papulosis, they completely disappeared within 6 weeks. 
Adalimumab was not stopped. This patient developed a large-cell anaplastic non-
Hodgkin lymphoma 2 years later.
d i s C u ss i o N
The present study is the first large prospective study focusing on dermatological 
conditions in RA patients on TNF blocking therapy. Of the patients studied, 25% 
needed a dermatological consultation, compared with 13% in a RA control group, 
naive to TNF blocking therapy. The number of dermatological events per patient-
year was significantly higher during treatment than after treatment with TNF 
blocking therapy. Dermatological events led to withdrawal of TNF blocking therapy 
in 19 patients of 72 patients (26%). The events recorded most frequently were skin 
infections, eczema, and drug-related eruptions. Some other interesting events were 
recorded, such as psoriasis, drug-induced systemic lupus erythematosus, dermato-
myositis, and a lymphomatoid papulosis like eruption.
RA is known to be associated with dermatological conditions such as vasculitis, 
nodulosis, palmar erythema, and bullous pemphigoid, among others [22,23]. At present, 
information on the incidence and prevalence of dermatological conditions in RA 
mainly originates from cross-sectional or retrospective studies [24-26]. Few prospective 
studies have been conducted focusing on specific conditions affecting the skin [27,28].
In establishing a relation between the use of a drug and the occurrence of derma-
tological conditions, various factors must be considered. Information on clinical 
and histological patterns, time and dose relation, dechallenge and rechallenge, and 
analogy with previously reported cases can provide support in assessing the plausi-
bility of such a relation [29]. The underlying disease and concomitant medication 
also need careful consideration, as they can provide alternative explanations.
In this study the largest group of dermatological events consisted of skin infec-
tions, mostly fungal infections and folliculitis. The use of TNF blocking therapy 
has raised concerns regarding an increased susceptibility to infections, as TNF 
plays an important role in host-defence mechanisms [30]. An increased incidence of 
tuberculosis has been described [31], as well as a growing number of serious infec-
tions with fungal, mycobacterial, and intracellular bacterial pathogens [32-34]. 
Infections of the skin have not been the subject of report in clinical trials and obser-
vational studies with TNF blocking therapy. Cases of severe necrotizing fasciitis 
have been described [35,36].
 Skin infections have been reported frequently in the normal population and 
especially in RA patients [24-26]. Host defence impairments resulting from the 
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underlying disease might play a role in an increased susceptibility to skin infections 
in RA patients, as well as the use of corticosteroids and DMARDs such as metho-
trexate [28,37], which were recorded frequently in the present study (see table 5.2). 
They could provide an alternative explanation for the occurrence of skin infec-
tions.
However, most infections occurred during active treatment with TNF blocking 
therapy, a finding that could suggest at least a relative contribution to an increased 
vulnerability to skin infections in the study population. In one patient, a bacterial 
superinfection of eczema occurred twice immediately after restart of adalimumab, 
showing a clear time relation.
 For the description of the recorded drug-related eruptions, a clinico-morphological 
classification was chosen [21]. Four eruptions with a time relation and clinically or 
histological distinct drug-induced patterns also showed an eczematous appearance, 
both clinically and histologically. This is an unusual presentation for a drug-induced 
eruption and warrants further investigation.
Two drug-related eruptions occurred during infusion with infliximab or adalim-
umab, whereas all the others occurred after infusion. This will most likely not reflect 
the true ratio between acute and delayed reactions involving the skin, since acute 
reactions with skin involvement occur in 4% of the infusions and are usually treated 
by the rheumatologist without dermatological consultation [38].
Eczema was reported frequently in this study, even with various dermatitis condi-
tions, such as xerosis cutis, stasis eczema, and seborrhoic eczema, classified as sepa-
rate entities. Previous studies have reported RA, in which Th1 (T helper cell type 1) 
immune responses dominate, to be negatively associated with Th2-cell-mediated 
atopic disorders, such as eczema [39-41], although a similar incidence of eczema in 
RA and non-RA patients has also been reported [42]. TNF blocking therapy down-
regulates Th1 immune responses [43], which might induce a shift of the Th1/Th2 
balance towards Th2-dominated immune responses and which might promote an 
increased susceptibility to atopic disorders, such as eczema.
Although the time between the initiation of TNF blocking therapy and the onset 
of dermatological conditions varied, a probable relation was seen in various events. 
These included, besides drug-related eruptions, events of cutaneous vasculitis, drug-
induced systemic lupus erythematosus, dermatomyositis, and a lymphomatoid papu-
losis-like eruption.
An association between the use of TNF blocking therapy and the induction of 
systemic lupus erythematosus and discoid lupus erythematosus is strongly suggested 
by the number of cases that have been published [10,11,13,44-46]. One case of discoid 
lupus erythematosus has been described on both etanercept and infliximab in the 
same RA patient [47].
Analogy with previous reports is also present for cutaneous vasculitis [13,47-49], 
although it is a known extra-articular manifestation of RA [22,23]. In the first case 
described, a probable relation with infliximab was present, based on the time rela-
tion and positive dechallenge. The other cases described were considered possibly 
related (Results section, Vaculitis, cases 2 and 3) and unlikely (cases 4 and 5). Almost 
all reported ulcers were considered secondary to other causes, as described.
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Dermatomyositis has been reported previously, although the patient affected in 
that case had a different presentation, with raised creatinine phosphokinase, muscle 
atrophy, mechanic’s hands, and vasculitis [17].
Another interesting finding was the occurrence of psoriasiform eruptions in three 
patients on TNF blocking therapy. This observation is particularly interesting, 
since etanercept has received and infliximab is close to receiving FDA approval for 
treatment of psoriasis, after remarkable efficacy results in clinical trials [7,50,51]. 
The occurrence of guttate psoriasis has been reported after initiation of etanercept 
therapy for psoriasis in a placebo-controlled trial [51]. Another case report described 
the occurrence of psoriasiform eruptions with histologically a lichenoid dermatitis 
pattern in a patient with Crohn’s disease [52].
An exacerbation of psoriasis was also seen in a patient with psoriatic arthritis 
receiving infliximab therapy. An additional analysis showed that 28 patients with 
various non-RA rheumatic diseases, including 12 juvenile idiopathic arthritis, 
6 psoriatic arthritis, and 3 ankylosing spondylitis, had been treated with TNF 
blocking therapy in the study centre. Five patients (18%) had visited a dermatologist 
for a dermatological condition during or after TNF blocking therapy. The events 
included a drug-related eruption, eczema, and a facial mycosis in three patients 
with juvenile idiopathic arthritis and a superficial spreading melanoma in a patient 
with ankylosing spondylitis. This indicates that the occurrence of dermatological 
events during TNF blocking therapy is not restricted to RA patients.
In the present study the control patients were matched for startdate and duration 
of follow-up period in order to control for time-related effects. A statistically significant 
relation between the use of TNF blocking therapy and the occurrence of dermato-
logical visits was shown. The two groups studied differed for most baseline charac-
teristics. These differences result from the indication for TNF blocking agents, 
which were reserved for patients who fulfilled criteria for active disease and DMARD 
failure (see methods section; study design), had a longer disease duration, and 
whose disease was perhaps more refractory.
However, it is considered unlikely that these factors influenced the relation 
between the use of TNF blocking therapy and dermatological visits. In a multivariate 
regression model, no baseline characteristic showed a predictive value for the occur-
rence of a dermatological event in RA patients on TNF blocking therapy. Also, a statis-
tically significantly higher number of dermatological events was recorded during active 
treatment with TNF blocking therapy than after the therapy had been stopped.
C o N C lu s i o N
This is the first prospective study showing a relation between TNF blocking therapy 
and the occurrence of dermatological conditions. Future prospective studies are 
needed to investigate the incidence and the pathogenesis of the encountered events, 
because they are a clinically significant problem in RA patients receiving TNF 
blocking therapy.
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6 Psoriasis and TNF blocking therapy
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Tumour necrosis factor alpha (TNF) blocking agents are used for the treatment 
of chronic inflammatory diseases, like psoriasis, rheumatoid arthritis (RA), 
Crohn’s disease (CD) and psoriatic arthritis (PsA). Three TNF blocking agents, 
adalimumab, infliximab and etanercept, have currently been registered for treat-
ment of moderate to severe plaque psoriasis after showing promising results 
in clinical trials. Interestingly, several cases of new onset psoriasis have been 
reported in the post-marketing phase. This case series describes the de novo 
development of psoriasiform skin lesions in 5 RA patients using TNF blocking 
agents. Furthermore we review the literature concerning 110 published cases of 
patients developing psoriasiform lesions after TNF blocking therapy. Most cases 
developed plaque psoriasis or psoriasis pustulosa palmoplantaris. Histology was 
consistent with psoriasis in 42 of 4 cases (6%).
The substantial number of cases with temporal associations and the positive 
rechallenge in some cases represent strong evidence for a relationship between 
the use of TNF blocking therapy and the development of psoriasiform skin 
disease. Furthermore, a class effect is suggested by recurrence of these lesions 
after switching to other TNF blocking agents. Immediate withdrawal of TNF 
blocking agents does not seem mandatory, but is associated with a higher 
improvement rate. Future studies are needed to gain insight in the pathogenic 
mechanisms having a role in TNF blocking therapy induced psoriasis.
2 TNF blocking therapy in RA
3
i N T r o d u CT i o N
Tumour necrosis factor alpha (TNF) blocking agents have proven important new 
therapeutic options in chronic inflammatory diseases, like psoriasis, rheumatoid 
arthritis (RA), Crohn’s disease (CD) and psoriatic arthritis (PsA), amongst others [1,2]. 
Currently three TNF blocking agents (adalimumab and infliximab, both mono-
clonal antibodies, and etanercept, a soluble TNF receptor) have been registered for 
treatment of moderate to severe plaque psoriasis, after showing promising results 
in clinical trials [3-5].
Interestingly, the occurrence of new onset psoriasiform lesions and (pustular) 
psoriasis after initiation of TNF blocking agents in RA patients has recently been 
described in several case reports [6-32]. Exacerbation of psoriasis during clinical trials 
has also been reported [13,15]. 
We describe five cases of new onset psoriasis in a cohort of 492 prospectively 
followed patients with RA on TNF blocking agents and review the literature on 
this intriguing and paradoxal subject, as TNF blocking agents have shown to be 
effective in reducing moderate to severe plaque psoriasis [12].
M E T h o d s
The patients described in this case series were part of a longitudinal observational 
cohort study with RA patients starting on TNF blocking agents, currently including 
492 patients [12]. Adverse events were collected every three months in a standardized 
fashion. Cases one to four were referred to a dermatologist for further evaluation. 
Case five was retrospectively reviewed by the authors.
For the literature review articles were collected systematically. The Pubmed medline 
database was searched using a query combining a search string for psoriasis (psoria* 
OR palmoplanta*) with a search string for TNF blocking agents (tumor necrosis 
factor OR tumour necrosis factor OR infliximab OR adalimumab OR etanercept OR 
anti-tumour necrosis factor OR anti-tumor necrosis factor OR TNF OR anti-TNF). The 
results were limited to publications after 1993 and in English, and were further 
specified by narrowing the query to citations including the terms: (onset OR induc* 
OR trigger* OR occur* [ti] OR develop* [ti]). Abstracts of retrieved citations were explored 
for cases describing the development of psoriasis or psoriasiform skin disease during 
TNF. Additionally the references of retrieved articles were searched for missed cases.
o b s E r vaT i o N s
Case 1 
A 68-year old female RA patient developed guttate psoriasis after 4 years of adalimumab 
therapy. She had a rheumatoid factor (RF) negative non-erosive RA since 22 years, 
secondary osteoporosis and hypertension. Personal and family history was negative 
for psoriasis. The patient was treated with adalimumab in a randomized clinical trial, 
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after treatment failure to various disease modifying anti-rheumatic drugs (DMARDs). 
Other medication included butazolidin, calcium, omeprazole and atenolol.
During a period with recurrent urinary tract infections, vaginal candidiasis and 
sinusitis she developed an erythematosquamous rash with papules and plaques on 
her legs, trunk and lower arms, with a larger plaque around her umbilicus (figure 
6.1a). Histology from a skin biopsy of her lower leg was consistent with the diagnosis 
papular eczema. Adalimumab was restarted and the lesions improved after treatment 
with topical steroids. 
One year later she developed an erythematosquamous rash on the anterior side 
of her lower legs (figure 6.1b). Histopathology of a biopsy from her legs showed 
epidermal confluent parakeratosis, spongiosis, and acanthosis. Moreover the epider-
mis was infiltrated with lymphocytes and multiple Munro abscesses were seen in 
the stratum corneum. The papillary dermis did show a perivascular mononuclear 
cell infiltrate and mild edema with vessel proliferation (figure 6.2a). The diagnosis 
guttate psoriasis was made.
Adalimumab was withdrawn and treatment with topical steroids and calcitriol 
was initiated. The lesions resolved over a period of 10 months and did not recur.
Case 2 
A 63-year old male patient presented with a pustular psoriasis after 9 months of 
adalimumab therapy. The patient had a 14-year history of RF positive erosive RA. His 
medical history further included epilepsy. Personal and family history was negative 
for psoriasis. He was enrolled in a clinical trial with intravenous (i.v.) adalimumab 
therapy, after treatment failure to various DMARDs, and he received 1 milligram per 
kilogram (mg/kg) every two weeks. Other medication included low dose prednisolone, 
piroxicam and diphantoin. 
The patient presented with a pustular erythematosquamous eruption on the 
palms and back of his hands and later on the plantar and lateral aspect of both feet. 
Histopathology of a biopsy showed confluent hyper and parakeratosis with micro-
pustules of Kogoj and microabcesses of Munro, irregular acanthosis and clubbing of 
the tips of the dermal rete ridges (figure 6.2b). In addition, the dermal papillae were 
edematous and contained dilated, tortuous capillaries. Histopathology was consistent 
with pustular psoriasis. Nineteen months after starting adalimumab, he developed 
typical nail pitting lesions on his fingernails and toenails.
Adalimumab was continued, topical corticosteroids and tar ointments were 
initiated. The skin lesions slowly resolved over the following year. The nail lesions 
persisted. Two years later he experienced a flare of psoriasis, which again slowly 
resolved, despite continuation of adalimumab. 
Case 3 
A 56-year old female patient was seen with a psoriasiform eruption after 16 months 
of adalimumab therapy. The patient had a 18-year history of refractory RF positive 
erosive RA. Her medical history consisted further of diabetes mellitus, Sjögren’s 
syndrome and congestive cardiomyopathy. Personal and family history was negative 
for psoriasis. Adalimumab intravenously had been initiated in combination with 
5
oral prednisolone 10 mg daily (d), after treatment failure of 7 different DMARDs. 
Concomitant medication was captopril, metoprolol, furosemide and insulin. She 
received adalimumab intravenously in a high dose of 5 mg/kg/week with reduction 
to 3 mg/kg/week after one year because of a good response. During adalimumab 
treatment she had experienced recurrent sinusitis and oral candidiasis. 
The patient developed itching erythematosquamous plaques and follicular bound 
papules on the medial aspects of her feet, spreading out to her legs, trunk, back and 
arms. Histology showed focal spotty hyperkeratosis and parakeratosis (figure 6.2c). 
No neutrofils were seen in the parakeratosis. Irregular acanthosis was seen of the 
epidermis. Histopathology was consistent with a psoriasiform dermatitis.
Adalimumab was stopped because of a coinciding granulocytopenia. The skin 
lesions resolved after initiation of topical corticosteroids and calcipotriol and did 
not recur.
Case 4
A 77-year-old male man with a 13-year history of a refractory RF negative non-erosive 
RA developed a guttate psoriasis- like eruption after start of infliximab therapy. His 
personal history was negative for psoriasis, but he had a positive family history 
(son).
Infliximab 3 mg/kg intravenously was added to low dose oral prednisolone after 
treatment failure to 7 different DMARDs. After the first infusion the patient devel-
oped sharply demarcated guttatiform erythematosquamous lesions on arms and 
legs and experienced itch now and then. 
A biopsy from the patient’s left upper leg showed spotty parakeratosis with Munro-
like micro-abcesses (figure 6.2d). Moreover, irregular acanthosis was seen, and the 
papillary dermis did show proliferation of vessels and extravasation of erythrocytes. 
The basal epidermis did not show an increased number of cycling keratinocytes. The 
histopathology was consistent with a psoriasiform dermatitis.
Potent topical corticosteroids were started and infliximab was stopped after five 
infusions (30 weeks of treatment), after which the lesions improved. Etanercept was 
started. The skin lesions slowly resolved during etanercept without recurrences.
Case 5 
A 61-year old male patient with a RF positive RA since 19 years developed guttatiform 
sharply demarcated erythematous lesions, consistent with guttate psoriasis, after 
the third infusion of infliximab. His personal history was negative for psoriasis but 
his son suffered from plaque psoriasis. Infliximab monotherapy 3 mg/kg was initiated 
after treatment failure to methotrexate and sulphasalazine. He responded well after 
the first infusion but had no response after the 2nd and 3rd infusion. After the third 
infusion (week 6) he developed the earlier described generalized eruption with sharply 
demarcated guttatiform lesions on his lower arms, legs and back. The clinical pre-
sentation was consistent with psoriasis. Between week 6 and 14 after initiation of 
infliximab the lesions slowly improved without therapy. Infliximab therapy was 
stopped because of ineffectiveness after the fourth infusion (week 14). No recur-
rence of the lesions was seen. 
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Figure 6.1. Erythematosquamous rashes (case 1)
Figure 6.1A) The clinical image shows an erythematosquamous rash with papules 
and plaques on her legs, trunk and lower arms, with a larger plaque around her  
umbilicus (case one). Figure 6.1B) One year later she develops a non-papular  
erythematosquamous rash on the anterior side of her lower legs.
Figure 6.2. Histopathology figures
A) Histopathology shows a papillary dermis with a perivascular mononuclear cell 
infiltrateand mild edema with vessel proliferation. Histopathology is consistent  
with guttate psoriasis.
B) Histopathology of a biopsy shows confluent hyper and parakeratosis with micro-
pustules of Kogoj and microabcesses Munro, irregular acanthosis and clubbing of 
the tips of the dermal rete ridges. This is consistent with psoriasiform dermatitis.
C) Histopathology shows focal spotty hyperkeratosis and parakeratosis. No neutro-
fils are seen in the parakeratosis. Irregular acanthosis is seen of the epidermis. 
Histopathology is consistent with psoriasiform dermatitis.
D) A biopsy from the patient’s left upper leg shows the following histopathology: 
Spotty parakeratosis with Munro-like micro-abcesses. Moreover, irregular acanthosis 
is seen, and the papillary dermis shows proliferation of vessels and extravasation 
of erythrocytes. The basal epidermis does not show an increased number of cycling 
keratinocytes. Histopathology is consistent with psoriasiform dermatitis.
a b
a b
C d

The five cases presented here belonged to a total group of 492 RA patients, treated 
with TNF blocking agents in both clinical practice and clinical trials. All patients 
were ANA negative at the onset of psoriasiform skin eruptions and had no history of 
allergy or atopy. Initial responses to TNF blocking agents were good in case 1 and 5, 
and moderate in case 2, 3 and 4. At onset of psoriasis disease activity was still low in 
case 1 (low inflammatory measures and no active arthritis) and moderate in case 2 
to 5. No relationship was observed between the activity of psoriasis lesions and RA.
r E v i E W  o F  C u r r E N T  l i T E r aT u r E
We describe the development of psoriasis and psoriasiform skin disease in 5 RA 
patients treated with TNF blocking agents. At present, a total of 115 cases of psoriasis 
or psoriasiform dermatitis occurring during TNF blocking treatment in patients 
treated for other diseases than psoriasis, have been published, including the cases 
in this report. Furthermore, nine cases of exacerbation have been reported in patients 
with plaque-psoriasis, sometimes developing on new localisations or with different 
morphology [4,15].
C l i N i Ca l  p r E s E N TaT i o N  a N d  h i s To lo gy
Exacerbation of previous inactive psoriasis was reported in 6 patients with RA 
[13,14,24] and 3 patients with psoriatic arthritis [14,18,19], whereas all other cases 
described new onset psoriasis [6-8,10,11,13,14,16-36]. Both plaque-type psoriasis and 
palmoplantar pustulosis (PPP) represent the most frequently reported morpholo-
gies, sometimes occurring in combination (table 6.1). Other morphologies include 
guttate psoriasis, papular eruptions and non-palmoplantar pustulosis.
The majority of reported cases concerns patients with rheumatoid arthritis, fol-
lowed by spondylarthropathies and Crohn’s disease (table 6.2). Most patients with 
diseases, other than RA, had used infliximab, most likely reflecting the fact that 
adalimumab has only been recently marketed and etanercept is not effective in 
inflammatory bowel diseases. In patients with RA, all three agents were reported in 
near equal frequencies. Psoriasiform lesions typically occurred within the first year 
of TNF blocking treatment (70%) with a reported median time to onset of 7 months 
(range 3 days - 62 months). No differences were seen between the three TNF blocking 
agents. Family history was positive in 7 of 64 cases (11%). Smoking habits, which 
have been reported to be present in 95% of PPP patients at onset [37], were addressed 
in only four cases of PPP; three were positive.
The clinical presentation of anti-TNF-induced psoriasis differs with respect to 
prevalence from the known psoriasis spectrum, as palmoplantar pustulosis and, to 
a lesser extend, scaling papular or guttatiform lesions were frequently described. 
Etanercept use was associated with a slighty lower number of PPP cases (8 of 24, 
33%), compared to infliximab (32 of 72, 44%) or adalimumab (12 of 19, 63%). Further-
more, PPP was less frequently reported in Crohn’s disease (2 of 14), than in rheumatoid 
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arthritis (30 of 63) or spondylarthropahy (15 of 27). In 49 cases histology was present. 
Histology of 42 cases was consistent with psoriasis or psoriasis-like dermatitis. Other 
described histological patterns were lichenoid and/or spongiotic [18,22,23], mostly 
in plaque-type psoriasis (see table 6.1). Biopsies from case 1 and 4 in the current report 
showed a histological pattern that could be consistent with psoriasiform dermatitis, 
whereas case 2 and 3 showed histology consistent with pustular psoriasis. 
aCT i o N  a N d  o u TC o M E
In the 115 reported cases TNF blocking treatment was withdrawn in 45 patients, 
continued in 59 patients and unmentioned in eleven. Skin lesions improved in all 
but seven patients who discontinued TNF blocking treatment. Thirty one patients 
permanently discontinued the use of TNF blocking agents. Ten patients restarted 
after improvement, six patients experienced a positive re-challenge. In four patients 
the lesions did no recur. In four other patients the lesions persisted despite a tempo-
rary discontinuation. 
Fifteen patients switched to another TNF blocking agent. Ten of these patients 
experienced a recurrence of psoriasis after start of a new TNF blocking agent. One 
RA patient experienced recurrences on two other TNF blocking agents [13]. Recur-
rences occurred after switching between the two monoclonal antibodies infliximab 
and adalimumab, as well as after switching between monoclonal antibodies and 
the soluble receptor fusion protein etanercept, and vice versa. These cases strongly 
suggest an association between the use of TNF blocking agents and the occurrence 
of psoriasiform lesions. They furthermore implicate a class effect of TNF blocking 
agents for inducing psoriasiform lesions, rather than a drug specific effect. 
In 59 patients who continued TNF blocking treatment improvement was reported 
in 32 cases with complete resolution in twelve cases (in ten other cases outcome was not 
mentioned). Psoriasis treatments consisted mostly of topical steroids and occasionally 
topical calcitriol, ultraviolet B treatment or systemic steroids. The outcome in the 
reported cases suggests that treatment of anti-TNF induced psoriasis does not always 
necessitate withdrawal of TNF blocking agents.
All five cases described here presented with RA (according to the revised ACR 
criteria) [38] so the possibility of an RA-mimicking psoriatic arthritis can be withdrawn. 
Skin lesions all occurred after reduction of RA disease activity by TNF blocking 
treatment. Furthermore, comedication that can induce psoriasis, like -blockers 
and certain NSAIDs (tenoxicam) had been used for many years, making a causative 
relation with the development of psoriasis-like dermatitis lesions unlikely. 
paT h o g E N E s i s
The pathogenesis of the development of psoriasiform lesions during TNF blocking 
therapy still remains unclear. Given the diversity in clinical presentation as well as 
histopathology in the five cases presented here, as well as published literature, we 
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consider the possibility of a variety of different reaction mechanisms. Another 
possibility may be different presentations due to interindividual diversity of (HLA)-
genetic make-up. 
TNF, a pro-inflammatory cytokine, plays a crucial role in the pathogenesis of 
inflammatory dermatoses such as psoriasis. This is illustrated by the fact that TNF 
blocking agents are highly effective in reducing psoriatic lesions [3-5]. In addition, 
in lesional psoriatic skin increased levels of TNF compared to controls have been 
found and correlated with the severity of the disease [39]. Moreover after successful 
treatment of psoriasis, TNF levels in skin and serum reduce significantly [40].
Activated T-cells, keratinocytes, monocytes and dendritic cells in human skin 
produce TNF. Key-players in the pathogenesis of psoriasis and target cells for TNF 
are T-helper cells (CD4+), cytotoxic T-cells (CD8+), NK-T cells (CD3+ and CD94+ or CD161+), 
regulatory T-cells (CD4+ and CD25+ ), (mature) dendritic cells, endothelial cells and 
keratinocytes [41]. The immunological effects of TNF include the expression of 
adhesion molecules, such as ICAM-1 and VCAM-1 and the production of vascular 
growth factors, facilitating the migration of activated T-cells into the epidermis 
[42,43]. Furthermore, TNF is able to stimulate the production of other pro-inflam-
matory cytokines and chemokines also enhancing T-cell trafficking [44,45]. Although 
only one cytokine is targeted with TNF blocking agents, its effect on the immuno-
logical network of the skin may be profound. 
The overproduction of pro-inflammatory cytokines such as TNF, or the lack of suf-
ficient expression of anti-inflammatory cytokines may lead to chronic inflammatory 
dermatoses. In this respect Banchereau et al. formulated an interesting hypothesis 
regarding auto-immunity [46]. They stated that auto-immunity is driven by a dynamic 
system of opposing vectors (IFN/IFN and TNF) stimulating the production of dis-
tinct types of dendritic cells. Overproduction of one type of cytokine/vector is able 
to induce auto-immunity. This hypothesis possibly holds true for psoriasis and drug 
induced psoriasiform lesions. Patients who develop psoriasiform lesions after starting 
TNF blocking agents may counteract the action of the drug by overexpressing 
TNF. This may explain the paradoxical reaction of the development of psoriasiform 
lesions after starting TNF blocking therapy. 
Another hypothesis concerns the role of bacterial infections in the pathogenesis 
of psoriasis. Bacterial infections of the upper respiratory tract may play a role in 
triggering guttate psoriasis [47,48]. In the presented cases two out of five patients 
presented with upper respiratory tract infections. In anti-TNF clinical trials upper 
respiratory tract infections occurred frequently and tended to predominate in the 
anti-TNF treatment groups [49]. Thus, anti-TNF might increase susceptibility to 
upper respiratoty tract infections in patients, who possibly already possess a higher 
risk for developing infections, originating from the underlying disease, like RA, or 
the use of comedication, like methotrexate and prednisolone. This could result in 
an increased risk for developing psoriasis, in which the initial triggering processes, 
including antigen processing and T-cell activation, are not primarily driven by TNF. 
Nevertheless the T-cell responses important in maintaining psoriasis inflammation 
are indeed driven by TNF [50].
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The role of fungal infections, which were also present in the reported 2 cases, in 
triggering psoriasis is less clear, as studies have been published with contradicting 
results [51,52].
C o N C lu s i o N
Substantial number of cases with temporal associations and the positive rechallenge 
in some cases represent strong evidence for a relationship between the use of TNF 
blocking therapy and the development of both plaque psoriasis and pustulosa palmo-
plantaris, as well as other psoriasiform skin disease. Furthermore, a class effect is 
suggested by recurrence with other TNF blocking agents. Immediate withdrawal 
of TNF blocking agents does not seem mandatory, but is associated with a higher 
improvement rate. Future studies are needed to strengthen the evidence for the 
relationship between psoriasis and TNF blocking therapy, to gain insight in the 
pathogenic mechanisms having a role in TNF blocking therapy induced psoriasis 
and to identify which patients on TNF blocking therapy are at risk for develop-
ment of psoriasis.
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o bj E CT i v E
The objective of this thesis was to study the drug survival, effectiveness and safety 
of TNF blocking therapy in RA patients. In addition to this treatment modulations 
of infliximab therapy were investigated. The main findings of these studies and 
their implications for clinical practice and future research will be discussed in this 
chapter in the context of current scientific literature on TNF blocking therapy.
M o N i To r i N g  T N F  b lo C k i N g  T h E r a p y
Large registries have been set up world-wide for monitoring long-term complications 
of TNF blocking therapy [1]. They have been initialised after the recognition of 
various potential hazards associated with the use of TNF blocking agents in the pre-
clinical and early post-marketing stages. In addition to safety aspects, these longitu-
dinal observational studies would also be able to provide information on long-term 
effectiveness of different treatment regimes in clinical practice.
In Europe, a proposal to establish these registries has been followed by several 
countries, amongst others, England, Sweden and Germany [2-4]. In the Netherlands a 
two-centre registry has been set up in Nijmegen to provide detailed monitoring on all 
RA patients starting TNF blocking therapy, as described in chapter one and chapter 
two. This initiative has later been followed by a more extended multicentre registry, 
called the DREAM-registry (Dutch Rheumatoid Arthritis Monitoring Registry) [5].
Differences between registries, like patients’ characteristics and national prescrip-
tion criteria, have to be taken into account, when comparing data on effectiveness and 
safety of this registry (chapter two) with data derived from other biologic registries. 
Table 7.1 provides an overview of the most important differences between this registry 
and three important reference registries.
Several registries have included larger patient numbers, sometimes nationwide 
(England and Germany) [2-4]. To date, they have reported mostly on etanercept and 
infliximab, as adalimumab registration followed late 2003. Some features distinguish 
the present registry from the other registries:
1. The registry collected detailed information on patient’ and disease characteristics, 
including, amongst others, three-monthly disease activity scores, biochemical 
and serological markers, and detailed information on concomitant medication.
2. Disease activity measurements were carried out by assessors who all had followed 
the same assessment training and regular standardisation trainings at the RUNMC 
[12].
3. Treatment assignment to TNF blocking agents occurred in a successive order, 
as the choice was primarily based on availability of TNF agents (due to etanercept 
reimbursement problems in the Netherlands) instead of patient or doctor prefer-
ences. Such a sequential assignment reduces the risk for confounding by indication, 
as for most patients only one treatment option was available per time period.
10
Table 7.1. Overview of some referenced biologic registries
registry (country) Nijmegen bsrbr ssaTg$ rabbiT
  biologics 
  registry
  Netherlands England Sweden Germany
National criteria for the use of TNF blocking agents
 Disease activity >3.2 >5.1 no restriction no restriction
 DMARD failure at least 2  at least 2  at least 2 at least 2
  DMARDs incl.  DMARDs incl.  DMARDs incl.  DMARDs incl. 
  MTX MTX MTX MTX
 Other criteria  compliance  compliance
   with BSRBR  with
   registration standardized 
    monitoring 
registry characteristics
 Start date 1 2001 1 2001
 TNF naïve yes yes yes no
 Participation regional nationwide southern  nationwide
    Sweden
 No. of centres involved 2 multiple  multiple
 Monitoring visits 3-monthly  6-monthly 3-monthly 
    during the 1st 
    year, subseq. 
    6 m 
 Disease activity measurements DAS2 DAS2 DAS2 DAS2
 Estimated compliance % >% 0% 0% -
patients’ characteristics from recently reported studies for ETa/iNF*
Patient numbers 30/36 126/1612 440/21 551/343
Age, y (mean) 52/56 55/56 55/55** 54/54
Female, % 4/4 / 5/2 /1
DAS2 at baseline (mean) 6.1/5. 6./6. 5.6/5. 6.1/6.0
Concomitant DMARDs, % 5/ 4/4 56/6 50/
 Concomitant MTX, % 33/50 2/6 41/6 34/66**
Concomitant steroids, % 5/2 50/4 ?/? ?/?
*Data extracted from chapter 2 and from references [2-4,6-11]. **Calculated estimates.  
$The STAGG is combined with the Stockholm registry (STURE) in the Anti-Rheumatic Therapy  
in Sweden registry (ARTIS), covering 5% of the Swedish population [2].
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4. The registry has included a large patient group, receiving long-term adalimumab 
therapy. The patients started adalimumab from 1997 onwards in RCTs, but were 
subsequently being treated in a compassionate use program similar to daily 
clinical practice.
d r u g  s u r v i va l 
Drug survival is a composite tool investigating both the effectiveness and the safety 
of therapy, as well as other factors influencing adherence to treatment, such as 
availability of other therapeutic options and withdrawal for other reasons, like for 
instance, patient preferences and pregnancy.
The drug survival rates reported in chapter two are relatively low, compared to 
survival rates reported previously in clinical trials and other longitudinal observa-
tional studies. Reported survival rates in RCTs vary around 80% after one year of treat-
ment [13-16]. However, results from RCTs do not always translate well into clinical 
practice. A recent observational study showed that more than two third of all RA 
patients treated with TNF blocking agents in daily clinical practice would not have 
been eligible for one or more of the major clinical trials, who have led to approval 
of these drugs [11]. In other words, these patients would not have been accepted for 
these trials on the basis of the inclusion and exclusion criteria which were used. In 
this observational study treatment response rates of eligible patients correlated 
well to the response rates reported in RCTs, but the response rates in patients not 
eligible were significantly lower; these patients were less successful on TNF blocking 
therapy. These ‘ineligible’ patients had lower baseline disease activity, lower func-
tional status and more severe comorbidity.
In post-marketing observational studies, the reported survival rates after one 
year of treatment ranged from 65% to 95% [2,4,17-20]. Differences between these 
studies might be explained by differences in patients’ characteristics, prescription 
criteria, comedication, and previous use or availability of TNF blocking agents. 
One difference is the relatively low percentage of patients treated with infliximab 
in our cohort who used concomitant methotrexate (MTX) (50% versus (vs) 66-86% in 
other registries), which has been shown to be associated with a better drug survival 
(see below). Half of the remaining patients used concomitant DMARDs, other than 
MTX, and half did not use any concomitant DMARD.
When taking a closer look at the different reasons for discontinuation, infliximab 
is stopped relatively more often because of toxicity, whereas etanercept is stopped 
relatively more often because of ineffectiveness. This difference has also been observed 
in another study [20].
E F F E CT i v E N E ss  o F  T N F  b lo C k i N g  T h E r a p y
Approximately 70% of all patients with severe longstanding RA responded to TNF 
blocking agents, with 20-30% achieving a EULAR good response and 10-20% achieving 
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remission (chapter two). These rates are comparable to results from other registries 
[8,18,21]. The same is true for changes in DAS28 [11,18,22,23]. Disease activity over time 
and response to therapy did not differ significantly between the three TNF blocking 
agents. However, to accurately study equivalence in effectiveness randomized head-
to-head studies are warranted. At present, no randomised studies comparing TNF 
blocking agents with each other have been carried out.
i M M u N o g E N i C i T y  a N d  E F F E CT i v E N E ss
For all three TNF blocking agents higher response rates have been shown in combi-
nation with methotrexate [14,24,25]. In patients treated with infliximab, antibodies 
directed against infliximab can occur. These anti-infliximab antibodies have been 
reported in up to 44% of the patients within one year after start of therapy [26,27]. 
The presence of anti-infliximab antibodies is associated with neutralization and 
increased clearance of infliximab, lower serum through levels of infliximab and 
lower response rates [26-29]. Concomitant use of methotrexate may suppress the 
formation of anti-infliximab antibodies [25]. In patients with Crohn’s disease a direct 
association has been shown between use of concomitant methotrexate and lower 
anti-infliximab antibody titres, associated with a longer duration of response and less 
infusion reactions [30]. So, concomitant MTX therapy may reduce the level of anti-
infliximab antibodies, thereby reducing clearance rates and yielding higher serum 
infliximab concentrations, which correlate with treatment response in RA patients 
[27,31,32]. Increasing the infliximab dose is another option that may reduce the level 
of anti-infliximab antibodies, possibly by induction of immune tolerance [27,31].
Formation of antibodies to TNF blocking agents has also been reported with 
etanercept and adalimumab, although at lower rates [13,33,34]. In a recent study 
anti-adalimumab antibodies appeared in 17% of adalimumab treated RA patients 
and were associated with a decline in clinical response [35]. Anti-etanercept anti-
bodies have not been associated with a decline in response [34].
C o M b i N aT i o N  o F  T N F  b lo C k i N g  ag E N T s  W i T h 
d M a r d s ,  oT h E r  T h a N  M T x
As shown in table 7.1, in a significant subgroup of patients anti-TNF is started either 
as monotherapy or in combination with DMARDs, other than methotrexate. The reason 
will most often be failure to or intolerability of methotrexate. In these patients 
leflunomide is an important alternative for combination with infliximab. In chapter 
three we show that administration of infliximab after or concomitantly with leflu-
nomide is safe and effective in RA patients. These observations are in line with other 
reports, although two small studies reported an increase in adverse events [36-41].
The combination with other DMARDs like azathioprine and cyclosporine is cur-
rently less extensively explored [36]. Combining infliximab with DMARD other than 
methotrexate needs further evaluation, including determination of anti-infliximab 
antibody rates.
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i N F l i x i M a b  d o s i N g  s C h E d u l E s
At present, anti-infliximab antibody testing is not part of daily clinical practice in 
case of insufficient response. Treating physicians can choose between increasing the 
dose up to a maximum of 7.5 mg/kg/8 weeks or reducing the interval to a minimum 
of 4 weeks. Pharmacokinetic modelling of infliximab RCT data showed that interval 
reduction might be more effective in raising serum concentrations [42]. In chapter 
four the effectiveness of both therapeutic options was shown in an open-label study 
where the choice for the adjustment was tailored by the observed disease activity 
pattern. The theoretical background for this strategy, as described in the chapter, 
followed from pharmacological and clinical observations [42-44]. However, for a direct 
comparison between interval reduction and dosage increase a randomised trial is 
warranted. Such a trial should include a treatment arm receiving no treatment 
adjustments, as in chapter four a delayed improvement response beyond 14 weeks 
was observed in some patients. Interestingly, the estimated cost of infliximab medi-
cation and day care showed a difference of approximately 1000 euro per 8 weeks per 
patient in favour of the interval reduction group.
s W i TC h i N g  o F  T N F  b lo C k i N g  ag E N T s
In chapter two a substantial number of patients switched from TNF blocking 
agent, mostly from infliximab to etanercept. The observed survival rates of second 
treatment courses were good and comparable to previous reports on switching of 
TNF blocking agents [45,46].
In patients switching from infliximab to etanercept drug survival of etanercept 
was not influenced by the reason for discontinuation of infliximab. However, the 
group size is relatively small to draw any firm conclusions. A larger cohort study 
recently showed that reasons for discontinuation of a second TNF blocking agent 
are related to the reasons for discontinuation of the first TNF blocking agent [47]. 
A Spanish cohort study showed that drug survival rates were better when replacing 
the first TNF blocking agent for adverse events [48]. Another retrospective study 
showed that etanercept maintained the same level of clinical benefit after stopping 
infliximab for adverse events [49]. 
Some studies have showed that survival rates of second TNF blocking agents 
were decreased, although still at acceptable levels, compared to survival rates of 
first TNF blocking agents [48,50]. These data are contradictory to a large cohort 
study showing a longer drug survival of the 2nd TNF blocking agent compared to 
the 1st agent in RA patients switching for ineffectiveness, and comparable survival 
rates of the 1st and 2nd TNF blocking agent in patients switching for adverse 
events [51].
In conclusion, switching between TNF blocking agents can be effective, regardless 
of the reason for discontinuation. Conflicting results have been published regarding 
drug survival of the 2nd treatment, especially in patients switching for reasons of 
effectiveness. At present, there are no indications that one switching strategy is 
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preferable above another. Future research should include the identification of pre-
dictive factors, which might explain the observed differences in secondary drug 
survival.
s a F E T y  o F  T N F  b lo C k i N g  T h E r a p y
The inhibition of TNF has an impact on cellular immunity and host defences against 
pathogenic micro-organisms. A number of disorders have been associated with the 
use of TNF blocking therapy, as summarized in table 7.2. Further concern remains 
regarding possible associations to the occurrence of malignancies, especially lym-
phoma’s. Although the incidence of lymphoma’s in RA patients on TNF blocking 
agents is increased, when compared to background incidence rates, the risk increment 
may result from the disease itself and the level of disease activity, which have been 
associated with an increased lymphoma risk [52,53].
infections
TNF blocking therapy may be associated with a significant increase in serious infec-
tions. Although a number of studies have reported similar infection rates between 
patient on TNF blocking agents and controls [14,15,54,55], a meta-analysis of nine 
RCTs with infliximab and adalimumab demonstrated a higher rate of serious infec-
tions in RA patients on infliximab and adalimumab [56].
Reactivation of tuberculosis has been associated with the use of TNF blocking 
agents [57-59]. To a lesser extend, opportunistic infections, like histoplasmosis, 
listeriosis, aspergillosis, coccidioidomycosis and candidiasis, and intracellular infec-
tions, like atypical mycobacteria and salmonella, are also seen more frequently during 
TNF blocking therapy [60-62]. In a recent meta-analysis of nine RCTs approximately 
10% of serious infections were attributable to opportunistic micro-organisms [56].
Three large observational studies also have shown an increased risk for serious 
infections in general with an emphasis on lower respiratory tract, skin/soft tissue 
infections and bone/joint infections [9,63,64]. Four percent serious intracellular 
bacterial infections were seen, including tuberculosis, listeria, legionella, atypical 
Mycobacteria and salmonella.
The observed rate of serious infections in our cohort of 4.6 per 100 pt-yrs (chapter 
two) is comparable to the estimated rates from clinical trials (1-6/100 pt-yrs) [15,24,42] 
and observational studies (5.3-6.4/100 pt-yrs) [9,63]. No other opportunistic or intra-
cellular infections were observed, except for three tuberculosis reactivations and 
one salmonella enterica septic arthritis.
skin condit ions
Dermatological conditions are frequently observed during TNF blocking therapy 
[33,65,66]. A broad variety of conditions, including skin infections, drug-induced 
eruptions, eczema, psoriasis and vasculitis, is reported in chapter five. An increased 
risk for skin infections during TNF blocking therapy has been shown by other obser-
vational studies [63]. 
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The event per patient-year ratio was higher during active treatment than after treat-
ment withdrawal. As some patients had stopped because of dermatological events, 
a possible selection bias may have influenced these results. To eliminate this bias an 
additional analysis was performed excluding all patients who stopped TNF blocking 
therapy because of dermatological events. The difference in events per patient-year 
decreased slightly, but remained statistically significant (0.14 vs 0.10, P<0.05).
Possible pathophysiological mechanisms in TNF associated skin conditions may 
include hypersensitivity reactions, reduced barrier function, cytokine imbalances 
and T-helper cell type 2 predominance [chapter six and seven] [67-70]. During follow-up 
a number of psoriasiform eruptions were recorded, which are described in detail in 
chapter six. Substantial evidence has emerged, linking the used TNF blocking agents 
Table 7.2. Adverse events associated with TNF blocking therapy
adverse event reference
infections
- Serious infections: increased risk [,56,63,64,1]
- Tuberculosis reactivation [5-5,2,3]
- Opportunistic micro-organisms: histoplasmosis, listeriosis,  [62,63,4-6]
 aspergillosis, coccidioidomycosis, candidiasis, cryptococcosis
- Other intracellular micro-organisms: atypical mycobacteria,  [60,62,6]
 salmonella species.
- Exacerbation of chronic hepatitis B virus infection [,] 
immune mediated disorders
- Hypersensitivity reactions; infusion and injection site reactions Chapter 6 [16,-2]
- drug-induced SLE [3-]
- demyelinating disease [,] 
skin disease
- vasculitis Chapter 6 [0,0-5]
- eczema Chapter 6 [66]
- psoriasiform eruptions Chapter  [6,6-]
- skin infections; bacterial (necrotizing fasciitis), viral (herpetic) 
 and fungal Chapter 6 [63,100,101]
 
heart disease
- progression of existing heart failure [102]
- possibility of new onset heart failure [103] 
haematological
- aplastic anemia/pancytopenia [104-106] 
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to new onset of psoriasiform reactions and exacerbations of pre-existing psoriasis 
[67,68]. New onset psoriasiform eruptions occur with all three TNF blocking agents 
and in all diseases in which TNF blocking agents are used. More than half of the 
reported cases describe palmoplantar pustular eruptions. Positive rechallenges after 
switching to another TNF blocking agent suggest a class effect. The pathogenesis 
of this interesting and paradoxal reaction has not yet been resolved, although the 
inhibition of a TNF regulated negative feedback mechanism of cytokine produc-
tion by dermal plasmacytoid dendritic cells has been implicated [67]. 
p r E d i CT i v E  FaCTo r s
Three studies in this thesis investigated the predictive value of patients’ character-
istics on outcome variables, all in stepwise multivariate analyses. In chapter two 
predictive factors were identified for drug survival, disease activity over time and 
adverse events. In chapter three the predictive value of ANA status on disease activity 
over time and adverse events was studied. In chapter five the predictive value of 
baseline characteristics on the development of clinically important dermatological 
events was studied.
predictive factors for drug survival
Drug survival was predicted in multivariate analysis by concomitant DMARD therapy, 
which is in accordance with reports from other biologic registries [4,10,22]. One of 
these studies further reported concomitant MTX to be superior to combinations 
with other DMARDs. In our cohort a slightly better survival was seen in patients on 
concomitant MTX, compared to other DMARDs, although not statistically significant 
(data not shown). Other reported predictors, as shown in table 7.3, are all indicators 
of disease severity. The predictive value of C-reactive protein (CRP) is controversial. 
A high CRP at baseline may, as an indicator of acute systemic inflammation, indicate 
a larger potential for improvement [10]. On the other hand, high baseline CRP levels 
have been shown to correlate inversely with serum infliximab concentrations and 
with response to therapy in RA patients treated with infliximab [32]. In chapter two 
a high disease activity before start of TNF blocking therapy was associated with 
high disease activity during treatment. In multivariate analysis no association with 
drug survival was seen.
predictive factors for effectiveness
Several predictive factors for disease activity over time were identified by multivariate 
analysis, after correction for treatment centre, TNF blocking agent and duration of 
follow-up. Results were in accordance with other observational studies, as shown in 
table 7.4. Some remarks can be made.
The observation in chapter two that concomitant corticosteroid use at baseline 
predicts higher disease activity over time may implicate that corticosteroid use is 
associated with more severe disease. This finding may not applicable across other 
registries, because of differences in prescription behaviour between countries. In 
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some countries TNF blocking agents are used more often in combination with 
corticosteroids, sometimes up to 95% [7]. 
In table 7.4 predictive factors for response to therapy, according to the EULAR 
response criteria [107], are shown. 
predictive factors for adverse events
In chapter two the predictive value of baseline characteristics was investigated for 
the occurrence of adverse events in general and for major adverse events, as well as 
for the most frequently reported events, namely infusion reactions, infections and 
dermatological conditions. An overview is presented in table 7.5.
Currently, only a few studies have investigated predictive factors for the occur-
rence of adverse events. Salliot et al reported concomitant steroids and the number 
of previous DMARDs to be univariately associated risk factors for infection, but in 
Table 7.3. Baseline factors in observational studies predicting drug survival of TNF 
blocking agents (in multivariate analysis)
outcome predictive factors at baseline** [references]
Longer survival on drug Concomitant MTX vs monotherapy [this thesis] [4,10,22], 
 (trend: [4])
 Concomitant DMARDs vs monotherapy [20]
 Concomitant non-MTX DMARDs vs monotherapy [this thesis]
 Concomitant MTX vs other DMARDs [10]
 Early RA [this thesis]
 Low age [4,10]
 High CRP [10]
 High functional capacity [10]
 Less previously used DMARDs [4,10]
 RF negativity [4]
 No previous use of biologics [50]
 
Longer survival to adverse event* Concomitant MTX vs monotherapy [this thesis] [10]
 Concomitant non-MTX DMARDs vs monotherapy [this thesis]
 Concomitant MTX vs non-MTX DMARDs [10]
 
Longer survival to ineffectiveness* Concomitant MTX vs monotherapy [this thesis], INF# only [10]
 Concomitant non-MTX DMARDs vs monotherapy, INF# only [10]
 Low disease activity at week 14 or 22 [20]
*Drug survival to discontinuation because of adverse event respectively ineffectiveness.  
**Unless stated otherwise. #INF = infliximab
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multivariate analysis only previous joint surgery was associated with an increased 
infection risk in a retrospectively investigated cohort of patients with various rheu-
matic diseases on TNF blocking therapy [108]. Another study suggested concomitant 
steroid use and older age to be risk factors for severe pyogenic infections in a cohort 
of 87 RA patients [109]. A more pronounced association between corticosteroids and 
serious infections was shown in a large prospective study of RA patients, aged 65 
years or more, on TNF blocking therapy or methotrexate [110].
In chapter three the clinical significance of anti nuclear antibodies as predictor 
for adverse events was investigated. Antinuclear antibodies (ANA) are common in 
RA patients. Half to three quarter of all RA patients will have positive ANA testing 
at some time-point in the course of the disease [111]. The numbers of ANA positive 
patients were in agreement with previous smaller studies: approximately 30-50% of 
the patients are ANA positive at start of therapy. 35-70% of the negative patients will 
Table 7.4. Baseline factors in observational studies predicting EULAR-response and  
remission on TNF blocking therapy (in multivariate analysis)
outcome predictive factors [references]
Low disease activity over time Male gender [this thesis]
 High age [this thesis]
 Less previously used DMARDs [this thesis]
 No concomitant corticosteroids [this thesis]
 Concomitant DMARDs [this thesis]
 Low baseline DAS2 [this thesis]
 
Higher EULAR-response rates Eligibility to major clinical trials: all [11]
 Concomitant MTX vs monotherapy: ETA* [,22], trend for INF* [22]
 Concomitant MTX vs other DMARDs: ETA [22], trend for INF [22]
 Concomitant NSAIDs: ETA and INF []
 High baseline functional status: ETA and INF []
 Absence of smoking: INF []
 
Higher EULAR-remission rates Concomitant MTX vs monotherapy: ETA [,22]
 Male sex: ETA and INF []
 Low baseline DAS2: all [21], ETA and INF []
 High baseline functional status: all [21], ETA and INF []
 Less previously used DMARDs: ETA and INF []
 Concomitant NSAIDs: ETA and INF []
 Low age at start: all [21]
 Absence of osteoporosis: all [21]
*ETA = etanercept, INF = infliximab
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convert to ANA positivity during therapy, while 83-96% of the ANA positive patients 
will remain positive [39,112-115].
ANA positivity at start and conversion to ANA positivity after start of TNF block-
ing therapy were not associated with the occurrence of adverse events. This is in 
agreement with previous reports [39,114], although a more recent study has identified 
ANA positivity at baseline as a risk factor for infusion reactions [116]. This risk was 
higher in patients without concomitant methotrexate. In chapter two ANA positivity 
at baseline did not predict the occurrence of infusion reactions in a multivariate model. 
Next to ANA, anti-infliximab antibodies have been associated with an increased risk 
for infusion reactions [30,106,117]. The incidence of anti-infliximab antibodies is 
higher among patients not receiving concomitant DMARDs [30,106,118].
Table 7.5. Baseline factors in observational studies predicting the occurrence of adverse 
events during TNF blocking therapy (in multivariate analysis)
adverse events predictive factor [references]
Any adverse event Concomitant steroid use [this thesis]
 Higher body weight [this thesis]
 
Major events Concomitant steroid use [this thesis]
 Higher age [this thesis]
 
Infections Concomitant steroids [this thesis] [110]
 Concomitant DMARDs [this thesis]
 Previous joint surgery [10]
 
Allergic reactions Female gender [this thesis]
 Higher no. of previously used DMARDs [this thesis]
 For INF: ANA positivity at baseline, Monotherapy or non-MTX  
 combinations, low age at disease onset, long RA duration [116]
 
Dermatological conditions Higher body weight [this thesis]
 Higher age [this thesis]
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summary of  conclusions
- Drug survival and response rates of TNF blocking agents in clinical practice 
are lower than the rates observed in clinical trials.
- Drug-survival and effectiveness of TNF blocking agents are positively influenced 
by the use of concomitant DMARDs, including MTX.
- The use of concomitant MTX and corticosteroids in RA patients on TNF 
blocking agents are associated with an increased risk for infection.
- The combination of infliximab with leflunomide is safe and efficacious in 
patients with RA.
- Anti-nuclear antibodies do not predict the effectiveness of infliximab therapy 
or occurrence of adverse events in RA patients
- Different patterns of disease activity can be observed in moderate responders to 
infliximab treatment; a constant moderate response, a flare of disease activity 
or a gradually improving response. Titrating infliximab dose and interval based 
on response patterns significantly reduces disease activity.
- Interval reduction of infliximab may have a better cost-effectiveness ratio than 
dosage increase in RA patients with a moderate response.
- Dermatological conditions are an important and clinically significant problem 
following TNF blocking therapy.
- Psoriasiform eruptions are paradoxal adverse events associated with TNF 
blocking therapy.
 General discussion
TNF blocking therapy in RA120
 r E F E r E N C E  l i s T
(1)  Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, van Riel P et al. Proposal to 
establish a register for the long term surveillance of adverse events in patients with 
rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for 
Biological Compounds. Ann Rheum Dis 2000; 59(6):419-420.
(2)  Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N et al. 
Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 
2006; 65(6):707-712.
(3)  Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology 
biologics register. Ann Rheum Dis 2005; 64 Suppl 4:iv42-iv43.
(4)  Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K et al. Treatment 
continuation in patients receiving biological agents or conventional DMARD therapy. 
Ann Rheum Dis 2005; 64(9):1274-1279.
(5)  Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ et al.  
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised 
controlled trials and clinical practice. Ann Rheum Dis 2007; 66(11):1473-1478.
(6)  Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in 
rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(10):1159-1161.
(7)  Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide 
in established rheumatoid arthritis: clinical experience using a structured follow up 
programme in southern Sweden. Ann Rheum Dis 2002; 61(9):793-798.
(8)  Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-
alpha therapy among patients with rheumatoid arthritis: results from the British 
Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 
45(12):1558-1565.
(9)  Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M et al. 
Infections in patients with rheumatoid arthritis treated with biologic agents. 
Arthritis Rheum 2005; 52(11):3403-3412.
(10)  Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy 
on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. 
Results from a six-year observational study in southern Sweden. Arthritis Res Ther 
2006; 8(6):R174.
(11)  Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M et al. 
Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an 
observational cohort study: comparison of patients according to their eligibility for 
major randomized clinical trials. Arthritis Rheum 2006; 54(11):3399-3407.
(12)  Creemers MC, Fransen J, van Riel P. Training, standardisation and calibration of 
tender and swollen joint counts in Rheumatoid Arthritis. Ann Rheum Dis 2007; 
66(suppl II):348.
(13)  Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS et al. Radio-
graphic, clinical, and functional outcomes of treatment with adalimumab (a human 
anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid 
arthritis receiving concomitant methotrexate therapy: a randomized, placebo-
controlled, 52-week trial. Arthritis Rheum 2004; 50(5):1400-1411.
121
(14)  Klareskog L, van der Heijde, de Jager JP, Gough A, Kalden J, Malaise M et al.  
Therapeutic effect of the combination of etanercept and methotrexate compared 
with each treatment alone in patients with rheumatoid arthritis: double-blind 
randomised controlled trial. Lancet 2004; 363(9410):675-681.
(15)  Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. 
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor 
Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study 
Group. N Engl J Med 2000; 343(22):1594-1602.
(16)  Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al.  
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, 
in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 
340(4):253-259.
(17)  Cientifico BIOBADASER C. Spanish Experience with a Registry of Adverse Events on 
Biological Therapy. Ann.Rheum.Dis. 61[suppl I], 388. 2002. 
(18)  Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT et al. Results 
from a nationwide postmarketing cohort study of patients in Sweden treated with 
etanercept. Ann Rheum Dis 2005; 64(2):246-252.
(19)  Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug 
resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum 
Dis 2006; 65(6):746-752.
(20)  Vand er Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F  
et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients  
with long-standing refractory disease: attrition and long-term evolution of disease 
activity. Arthritis Res Ther 2006; 8(4):R112.
(21)  Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T et al. Clinical and 
functional remission: even though biologics are superior to conventional DMARDs 
overall success rates remain low--results from RABBIT, the German biologics register. 
Arthritis Res Ther 2006; 8(3):R66.
(22)  Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to 
infliximab or etanercept monotherapy with the response to cotherapy with  
methotrexate or another disease-modifying antirheumatic drug in patients with 
rheumatoid arthritis: results from the British Society for Rheumatology Biologics 
Register. Arthritis Rheum 2006; 54(6):1786-1794.
(23)  Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid 
arthritis in clinical practice: costs and outcomes in a follow up study of patients  
with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 
2004; 63(1):4-10.
(24)  Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R 
et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of 
combination therapy with adalimumab plus methotrexate versus methotrexate 
alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis 
who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54(1): 
26-37.
(25)  Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic 
efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha 
 General discussion
TNF blocking therapy in RA122
monoclonal antibody combined with low-dose weekly methotrexate in  
rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-1563.
(26)  Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.  
Individualized monitoring of drug bioavailability and immunogenicity in  
rheumatoid arthritis patients treated with the tumor necrosis factor alpha  
inhibitor infliximab. Arthritis Rheum 2006; 54(12):3782-3789.
(27)  Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT et al.  
Development of antiinfliximab antibodies and relationship to clinical response  
in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(3):711-715.
(28)  Infliximab (Remicade) revised prescribing information. 2006. 
(29)  Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with  
anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab 
antibodies. Rheumatology (Oxford) 2007; 46(12):1828-1834.
(30)  Baert F, Noman M, Vermeire S, van Assche G, D’ Haens G, Carbonez A et al.  
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s 
disease. N Engl J Med 2003; 348(7):601-608.
(31)  St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A et al.  
The relationship of serum infliximab concentrations to clinical improvement in 
rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-
blind, placebo-controlled trial. Arthritis Rheum 2002; 46(6):1451-1459.
(32)  Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP et al. 
Relationship between serum trough infliximab levels, pretreatment C reactive 
protein levels, and clinical response to infliximab treatment in patients with 
rheumatoid arthritis. Ann Rheum Dis 2005; 64(5):704-707.
(33)  Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al.  
A comparison of etanercept and methotrexate in patients with early rheumatoid 
arthritis. N Engl J Med 2000; 343(22):1586-1593.
(34)  Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A et al. The  
immunogenicity, safety, and efficacy of etanercept liquid administered once weekly  
in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25(1):40-46.
(35)  Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L et al. 
Clinical response to adalimumab: The relationship with anti-adalimumab antibodies 
and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007.
(36)  Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL et al. Safety of 
infliximab used in combination with leflunomide or azathioprine in daily clinical 
practice. J Rheumatol 2006; 33(5):865-869.
(37)  Cobo IT, Yehia TM, Balsa CA, Hernandez SA, Martin ME. Safety and efficacy of 
leflunomide and infliximab versus methotrexate and infliximab combination 
therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44(11):1467-1468.
(38)  Ortiz Garcia AM, Gonzalez-Alvaro I, Rosello PR, Carmona L, Fabregas C,  
Monteagudo S, I. Effectiveness and safety of infliximab combined with  
leflunomide in chronic polyarthritis. Clin Exp Rheumatol 2004; 22(6):790.
(39)  Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety  
of leflunomide plus infliximab combination therapy in rheumatoid arthritis.  
Clin Exp Rheumatol 2004; 22(3):328-330.
123
(40)  Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR et al. The safety and 
efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. 
Arthritis Rheum 2004; 51(2):228-232.
(41)  Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in  
rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 2002; 41(6):631-637.
(42)  St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al. 
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: 
a randomized, controlled trial. Arthritis Rheum 2004; 50(11):3432-3443.
(43)  Creemers MC, den Broeder AA, van Gestel AM, van Riel PL. Dose titration using the 
disease activity score (DAS28) in rheumatoid arthritis (RA) patients treated with  
anti-TNF-alpha. Arthritis Rheum. 61[suppl. 1], s177. 2002. 
(44)  den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the 
Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti- 
TNF-alpha. Rheumatology (Oxford) 2002; 41(6):638-642.
(45)  van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab 
(Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE 
registry showing that switching tumour necrosis factor alpha blockers can make 
sense. Ann Rheum Dis 2003; 62(12):1195-1198.
(46)  Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.  
Adalimumab (Humira) restores clinical response in patients with secondary loss of 
efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE 
registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34(5):353-358.
(47)  Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching 
from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis 
factor alpha agent in patients with rheumatoid arthritis: Results from a large UK 
national cohort study. Arthritis Rheum 2006; 56(1):13-20.
(48)  Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic 
arthritis: an observational study of 488 patients over a four-year period. Arthritis  
Res Ther 2006; 8(1):R29.
(49)  Iannone F, Trotta F, Monteccuco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M et al. 
Etanercept maintains the clinical benefit achieved by infliximab in patients with 
rheumatoid arthritis who discontinued infliximab because of side effects. Ann 
Rheum Dis 2007; 66(2):249-252.
(50)  Kishimoto C, Greenberg J, Abramson SB, Harrington T, Olenginski TP, Kafka S et al. 
Drug Survival Time on Anti-TNF Agents: Does Prior Anti-TNF Use Influence RA 
Outcomes? Arthritis Rheum 2005. 52[9 (suppl.)]:5.
(51)  Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J et al. Do rheuma-
toid arthritis patients in clinical practice benefit from switching from infliximab to  
a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007;66(9):1184-1189.
(52)  Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F et al. Association  
of chronic inflammation, not its treatment, with increased lymphoma risk in 
rheumatoid arthritis. Arthritis Rheum 2006; 54(3):692-701.
(53)  Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk  
of lymphoma in patients with rheumatoid arthritis: nested case-control study.  
BMJ 1998; 317(7152):180-181.
 General discussion
TNF blocking therapy in RA124
(54)  Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R et al.  
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.  
J Rheumatol 2001; 28(6):1238-1244.
(55)  Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al. 
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, 
for the treatment of rheumatoid arthritis in patients taking concomitant  
methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48(1):35-45.
(56)  Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF 
antibody therapy in rheumatoid arthritis and the risk of serious infections and 
malignancies: systematic review and meta-analysis of rare harmful effects in  
randomized controlled trials. JAMA 2006; 295(19):2275-2285.
(57)  Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L et al. Risk and  
case characteristics of tuberculosis in rheumatoid arthritis associated with tumor 
necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52(7):1986-1992.
(58)  Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of 
rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to 
significant increase in tuberculosis risk: a multicenter active-surveillance report. 
Arthritis Rheum 2003; 48(8):2122-2127.
(59)  Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. 
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing 
agent. N Engl J Med 2001; 345(15):1098-1104.
(60)  Netea MG, Radstake T, Joosten LA, Van der Meer JW, Barrera P, Kullberg BJ. Salmonella 
septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor 
therapy: association with decreased interferon-gamma production and Toll-like 
receptor 4 expression. Arthritis Rheum 2003; 48(7):1853-1857.
(61)  Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha  
antagonists. Pharmacotherapy 2005; 25(9):1181-1192.
(62)  Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous 
infectious diseases associated with tumor necrosis factor antagonists. Clin Infect  
Dis 2004; 38(9):1261-1265.
(63)  Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious 
infection, including site-specific and bacterial intracellular infection, in rheumatoid 
arthritis patients receiving anti-tumor necrosis factor therapy: results from the 
British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 
54(8):2368-2376.
(64)  Kievit W, Creemers MC, Fransen J, Kuper IH, van de Laar MA, Jansen TL et al.  
A Higher rate of Serious Infections in Patients Treated with TNF Alpha Blocking 
Agents. Arthritis Rheum. 54[suppl], S365. 2006. 
(65)  Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab 
(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in 
rheumatoid arthritis patients receiving concomitant methotrexate: a randomised 
phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194):1932-1939.
(66)  Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J et al. Cutaneous side-
effects in patients with rheumatic diseases during application of tumour necrosis 
factor-alpha antagonists. Br J Dermatol 2007; 156(3):486-491.
125
(67)  de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S et al. Psoriasis and 
pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with  
rheumatologic conditions. Arch Dermatol 2007; 143(2):223-231.
(68)  Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol 2007; 
143(2):233-236.
(69)  Krueger JG. The immunologic basis for the treatment of psoriasis with new  
biologic agents. J Am Acad Dermatol 2002; 46(1):1-23.
(70)  Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated 
with both etanercept and infliximab. Scand J Immunol 2005; 61(4):329-336.
(71)  Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with 
infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol 
Hepatol 2007; 5(6):729-735.
(72)  Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis 
following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 
2004; 39(3):295-299.
(73)  Vonkeman HE, van der Valk PD, Mulder L, van de Laar MA. [Fatal miliary tuberculosis 
during treatment with infliximab]. Ned Tijdschr Geneeskd 2002; 146(25):1196-1199.
(74)  Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha 
therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004; 
63(12):1538-1543.
(75)  Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN et al.  
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis 
factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 
46(10):2565-2570.
(76)  Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha 
therapy. Arthritis Rheum 2003; 48(11):3013-3022.
(77)  Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with 
immunosuppressive therapy in rheumatic diseases: assessment and preventive 
strategies. Ann Rheum Dis 2006; 65(8):983-989.
(78)  Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B 
reactivation following infliximab therapy in Crohn’s disease patients: need for 
primary prophylaxis. Gut 2004; 53(9):1363-1365.
(79)  Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L et al. The incidence  
and management of infusion reactions to infliximab: a large center experience.  
Am J Gastroenterol 2003; 98(6):1315-1324.
(80)  Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-associated 
injection-site reactions. Arch Dermatol 2000; 136(4):556-557.
(81)  Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, 
and immunophenotypic characteristics of injection site reactions associated with 
etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. 
Arch Dermatol 2001; 137(7):893-899.
(82)  Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related 
reactions to infliximab in patients with rheumatoid arthritis in a clinical practice 
setting: relationship to dose, antihistamine pretreatment, and infusion number.  
J Rheumatol 2004; 31(10):1912-1917.
 General discussion
TNF blocking therapy in RA126
(83)  De Bandt M, Sibilia J, Le L, X, Prouzeau S, Fautrel B, Marcelli C et al. Systemic lupus 
erythematosus induced by anti-tumour necrosis factor alpha therapy: a French 
national survey. Arthritis Res Ther 2005; 7(3):R545-R551.
(84)  Langen-Wouterse JJ, Bijl AM, van Grootheest AC. [Drug-induced systemic lupus  
erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb].  
Ned Tijdschr Geneeskd 2007; 151(6):367-370.
(85)  Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus  
erythematosus associated with etanercept therapy. Lancet 2002; 359(9306):579-580.
(86)  Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case 
report and review of the literature. Arthritis Rheum 2006; 55(1):163-166.
(87)  Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus 
erythematosus and TNF-alpha blockers. Lancet 2002; 360(9333):646.
(88)  Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al.  
Demyelination occurring during anti-tumor necrosis factor alpha therapy for 
inflammatory arthritides. Arthritis Rheum 2001; 44(12):2862-2869.
(89)  Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events 
reported in association with tumor necrosis factor alpha antagonism: by what 
mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid 
arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44(9):1977-1983.
(90)  Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated 
with infliximab in the treatment of rheumatoid arthritis. Intern Med J 2005; 
35(10):638-640.
(91)  Devos SA, Van Den BN, De Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-
alpha monoclonal antibody therapy. Dermatology 2003; 206(4):388-390.
(92)  Guillevin L, Mouthon L. Tumor necrosis factor-alpha blockade and the risk of 
vasculitis. J Rheumatol 2004; 31(10):1885-1887.
(93)  Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA et al.  
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.  
J Rheumatol 2003; 30(10):2287-2291.
(94)  McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with  
cutaneous vasculitis. Rheumatology (Oxford) 2002; 41(1):116-117.
(95)  Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN et al. Leukocytoclastic 
vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 
2004; 31(10):1955-1958.
(96)  Adams DR, Buckel T, Sceppa JA. Infliximab associated new-onset psoriasis.  
J Drugs Dermatol 2006; 5(2):178-179.
(97)  Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H et al. New onset or 
exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis 
receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006; 65(3):405-407.
(98)  Dereure O, Guillot B, Jorgensen C, Cohen JD, Combes B, Guilhou JJ. Psoriatic lesions 
induced by antitumour necrosis factor-alpha treatment: two cases. Br J Dermatol 
2004; 151(2):506-507.
(99)  Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by  
anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 
2005; 52(8):2513-2518.
12
(100)  Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis 
in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 
76(6):653-656.
(101)  Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab 
for rheumatoid arthritis. Postgrad Med J 2002; 78(915):47-48.
(102)  Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, 
placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to 
tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results 
of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 
2003; 107(25):3133-3140.
(103)  Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after 
therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138(10):807-811.
(104)  Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al Saab S et al. Aplastic 
anemia following administration of a tumor necrosis factor-alpha inhibitor.  
Eur J Haematol 2003; 71(5):396-398.
(105)  Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003; 2(4):375-377.
(106)  FDA. FDA Safety Update on TNF-a Antagonists: Infliximab and Etanercept. 2001. 
(107)  van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis  
improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 
41(10):1845-1850.
(108)  Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S et al. Infections 
during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in 
daily practice: a systematic retrospective study of 709 patients. Rheumatology 
(Oxford) 2007; 46(2):327-334.
(109)  Maillard H, Ornetti P, Grimault L, Ramon JF, Ducamp SM, Saidani T et al. Severe 
pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone 
Spine 2005; 72(4):330-334.
(110)  Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE et al. Anti-tumor 
necrosis factor alpha therapy and the risk of serious bacterial infections in elderly 
patients with rheumatoid arthritis. Arthritis Rheum 2007; 56(6):1754-1764.
(111)  Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. 
Am J Med 1996; 100(2A):16S-23S.
(112)  Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during 
prolonged treatment with infliximab. J Rheumatol 2003; 30(12):2557-2562.
(113)  Bingham SJ, Buch MH, Kerr MA, Emery P, Valadao Barcelos AT. Induction of  
antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab 
and leflunomide. Arthritis Rheum 2004; 50(12):4072-4073.
(114)  Allanore Y, Sellam J, Batteux F, Job DC, Weill B, Kahan A. Induction of autoantibodies 
in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol 2004; 
22(6):756-758.
(115)  Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to 
double-stranded DNA induced in rheumatoid arthritis patients following treatment 
with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in 
open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 
43(11):2383-2390.
 General discussion
TNF blocking therapy in RA12
(116)  Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors  
of infusion reactions during infliximab treatment in patients with arthritis.  
Arthritis Res Ther 2006; 8(4):R131.
(117)  van der Laken CJ, Voskuyl AE, Roos JC, Stigter vW, de Groot ER, Wolbink G et al. 
Imaging and serum analysis of immune complex formation of radiolabelled  
infliximab and anti-infliximab in responders and non-responders to therapy for 
rheumatoid arthritis. Ann Rheum Dis 2007; 66(2):253-256.
(118)  Vermeire S, Noman M, van Assche G, Baert F, D‘Haens G, Rutgeerts PJ. The  
effectiviness of concomitant immunosuppressive therapy to suppress formation  
of antibodies to infliximab in crohn’s disease. Gut 2007.
12
C h a p T E r  8
Summary
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i N T r o d u CT i o N
Over the past two decades major advances have been made in unraveling the inflam-
matory process in rheumatoid arthritis (RA). A dominant role for TNF has been 
implicated, which has led to the development of a new class of drugs: TNF blocking 
agents. Currently three TNF blocking agents have been approved for the treatment 
of RA: the soluble p75 TNF receptor fusion protein Etanercept (Enbrel®), the chimeric 
monoclonal anti-TNF antibody infliximab (Remicade®) and the human monoclonal 
anti-TNF antibody adalimumab (Humira®).
These agents have shown remarkable efficacy and acceptable safety profiles in 
clinical trials. Long-term safety and effectiveness, however, needs further elucidation 
in post-marketing observational studies, because patients participating in clinical 
trials are model patients and are not representable for our patients in daily clinical 
practice. Furthermore, important safety issues have emerged from the use of TNF 
blocking agents, which warrant long-term observation.
In two rheumatological centres in Nijmegen (Radboud University Nijmegen Medical 
Centre and St. Maartenskliniek Nijmegen) a longitudinal observational study was 
set up to monitor the long-term effects of TNF blocking therapy. The purpose of this 
study was to investigate the clinical aspects of TNF blocking therapy in patients 
with RA. These aspects include, amongst others, drug survival, effectiveness, toxicity 
and treatment modulation, which form the main subject of this thesis.
C h a p T E r  2
Chapter two describes the long-term drug-survival, effectiveness and safety of etaner-
cept, infliximab and adalimumab in patients with refractory RA. Adalimumab patients 
originated from clinical trials. The results show comparability in disease activity 
and response percentages during follow-up, however, drug survival rates differed 
between the agents. Overall responses over time were: moderate 41-49%, good 22-33%, 
remission 12-24%. Adalimumab showed a more favourable survival, possibly due to 
trial effects. Infliximab showed a less favourable drug survival course due to adverse 
events and etanercept showed a less favourable survival due to ineffectiveness, possibly 
resulting form the small number of patients treated with etanercept. Overall, observed 
drug survival rates were relatively low, as compared to rates reported previously in 
clinical trials and observational studies.
Patients who switched to a second TNF blocking agent showed no decrease in 
drug survival of the second treatment course. The largest group consisted of patients 
switching from infliximab to etanercept. In this group the reasons for infliximab 
discontinuation did not influence etanercept survival. Adverse events were reported 
frequently throughout the follow-up period, but led to drug discontinuation in less 
than 15%. Etanercept treated patients reported less adverse events, although patient 
numbers were small.
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Predictive factors were identified by multivariate analysis for drug survival (con-
comitant DMARDs, disease duration), disease activity (gender, age, baseline DAS28, 
DMARD history, concomitant DMARDs and corticosteroids) and adverse events (weight, 
age, gender, DMARD history, concomitant DMARDs and corticosteroids).
C h a p T E r  3
Most clinical trials have investigated TNF blocking agents either as monotherapy 
or in combination with methotrexate. Although infliximab has been proven effica-
cious as monotherapy, combining it with methotrexate has yielded better treatment 
responses. In patients who fail on methotrexate or do not tolerate it, the concomitant 
administration of leflunomide can be an important alternative, but this combination 
has not been studied in clinical trials.
In chapter three the combination of infliximab and leflunomide in 57 patients 
is studied prospectively and compared to infliximab in combination with other 
DMARDs in 105 patients. No statistical significant differences were observed between 
the groups regarding baseline characteristics, drug survival, disease activity, treat-
ment response and adverse events, indicating that the administration of infliximab 
after or simultaneously with leflunomide is safe and effective in RA patients. 
In a subanalysis the incidence of antinuclear antibodies (ANA) at start and sero-
conversion during TNF blocking therapy was studied, together with the predictive 
value of ANA positivity on effectiveness and safety. In both groups an increase in 
ANA positive patients was seen. ANA positivity at start did not predict response to 
therapy or the occurrence of adverse events. Conversion to ANA positivity during 
therapy also did not predict the occurrence of adverse events.
C h a p T E r  4
In chapter four the disease activity and response to infliximab was investigated in an 
open label study with 76 RA patients. The aim of the study was to investigate different 
patterns of response with a focus on patients with a moderate (suboptimal) response 
and to investigate methods of optimizing treatment response in these patients. In 
patients with a moderate response after 14 weeks the disease activity was closely 
observed during the next interval and was used to guide treatment adjustments. 
Three distinct disease courses were observed after week 14: a further improvement 
to good response, a temporary response and a stable disease activity course. The latter 
two groups received an interval reduction respectively dose increase. Both resulted in 
significant improvements in disease activity, however, with different mean infliximab 
dosages. In good responders at week 14 the response was often sustained over follow-
up, whereas non-responders showed modest or no improvement despite dose adjust-
ments.
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C h a p T E r  5
Various dermatological conditions have been reported during TNF blocking therapy, 
but until now no prospective studies have been focused on this aspect. In chapter five 
a prospective study is described investigating the number and nature of clinically 
important dermatological conditions in RA patients receiving TNF blocking therapy. 
One fourth of all patients on TNF blocking therapy experienced one or more derma-
tological event, and in one fourth of these patients therapy was permanently dis-
continued. 
When compared with a group of prospectively followed RA patients, serving as con-
trol patients naive to TNF blocking therapy and matched for follow-up period, patients 
on TNF blocking therapy were referred to a dermatologist twice as frequently.
The events recorded most frequently consisted of skin infections, eczema, and drug-
related eruptions. Other reported events with a possible relation to TNF blocking 
therapy included vasculitis, psoriasis, drug-induced systemic lupus erythematosus, 
dermatomyositis, and a lymphomatoid-papulosis-like eruption. This study is the first 
large prospective study describing the frequent occurrence of various dermatological 
conditions during TNF blocking therapy. 
C h a p T E r  6
Psoriasis occurring during TNF blocking therapy is a paradoxal and interesting 
phenomenon, as all three TNF blocking agents are recently accepted as effective 
treatment options for moderate to severe plaque psoriasis. This chapter describes in 
detail the development of psoriasis and psoriasiform skin lesions in 5 RA patients 
during TNF blocking therapy. These cases were added to the 110 already published 
cases in which temporal associations and positive rechallenges provide strong evidence 
for a causative relationship between the use of TNF blocking therapy and the develop-
ment of psoriasis and psoriasiform skin disease. Furthermore, recurrences on other 
TNF blocking agents suggests a class effect. When observing the outcome of pub-
lished cases withdrawal of TNF blocking agents does not seem mandatory, but is 
associated with a higher improvement rate.
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C h a p T E r  9
Samenvatting
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i N T r o d u CT i E
Reumatoïde artritis (RA, ook wel chronische gewrichtsreuma genoemd) is een vorm 
van reuma die voorkomt bij een half tot één procent van de wereldbevolking. RA is 
een chronische ziekte die gekenmerkt wordt door een ontsteking aan de gewrichten. 
Deze zijn gezwollen, stijf en pijnlijk. Op den duur kan schade optreden aan het 
kraakbeen en het bot van het gewricht. Hierdoor ontstaan vergroeiingen en stand-
afwijkingen, waardoor de functie van de gewrichten permanent verloren kan gaan. 
De ziekte wordt gekenmerkt door een wisselend beloop met rustige en actieve fasen 
van ontsteking. Tussen mensen met RA bestaan grote verschillen in de activiteit en 
het beloop van de ziekte.
Het genezen van de ziekte is (nog) niet mogelijk. Met ontstekingsremmende 
medicijnen probeert men de ziekte te onderdrukken. Stap één in de behandeling 
bestaat uit de zogenaamde NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), zoals 
ibuprofen en naproxen. Deze verminderen de pijn en de stijfheid, maar remmen het 
ziekteproces niet. Stap twee bestaat uit het toevoegen van krachtigere ontstekings-
remmers, zoals prednison en DMARDs (Disease Modifying AntiRheumatic Drugs, 
bijvoorbeeld methotrexaat). Het remmen van de ontsteking met behulp van boven-
genoemde medicijnen lukt bij een aantal mensen met RA, maar niet bij iedereen. 
Daarom blijft er een zoektocht gaande naar nieuwe en betere medicijnen voor de 
behandeling van RA.
De oorzaak van RA is onbekend. Bij mensen met RA vallen afweercellen de eigen 
lichaamscellen aan. Het eiwit Tumour Necrosis Factor alfa (TNF) speelt hierbij een 
belangrijke rol, zo heeft men ontdekt in de laatste twee decennia. TNF functioneert 
als een ‘boodschapper eiwit’ tussen de afweercellen in het lichaam en stimuleert 
ontstekingsreacties. Bij mensen met RA is er een teveel aan TNF in hun gewrichten.
De ontdekking van de rol van TNF bij RA heeft geleid tot de ontwikkeling van 
een nieuwe groep geneesmiddelen: de TNF blokkerende middelen. Momenteel zijn 
in Nederland drie TNF blokkerende middelen goedgekeurd voor de behandeling 
van RA: 
• Etanercept (merknaam Enbrel®), een oplosbare TNF receptor fusie eiwit.
• Infliximab (merknaam Remicade®), een chimerisch (opgebouwd uit een deel 
muizeneiwit en een deel menselijk eiwit) antilichaam tegen TNF.
• Adalimumab (merknaam Humira®), een humaan (volledig menselijk) antilichaam 
tegen TNF.
Alle drie de middelen binden zich aan TNF moleculen en maken de TNF moleculen 
onschadelijk. Wetenschappelijk onderzoek heeft laten zien dat deze middelen een 
sterke remming geven van de ontsteking bij RA. De effectiviteit en veiligheid op 
lange termijn dienen echter nader te worden onderzocht, mede omdat een aantal 
patiënten ernstige bijwerkingen heeft gekregen na gebruik van deze middelen. Een 
voorbeeld daarvan is het reactiveren van tuberculose, waardoor patiënten die vroeger 
tuberculose hebben gehad deze infectie opnieuw kunnen krijgen.
Twee reumatologie afdelingen in Nijmegen (van het Universitair Medisch Centrum 
Sint Radboud en de Sint Maartenskliniek Nijmegen) hebben samen een studie opge-
zet om de lange termijn effecten van behandeling met TNF blokkerende middelen 
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te onderzoeken. Het onderzoek richt zich op aspecten van de behandeling in de dage-
lijkse praktijk, zoals
• De geneesmiddeloverleving: hoe lang gebruiken patiënten met RA TNF blokke-
rende middelen vóórdat ze daarmee stoppen, bijvoorbeeld wegens bijwerkingen 
of omdat het middel de ziekte activiteit te weinig onderdrukt?
• De effectiviteit: in welke mate verminderen deze medicijnen de ziekte activiteit? 
Dit wordt uitgedrukt door onder andere het aantal gezwollen en pijnlijke ge-
wrichten.
• De behandelrespons: hoeveel patiënten ondervinden een effect van de behande-
ling?
• De bijwerkingen.
• Het optimaliseren van de doseringsschema’s: leiden individuele aanpassingen 
tot een betere behandeling?
Deze aspecten vormen de hoofdonderwerpen van dit proefschrift.
h o o F d s T u k  2
Hoofdstuk 2 beschrijft de effectiviteit, veiligheid en geneesmiddeloverleving op de 
lange termijn van etanercept, infliximab en adalimumab bij patiënten met ernstige 
RA. De studie laat zien dat de drie middelen vergelijkbaar zijn wat betreft de ver-
mindering van ziekte activiteit en het percentage patiënten dat een effect onder-
vond van de behandeling (behandelrespons). Gemiddeld hadden 65% tot 80% van de 
patiënten een vermindering van de ziekte activiteit en was bij 12% tot 20% de ziekte 
activiteit verdwenen.
Het tijdstip waarop patiënten gemiddeld stoppen met de behandeling (de genees-
middeloverleving) verschilde tussen de drie geneesmiddelen. Oorzaken voor deze 
onderlinge verschillen kwamen mogelijk voort uit het feit dat de groepen zelf te ver-
schillend waren: de groep met etanercept patiënten was erg klein en de adalimumab 
patiënten hadden mee gedaan aan een wetenschappelijk onderzoek en waren dus 
vooraf geselecteerd. De drie middelen werden relatief sneller gestopt in vergelijking 
met eerder uitgevoerd wetenschappelijk onderzoek met deze middelen. 
De groep met RA patiënten die overstapten naar een tweede TNF blokkerend 
middel gebruikten dit tweede middel gemiddeld net zo lang als het eerste middel ge-
bruikt werd. De grootste groep bestond uit patiënten die van infliximab overstapten 
naar etanercept. De redenen voor het stoppen van infliximab hadden geen invloed 
op de geneesmiddeloverleving van etanercept.
Tijdens de behandeling met de drie TNF blokkerende middelen traden frequent 
bijwerkingen op, zoals infecties, huidafwijkingen en allergische reacties. Slecht 15% 
van deze bijwerkingen leidden tot het permanent stoppen van de behandeling. Tijdens 
behandeling met etanercept werden minder bijwerkingen gerapporteerd, maar het 
aantal patiënten dat met etanercept behandeld werd was klein, waardoor de resul-
taten vertekend kunnen zijn.
Voorspellende factoren konden worden aangetoond voor geneesmiddeloverleving 
(het gelijktijdig gebruiken van DMARDs, de ziekteduur), ziekte activiteit (geslacht, 
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leeftijd, ziekte activiteit bij start, DMARD voorgeschiedenis, gelijktijdig gebruik van 
DMARDs en corticosteroïden) en bijwerkingen (gewicht, geslacht, leeftijd, DMARD 
voorgeschiedenis, gelijktijdig gebruik van DMARDs en corticosteroïden).
h o o F d s T u k  3
Van therapie met infliximab is bewezen dat deze effectief als monotherapie, dat wil 
zeggen zonder gelijktijdig gebruik van DMARDs. Wanneer infliximab echter gelijk-
tijdig gebruikt wordt met methotrexaat (combinatie therapie), dan leidt dit tot een 
sterkere vermindering van de ziekte activiteit bij patiënten met RA. Daarom wordt 
geadviseerd infliximab altijd in combinatie met methotrexaat te gebruikten. Bij pa-
tiënten die geen effect ondervinden van methotrexaat of het middel niet kunnen ver-
dragen kan de combinatie met een ander DMARD zoals leflunomide met infliximab 
een belangrijk alternatief vormen. De combinatie van infliximab met leflunomide 
is echter nog niet goed onderzocht.
In hoofdstuk 3 is de combinatie van infliximab met leflunomide bestudeerd bij 57 
RA patiënten en vergeleken met 105 RA patiënten die infliximab gebruikten in com-
binatie met andere DMARDs. De twee groepen waren vergelijkbaar met betrekking 
tot de patiënt karakteristieken bij de start, de geneesmiddeloverleving, de effecten 
op ziekte activiteit, behandelrespons en de bijwerkingen. De resultaten laten zien 
dat de behandeling met infliximab samen met of aansluitend op behandeling met 
leflunomide veilig en effectief is bij patiënten met RA.
Tevens werd in deze studie gekeken naar de betekenis van het voorkomen van 
antinucleaire antilichamen (ANA) in het bloed van RA patiënten die infliximab 
gebruikten. Antinucleaire antilichamen zijn antilichamen die gericht zijn tegen 
bestanddelen van de celkern (nucleus). Zij kunnen incidenteel voorkomen bij ge-
zonde personen, maar worden vaker gezien bij mensen met bepaalde vormen van 
reuma. Uit het onderzoek bleek dat het hebben van antinucleaire antilichamen bij 
therapie met infliximab geen relatie had met het optreden van bijwerkingen of met 
minder effect van infliximab behandeling.
h o o F d s T u k  4
In hoofdstuk 4 is de ziekte activiteit en behandelrespons op infliximab therapie onder-
zocht in een studie met 76 RA patiënten. Infliximab wordt via een infuus (via een 
plastic buisje in een ader in de arm) direct in de bloedbaan toegediend. Na een op-
startfase van 6 weken met 3 infusen krijgen patiënten elke 8 weken een nieuw infuus. 
Een infuus duurt gemiddeld twee a drie uur.
Het doel van de studie in hoofdstuk 4 was om verschillende patronen in het beloop 
van de ziekte activiteit tussen twee giften infliximab te bestuderen en zo verschil-
lende typen in de behandelrespons te identificeren.
Hierbij lag de nadruk op de patiënten met een matige behandelrespons. Bij de 
patiënten met een matige behandelrespons na 14 weken behandeling werd de ziekte 
13
activiteit nauwkeurig gemeten tijdens het volgende 8-weekse interval. Deze metingen 
werden vervolgens gebruikt als leidraad voor aanpassing van de behandeling. Drie 
verschillende respons typen konden op deze manier van elkaar worden onderschei-
den na 14 weken: verdere verbetering tot een goede respons, een matige stabiele 
behandelrespons, en een goede maar tijdelijke behandelrespons waarna sprake was 
van een terugval met opvlammen van de ziekte activiteit. De laatste twee respons 
typen werden gevolgd door een behandelaanpassing, te weten een ophoging van de 
dosis respectievelijk een inkorting van het interval tussen twee infusen met inflixi-
mab. Beide aanpassingen leidden tot een duidelijke verbetering in ziekte activiteit. 
De gemiddelde dosering van infliximab verschilde tussen de twee aanpassingen. Bij 
patiënten met initieel al een goede respons bleef deze meestal aanhouden gedu-
rende de totale follow-up, terwijl mensen zonder initiële verbetering na de start van 
infliximab ook geen of slechts een minimale verbetering lieten zien na latere dosis 
ophoging.
h o o F d s T u k  5
Verschillende huidafwijkingen zijn beschreven gedurende het gebruik van TNF 
blokkerende middelen, maar tot op heden zijn er geen prospectieve (toekomst-
gerichte) studies gepubliceerd die dit aspect belichten. Hoofdstuk 5 beschrijft een 
studie die de soort en het aantal huidafwijkingen bestudeert in RA patiënten die 
gevolgd worden tijdens hun behandeling met TNF blokkerende middelen. Een 
vierde van alle patiënten ontwikkelde een of meer huidafwijkingen. In een vierde 
van deze groep werd het TNF blokkerende middel permanent gestopt.
In vergelijking met patiënten, die geen TNF blokkerende middel gebruikten of 
hadden gebruikt, werden patiënten met TNF blokkerende middelen twee maal zo 
vaak naar een dermatoloog verwezen vanwege huidafwijkingen.
De huidafwijkingen die het meest voorkwamen waren huidinfecties, eczeem en 
geneesmiddelenreacties. Andere huidafwijkingen met een mogelijke relatie tot het 
gebruik van TNF blokkerende middelen waren onder andere vasculitis, psoriasis, 
systemische lupus erythematosus en dermatomyositis. Deze studie is de eerste grote 
prospectieve studie die aantoont dat het optreden van huidafwijkingen tijdens 
behandeling met TNF blokkerende middelen een klinisch belangrijk probleem zijn.
h o o F d s T u k  6
Alle drie de TNF blokkerende middelen zijn ook effectief gebleken als behandeling 
van psoriasis en mogen sinds kort hiervoor worden toegepast door huidartsen. Het is 
echter zeer merkwaardig en interessant dat tijdens de behandeling met TNF blokke-
rende middelen bij patiënten die geen psoriasis hebben, psoriasis en psoriasiforme 
(psoriasis-achtige) huidafwijkingen kunnen ontstaan.
Dit hoofdstuk beschrijft in detail de ontwikkeling van psoriasiforme huidafwij-
kingen bij 5 RA patiënten tijdens TNF blokkerende behandeling. Deze patiënten 
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werden samengevoegd met 110 al gepubliceerde gevallen, waarbij zowel een relatie 
in de tijd als het heroptreden na herstart van de TNF blokkerende behandeling een 
sterk bewijs leveren voor een oorzakelijke relatie tussen het gebruik van TNF blok-
kerende middelen en het ontstaan van psoriasis en psoriasiforme huidafwijkingen. 
Bovendien kwamen de huidafwijkingen terug de na de overstap op een ander TNF 
blokkerend middel. Het stoppen van de TNF blokkerende behandeling lijkt niet 
direct niet noodzakelijk, maar leidt wel vaker tot volledig herstel.
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List of abbrevations
95%CI = 95% confidence interval
ACR = American College of  
Rheumatology
ADA = adalimumab
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ANA = antinuclear antibodies
ANOVA = analysis of variance
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BD = Beçhets disease
CD = Crohn’s disease
CI = confidence interval
CU = Colitis ulcerosa
DAS28 = disease activity score  
including 28-joint counts
DCP = daily clinical practice
DMARD = disease modifying  
antirheumatic drug
ELISA = enzyme-linked  
immunosorbent assay
ETA = etanercept
GEE = Generalized Estimating  
Equations
HCQ = hydroxychloroquine
HR = Hazard ratio
i.v. = intravenously
ICAM-1 = Intercellular adhesion 
molecule-1
IFN = Interferon 
IFNß = Interferon ß
INF = infliximab
JIA = juvenile idiopathic arthritis
LEF = leflunomide
MoAb = monoclonal antibody
MTX = methotrexate
n.s. = not significant
NSAID = Non-steroidal anti- 
inflammatory drug
OR = Odds ratio
PPP = palmoplantar pustulosis
PsA = Psoriatic arthritis 
pt = patients
pt-yr = patient-year
RA = rheumatoid arthritis
RCT = randomized clinical trial
RF = rheumatoid factor
RUNMC = Radboud University  
Nijmegen Medical Centre
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SASP = salazopyrin (sulphasalazine)
sd = standard deviation
SMN = Sint Maartenskliniek Nijmegen
SpA = Spondylarthropathy
ssp. = species
St. = Staphylococcus
Th1/Th2 = T helper cell type 1/type 2
TNF = tumour necrosis factor alpha
VCAM-1 = Vascular adhesion  
molecule-1 
vs = versus
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